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I. Het roken van twee sigaretten vermindert het aantal eosinofiele granulocyten in 
het bloed van gezonde gelegenheidsrokers (dit proefschrift). 
2. Een acuut rookmodel heeft toegevoegde waarde voor het bestuderen van de 
effecten van sigarettenrook op inflammatie en oxidatieve stress ( dit proefschrift) . 
3. Het kortdurend geven van de TNF·a blokker infliximab heeft geen positief effect 
op inflammatie in sputum en luchtwegklachten bij patienten met mild tot 
matig ernstig COPD (dit proefschrift). 
4. Het herhalen van sputuminducties binnen 48 uur moet vermeden warden 
vanwege het optreden van een inflammatoire respons hierop (dit proefschrift). 
5. Meeroken is gratis, maar de rekening wordt achteraf gepresenteerd. 
6. De beschikbaarheid van wetenschappelijke artikelen op het internet draagt niet 
veel bij aan de afname van papierverbruik. 
7. Elk onderzoek naar COPD opent weer een stukje van het rookgordijn. 
8. Door het invoeren van een rookverbod in de horeca zal naast het aantal 
meerokers oak het aantal 'partysmokers' afnemen. 
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Chronic obstructive pulmonary disease 
1.1 Definition 
According to the Chronic Obstructive Lung Disease (GOLD) guidelines ( 1 ), chronic 
obstructive pulmonary disease (COPD) "is a disease state characterised by airflow limitation 
that is not fully reversible. The airflow limitation is usually progressive and associated with 
an abnormal inflammatory response of the lungs to noxious particles or gases. Symptoms 
of COPD include cough, sputum production and dyspnea on exertion. Episodes of acute 
worsening of these symptoms often occur". Airflow limitation in COPD is characterised by 
a Forced Expiratory Volume in one second (FEV 1)/Forced Vital Capacity (FVC) ratio below 
70%. In the most current guidelines COPD is classified into four stages of disease severity 
based on FEV 1 % predicted (GOLD 1-4) table 1 ) . The stages of disease reflect the prognosis 
of COPD, in that more severe disease is associated with higher mortality. Patients classified as 
GOLD 0, do not have airflow limitation but present with symptoms of cough and/or dyspnea, 
and are at risk to develop COPD. 
COPD is not one disease entity. The term COPD encompasses chronic obstructive bronchitis, 
with obstruction of the small and large airways, and emphysema, with predominantly 
enlargement of airspaces, destruction of lung parenchyma, loss of lung elasticity and closure 
of small airways. Chronic bronchitis, by contrast, is defined by the presence of cough and 
sputum production for at least three months in each of two consecutive years, but does 
not include the presence of airway obstruction. Not all patients with chronic bronchitis 
will develop airflow limitation, and thus fit a diagnosis of COPD. Most COPD patients have 
characteristics of both emphysema and chronic obstructive bronchitis, although the extent 
within individual patients may vary. 
1.2 Prevalence 
The 2002 World Health Report of the World Health Organisation listed COPD as the fifth 
leading cause of death in the world and further increases in its prevalence and mortality 
are expected in the coming decades [www.who.int/whr/2002]. In the Netherlands the 
prevalence of COPD was 328.600 inhabitants in the year 2000 based on registration by 
general practitioners [www.rivm.nl]. The prevalence and morbidity data probably greatly 
underestimate the true burden of the disease, because COPD is usually not recognised until it 
is clinically apparent and moderately advanced. A large survey on COPD in 2000 in the USA 
reported that an estimated 10 million of people had reported physician diagnosed COPD, yet 
an estimate of 24 million people had evidence of airflow limitation (2). 
1.3 Risk factors 
Major risk factors for COPD are tobacco smoke, passive smoking, (indoor) air pollution and 
genetic factors. Cigarette smoking is the most important risk factor for the development of 
COPD, as it accounts for 80% of the mortality attributed to COPD (3) . However, only 15-20% 
of all smokers develop COPD. Higher cumulative lifetime home and work environmental 
tobacco smoke exposure are associated with a greater risk of COPD (4). Indoor air pollution 
from biomass fuel used for cooking and heating in poorly ventilated rooms is an important 
cause of COPD in developing countries (5) . Outdoor air pollution adds to the total burden 
of inhaled particles, although its specific role in the pathogenesis of COPD is not completely 
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understood (6). Genetic factors likely influence the variable susceptibility to develop COPD, 
as has been shown by a-1 antitrypsin deficiency and more recently by polymorphisms of a 
disintegrin and metalloprotease (ADAM)33 (7, 8) and transforming growth factor [TGF) (9, 
10). Though not all results are consistent between studies ( I I). 
1.3.1 Cigarette smoke 
Cigarette smoke is a complex, heterogeneous mixture containing more than 5000 chemical 
compounds ( I 2). Cigarette smoke can be divided in a gas phase, an organic apolair phase 
soluble in organic solvents, a water-soluble phase and a particulate phase. The main gas phase 
components include carbon dioxide, carbon monoxide (CO), nitric oxide (NO) and nitric 
dioxide, different (oxygen) radicals, and irritants. The organic soluble components contain 
various aromatic hydrocarbons (often referred to as tar) consisting of a mixture of nicotine, 
hydroquinones, catechols and a group of carcinogens (13). Tar also contains carcinogens and 
radioactive elements. The composition of the smoke directly inhaled through the cigarette 
into the lung (mainstream smoke) is different from that formed between puffs (side stream 
smoke) and exhaled smoke (figure I) (14). 
Only little is known as to which particular constituents of cigarette smoke are inducing 
COPD. Several studies have failed to demonstrate a clear, direct association between the tar 
yield and nicotine and the development of airway obstruction [ I 5, 16). A number of irritants 
can act directly on the airways, damaging the mucocilliary apparatus of the bronchial mucosa, 
which may result in the development of chronic bronchitis (17). Otherwise, some irritants 
can act indirectly on the airways, by recruiting and activating inflammatory cells, which 
in their turn can enhance lung destruction and airway fibrosis (18). Finally, oxidants are 
important constituents of cigarette smoke. The role of these free radicals in the development 
of COPD has been well established and will be discussed in more detail in the next paragraph 
(I 8, 19). 
1.4 Pathogenesis 
An important question in COPD research is why only 15-20% of the smokers develop 
symptomatic airflow limitation. Therefore, the pathogenetic mechanisms underlying COPD 
have been extensively studied. Three important contributing mechanisms have been put 
forward with respect to development of COPD due to cigarette smoke exposure: 
1. Oxidative stress / 
2. Protease-anti-protease imbalance 
3. Tissue remodelling 
Since airway inflammation is involved in all three mechanisms, this will be discussed first. 
1.4.1 Inflammatory cells 
Airway inflammation in COPD is characterised by the presence of several inflammatory cells 
and multiple inflammatory mediators. Many studies have been performed on their role in the 
pathogenesis of COPD, but many questions remain still unanswered. The most important 
cells and mediators and their role in COPD are discussed below. 
Neutrophils 
A considerable increase in numbers of activated neutrophils is found in sputum and 
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bronchoalveolar lavage fluid (BALF) of patients with COPD compared with control subjects. 
Recently an increase in neutrophils has been observed in the smooth muscle layer of small 
airways in COPD patients as well (20). But only relatively small increases are found in 
the airways or the Jung parenchyma (21, 22). Neutrophil recruitment to the airways and 
parenchyma requires adhesion to endothelial cells. This is compatible with up-regulation of 
the endothelial adhesion molecule E-selectin in the airways of COPD patients (23). Adherent 
neutrophils migrate into the respiratory tract under the direction of neutrophil chemotactic 
factors, which include interleukin (IL)-8 and leukotriene B4 (LTB4). These mediators may 
derive from alveolar macrophages and epithelial cells, but IL-8 may also be released from the 
neutrophil itself, which is a major source of IL-8 (24). 
Neutrophils have the capacity to induce airway wall and/or lung tissue damage through the 
release of serine proteases and oxidants (25, 26). Furthermore, airway neutrophilia may also 
induce mucus hypersecretion in chronic bronchitis, since serine proteases from neutrophils 
are potent stimulants of mucus secretion from submucosal glands and goblet cells in the 
epithelium (27). Although the exact role of neutrophils in COPD is not yet clear, data suggests 
they contribute at least to disease severity: higher numbers of neutrophils in bronchial biopsies 
and induced sputum correlate with a lower level of FEV, (28, 29). However, it is not excluded 
that a more severe airway obstruction in COPD is the primary event followed by recruitment 
of neutrophils to support a repair mechanism. 
Macrophages 
Macrophages are thought to play an important role in the pathogenesis of COPD. Their 
numbers are increased in the airways, lung parenchyma, BALF and sputum of patients with 
COPD (30, 31 ). Furthermore, macrophage numbers in the airways correlate with COPD 
severity (28). This may be due to increased recruitment of monocytes from the bone marrow, 
but also to increased proliferation and prolonged survival in the lung (32). Monocyte 
chemoattractant protein (MCP)-1 and growth-regulated oncogene (GRO)-a, two chemokines 
for monocytes are increased in sputum of patients with COPD (33). 
Alveolar macrophages from patients with COPD secrete more inflammatory proteins and 
have a greater elastolytic activity than those from normal smokers and this is further increased 
by exposure to cigarette smoke (34-36). The predominant elastolytic enzyme secreted by 
alveolar macrophages in COPD patients is matrix metalloproteinase (MMP)-9. The expression 
of the anti-oxidant enzyme haem oxygenase-1 (HO-1) is decreased in alveolar macrophages 
in COPD patients (37, 38) and a polymorphism in the promoter region of HO-1 is associated 
with COPD (39). HO-1 is proposed to be inhibitory in inflammatory reactions by the release 
of e.g. CO. Therefore, it might be that insufficient upregulation of HO-1 and corresponding 
loss of inhibition of inflammation, plays a role in the development of the disease. 
T and B lymphocytes 
The total number of T lymphocytes is increased in lung parenchyma, peripheral and central 
airways of patients with COPD, with a greater increase in CD8 than CD4 cells (31, 40-43). 
Furthermore, the number of T cells correlates with the amount of alveolar destruction and 
the severity of airflow limitation (31, 43). 
Three studies have reported increased numbers of B cells in the large and small airways 
of COPD patients (44-46) and a higher absolute volume of B cells in the Jung parenchyma 
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correlated with a lower FEV, (46). The role of T and B cells in COPD is not yet clarified, but 
their presence may reflect an adaptive immune response to chronic microbial colonisation, 
smoke particles and/or matrix degradation products. 
Eosinophils 
The role of eosinophils in COPD is uncertain. Increased numbers of eosinophils have been 
reported in sputum in a subgroup of stable COPD patients (47) and during exacerbations of 
patients with COPD (48, 49). Furthermore, bronchial hyperresponsiveness is associated with 
eosinophils in sputum of COPD patients (50) and sputum eosinophils correlate negatively 
with FEV 1 and FEV/FVC (51 ). The response to inhaled and oral steroids in COPD patients 
is associated with sputum eosinophilia (52, 53). In spite of this, some studies have not found 
increased numbers of eosinophils in airway wall biopsies, BALF or induced sputum (54-57). 
Epithelial cells 
Afrway and alveolar epithelial cells may be an important source of inflammatory mediators, 
proteases, anti-proteases and anti-oxidants in COPD (58). The epithelial cell is one of the 
first cells that is encountered by the inhaled cigarette smoke. Cigarette smoke can activate 
these cells to produce inflammatory mediators (59-61 ), which may recruit and activate 
inflammatory cells into the lungs. Primary epithelial cells from COPD patients secrete more 
IL-8 compared to those of healthy smokers (62, 63). 
Afrway and alveolar epithelial cells with their epithelial lining fluid are the first line of defence 
against toxic inhalants. Cigarette smoke may alter this epithelial barrier and impair epithelial 
function (64), which may potentiate the damaging effects of toxic agents in the lung. Afrway 
epithelium in chronic bronchitis and COPD often shows structural changes as hypertrophy, 
squamous metaplasia, loss of ciliated epithelial cells and reduced cilia height and function 
(65). Furthermore, the airways are characterised by goblet cell hyperplasia, mucous gland 
hypertrophy and increased expression of the mucins MUC5AC and MUC5B, which are 
associated with mucus hypersecretion (66-68). 
The alveolar wall is covered by two types of epithelial cells, type I and type II alveolar 
epithelial cells (69). Several studies have shown that alveolar epithelial and endothelial cells 
of emphysema patients show increased rates of apoptosis, which might account for the loss 
of alveoli that is characteristic for the lungs of patients with emphysema (70, 71 ). Apoptosis 
can be induced by various stimuli, including oxidative stress, proteases, cigarette smoke and 
CD8 T cells (72-74). 
Fibroblasts 
Fibroblasts are mesenchymal cells that constitute 35-40% of the cells in the pulmonary 
interstitium. They are one of the most important cells in tissue repair in the lung, which is 
reflected by fibroblast proliferation and the production of extracellular matrix (ECM) proteins 
(75). Furthermore fibroblasts can release inflammatory mediators and subsequently interact 
with and regulate the influx of inflammatory cells into lung tissue. Little is known about 
the role of lung fibroblasts in (inadequate) tissue repair in COPD. It has been shown that 
fibroblasts from emphysema patients have decreased proliferative capacity (76), produce less 
growth factors compared to healthy fibroblasts (77) and less decorin after modulation with 
cytokines (78). Furthermore, cigarette smoke can directly impair fibroblast function and can 
induce fibroblast cell death (79-83). 
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1.4.2 Inflammatory mediators 
Migration and activation of inflammatory cells are regulated by cytokines and chemokines, 
of which some are increased in sputum and/or BALF from patients with COPD. Cytokines 
associated with COPD include tumor necrosis factor (TNF)-a., interferon (IFN}-y, IL-Ip and 
IL-6. Chemokines associated with COPD are IL-8, MCP-1, GRO-a. and LTB4 (33, 84). One of 
the interesting cytokines in smoking induced COPD is TNF-a., and its role will be discussed 
below. TGF-P I is another interesting cytokine in COPD, especially because of its role in tissue 
repair, and will also be discussed in more detail below. 
TNF-a 
TNF-a. is a potent pro-inflammatory cytokine involved in many immunological and 
inflammatory processes. TNF-a. can be produced by macrophages, monocytes, epithelial 
cells and mast cells (85). Because TNF-a may stimulate the production of cytokines (e.g. 
IL-6) and chemoattractants (e.g. IL-8), upregulate endothelial adhesion molecules and inhibit 
apoptosis of neutrophils, this cytokine is thought to play an important role in the development 
of neutrophilic airway inflammation in COPD (86, 87). Furthermore, it can also activate 
most inflammatory cell types e.g. monocytes, macrophages, neutrophils and T cells (84). 
An animal TNF-a. knockout model has shown that TNF-a. is a key factor in cigarette smoke 
induced airway inflammation and emphysema (88, 89). In vivo, elevated levels of TNF-a. 
have been demonstrated in peripheral blood, sputum and BALF of patients with stable COPD 
(29, 90). Two polymorphisms of the TNF-a. gene are associated with the presence, severity 
and mortality of COPD (91-94). The administration of inhaled recombinant human TNF-a. to 
healthy subjects resulted in an increase of airway hyperresponsiveness, which was associated 
with an increase in neutrophils in induced sputum (95). This might be compatible with 
the observation that a large part of the COPD population shows hyperresponsiveness, but 
whether this is a causal relation is unknown. 
It has become clear over the past decade that COPD is not exclusively a disease of the lung 
but that it has a systemic component as well (96, 97). Nutritional depletion can be seen as 
an expression of this systemic component. It is present in 35-60% of patients with moderate 
to severe COPD (98) and is associated with an increase in daily energy expenditure and 
levels of inflammatory mediators (99). Especially TNF-a. seems to be important among these 
inflammatory mediators since it correlates with increased energy expenditure and furthermore 
increased serum TNF-a. levels are found in a subgroup of patients with nutritional depletion 
(90, 100, IOI). 
In conclusion, TNF-a. probably plays a key role in the induction and maintenance of airway 
inflammation and increased energy metabolism in COPD. Therefore it would be interesting 
to investigate the effect of a monoclonal antibody anti-INF-a in COPD. 
TGF{Jl 
One of the most important cytokines in tissue repair is TGF-P I. In the lung TGF-P I can be 
released by macrophages, lymphocytes, epithelial cells and fibroblasts (I 02). TGF·P I enhances 
fibroblast proliferation, survival and extracellular matrix deposition ( I 03, I 04], but at higher 
concentration TGF-P 1 can also inhibit fibroblast proliferation ( 1 OS}. Binding to components of 
the ECM neutralises the action of TGF-P I ( I 05)_ Insufficient binding of TGF-P I to the ECM, 
as can occur in destructed emphysema lungs, might result in locally high concentrations of 
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TGF-�l and unwanted inhibition of tissue repair by fibroblasts. Indeed, TGF-�l expression 
is increased in alveolar and bronchial epithelial cells in patients with COPD and the latter 
correlates negatively with FEV1 (106). In another study TGF-�l correlated positively with 
the number of smoked pack-years in smokers with and without COPD ( 1 07). Finally, two 
polymorphism of TGF-� 1 have been associated with susceptibility of COPD (9, 10). 
1.4.2 Oxidative stress 
Oxidative stress occurs when there is an imbalance between excess of oxidants (reactive 
oxygen species (ROS}} and protecting anti-oxidants. This can damage cell lipids, proteins and 
DNA. Oxidative stress is thought to have an important role in the pathogenesis of COPD 
( 1 08, 109). Two major sources of ROS are responsible for the oxidative stress in patients 
with COPD. First, cigarette smoke itself contains a high concentration of ROS. Second, 
inflammatory cells in the airways can generate ROS when activated (11 0). The normal 
production of oxidants in the airways can be counteracted by anti-oxidants, of which the 
glutathione system is the most important. However, in situations of repeated high levels of 
oxidants, the defence by anti-oxidants may be insufficient, which may result in oxidative 
stress and tissue damage. ROS may also amplify the inflammatory response by activating 
the transcription factor, NF-KB, with subsequent increase of pro-inflammatory cytokines 
( 19, 111 ). Furthermore, oxidative stress may impair the function of anti-proteases, as a-1 
anti-trypsin I 1 I 2) and secretory leukoprotease inhibitor ( 113) ,  and thus may enhance the 
breakdown of elastin in the lung parenchyma. 
1.4.3 Protease-anti-protease imbalance 
It has long been proposed that various proteases break down connective tissue components, 
particularly elastin, in lung parenchyma of COPD patients. Attention has focussed specifically 
on neutrophil elastase (NE} and proteinase 3, neutrophil derived proteases, and on cathepsins. 
These proteases all produce emphysema in animal models ( 1 14). In emphysema patients 
urinary excretion of desmosin, a degradation product of elastin, is increased compared with 
healthy smokers ( 115). NE is normally inhibited by a-1 anti trypsin, and certainly accounts for 
the development of emphysema in patients with a-1 antitrypsin deficiency. However, its role 
in smoking induced emphysema is less certain. The complex NE-a-1 antitrypsin is elevated in 
emphysema patients ( 116), and NE and cathepsin G can increase mucus secretion in vitro, as 
is characteristic for chronic bronchitis (27). 
There is increasing evidence that MMPs, derived from macrophages and neutrophils, play 
a role in COPD ( 117). MMP-1 and MMP-9 are increased in BALF of COPD patients ( 118-
120) and activated MMP-2 and MMP-9 are found in the lung parenchyma in COPD (121 ). 
In sputum from patients with COPD, MMP-8 and MMP-9 activity negatively correlate with 
the level of airflow limitation ( 1 22). In mice, deletion of the MMP- 1 2  gene prevents the 
development of smoking induced emphysema (123), although the relevance of MMP-12 
in humans is uncertain. Furthermore, proteases may generate chemotactic peptides, which 
can recruit inflammatory cells into the lung ( 1 24). MMPs are counteracted by three tissue 
inhibitor matrix metalloproteinases, (TIMP)-1, -2 and -3. 
The concept of the protease-anti-protease imbalance is that cigarette smoke induces the 
release of both proteases and also sufficient anti-proteases to prevent parenchymal damage 
in healthy smokers. However, the paradigm predicts that in smokers who develop COPD, 
Gcneral introduction on chrome obsrrumve pulmonary disease 15 
the production of anti-proteases may be insufficient to neutralise the proteases, resulting in 
a protease-anti-protease imbalance, which subsequently leads to parenchymal injury and 
perpetuation of the inflammatory response. 
1.4.4 Tissue remodelling 
Ttssue repair 
Repair of pulmonary tissue normally follows lung injury due to proteolysis and oxidative stress. 
Tissue repair consists of a series of co-ordinated events involving cell division, migration, cell 
differentiation and extra cellular matrix production, which are all strictly regulated by locally 
released mediators. One of the most important cytokines in tissue repair is TGF-� 1, which 
enhances fibroblast proliferation by myofibroblasts, formation and migration, extracellular 
matrix deposition, and survival ( 103, 104). Next to disturbances in the balance between 
oxidants and anti-oxidants and proteases and anti-proteases, disturbances in tissue repair may 
also contribute to the development of COPD, especially in emphysema (75). 
Several lines of evidence suggest that inadequate repair contributes to the development 
of emphysema. First the extracellular matrix proteoglycans decorin, biglycan and heparan 
sulphate are decreased in the peribronchial area and lung parenchyma of patients with 
emphysema compared to healthy controls [ 125) .  This interstitial loss of proteoglycans may be 
crucial for the loss in elastic recoil and subsequent bronchiolar obstruction. Proteoglycans also 
have a regulatory role in inflammation and repair, as reflected by their various cytokine-binding 
capacities ( 105, 126 ). Loss of these binding capacities may enhance local inflammation and 
disturb repair. Furthermore, cigarette smoke can inhibit elastin cross-linking in vitro ( I 27), 
which might result in insufficient repair of elastin fibres in the ECM. Second, since fibroblasts 
play a pivotal role in tissue repair, altered fibroblast function could also be responsible for 
insufficient tissue repair in emphysema. Noordhoek et al (76) have shown that fibroblasts from 
emphysema patients have decreased proliferative capacity and that fibroblasts from patients 
with severe emphysema produce less decorin after cytokine stimulation (78). Furthermore, 
cigarette smoke can directly impair fibroblast function and can induce fibroblast cell death 
(79, 83, 128, 129). Both may result in insufficient repair of the ECM. 
The concept that insufficient tissue repair contributes to the development of COPD is as 
follows: dysfunction of fibroblasts in emphysema patients either intrinsically or induced by 
epigenetic factors may result in inadequate production of extracellular matrix proteins, either 
qualitatively or quantitatively. This also will affect the regulation of matrix bound cytokines. 
The dysfunction of fibroblasts will probably only become apparent after chronic exposure to 
smoke, in the situation that they are stimulated to a repair response (75). 
Cell death 
In general there are two principal forms of cell death: apoptosis and necrosis [ 130). Necrosis is 
pathological cell death with destruction of the cell membrane and release of cellular contents. 
This pathway of cell death may result in considerable local tissue damage. Apoptosis is 
physiological cell death that occurs as a result of an internally controlled 'suicide' program 
with remaining intact cell membrane and without release of (potential damaging) contents. 
Thereafter, the apoptotic cells are removed with minimal interruption of the surrounding 
tissue. Two main pathways are involved in the induction of apoptosis. First, receptor­
mediated apoptosis, which is initiated by binding death receptors, like Fas and TNF-a acts 
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via the activation of the caspase cascade, which ultimately activates the effector caspase-3. 
Second, mitochondria mediated apoptosis, which is initiated by stimuli as oxidative stress 
and ultraviolet (UV) radiation, results in depolarisation of the mitochondrial membrane and 
ultimately activation of the effector caspase-3. Cigarette smoke may impair apoptotic cell 
death by inhibiting formation of mitochondrial ATP, necessary for apoptosis, thereby changing 
an apoptotic stimulus into a necrotic death, with corresponding increased tissue damage. This 
type of cell death has been shown for both epithelial cells ( 1 3 1 )  and fibroblasts (83, 128 ). 
In this context, fibroblast cell death may contribute to insufficient tissue repair in emphysema, 
since decreased numbers of fibroblasts in the lung may delay or impair repair of damaged 
tissue by cigarette smoke. Furthermore, cigarette smoke induced necrosis of fibroblasts may 
even enhance local inflammation and contribute to the ongoing destruction of the alveolar 
walls. 
1 .5 Tools to investigate airway inflammation 
Airway inflammation can be investigated by several invasive and non-invasive techniques. 
The introduction of the fiberoptic bronchoscope in the early seventies has facilitated invasive 
research of the airways and has contributed to the understanding of the pathology of COPD. 
Biopsies obtained with the bronchoscope have provided information on inflammatory cells 
and structural changes in the airway walls and the lung parenchyma in COPD. BALF can be 
used to investigate inflammatory cells and mediators in the airway lumen and more distally 
in the alveoli. Since the inflammatory parameters in BALF correlate only moderately with 
those from bronchial biopsies ( 132), these tools thus provide different information. Though 
both BALF and biopsies provide information needed to better understand the pathology of 
COPD, the invasiveness of both tools makes them less feasible for large-scale diagnostic and 
follow-up studies. 
In the past decade, less invasive techniques have been developed to investigate especially 
inflammation of the larger airways, e.g. sputum induction, exhaled NO and breath condensate. 
Sputum induction constitutes an important method in this thesis and will therefore be discussed 
in more detail below. Exhaled breath contains volatile mediators like NO and CO and non· 
volatile substances in the liquid phase (e.g. Hp2 and nitrite), termed breath condensate. 
Exhaled NO measurements have been validated against measurements of inflammation by 
bronchoscopy and sputum in asthma ( 133), but not in COPD. NO measurements are thought 
to reflect both airway and alveolar inflammation depending on the flow used (134). Analysis 
of breath condensate is a promising new technique, which needs further methodological 
standardisation and validation before it can be used to monitor airway inflammation (135). 
1 .5.1 Sputum induction 
Since the 1990s sputum induction is used extensively to study airway inflammation in 
patients with asthma and later on also in patients with COPD. Sputum induction is performed 
by inhaling hypertonic or isotonic saline, resulting in the induction of airway secretions. The 
mechanism by which this occurs is not completely understood, but it may result from local 
differences in osmolarity. This may induce production of mucus, influx of inflammatory cells 
and an increase in vascular permeability (136). 
The technique of sputum induction consists of inhaling nebulised hypertonic or isotonic saline 
over different time periods. Subjects are instructed to expectorate into a container. Processing 
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is performed by using the whole specimen of sputum or by selecting sputum plugs, both being 
valid and reliable methods ( 1 37) .  Prior to sputum induction a 132-agonist is administered, in 
order to prevent bronchoconstriction that can be induced by hypertonic saline ( 1 38). 
Different protocols of sputum induction and processing are being used, which makes 
comparison between studies quite difficult. The European Respiratory Society (ERS) 
working group on sputum induction ( 1 36) has made several recommendations with regard 
to a universe protocol, concerning concentration of the inhaled saline, duration of saline 
inhalation, expectoration technique and frequency of sputum inductions. 
The major advantage of sputum induction is that it is a non-invasive, safe and validated 
technique ( 1 39- 142). Furthermore, it can be performed repeatedly provided that a certain 
time interval between the inductions is being used (5 1 ,  1 43). Since it correlates only 
moderately with inflammatory parameters in bronchial biopsies ( 1 44) it seems to reflect a 
different compartment in the lung and provides additional information to the biopsies. 
1.6 Anti-inflammatory treatment of COPD 
Several guidelines for the treatment of COPD are available, e.g. the American Thoracic 
Society, ERS and GOLD guidelines ( 1 ,  145, 146 ). A stepwise approach to therapy has been 
suggested by the recent update of the GOLD guidelines ( 1 ). Since the focus of this thesis 
is on the inflammatory aspects of smoking and COPD, we will discuss only the currently 
accepted anti-inflammatory therapies and the first step of management in COPD, i.e. smoking 
cessation. 
1.6. 1 Smoking cessation 
Smoking cessation at an early stage of the disease is the most important intervention to slow 
down lung function loss (figure 2) ( 147, 1 48) and it can also improve symptoms of cough and 
sputum production ( 149). Mrway hyperresponsiveness in ex-smoking COPD patients is lower 
compared to current smoking COPD patients ( 1 50, 1 5 1  }. Only few cross-sectional studies 
have investigated the effects of smoking cessation on airway inflammation in smoking and 
ex smoking COPD patients. They suggest a decrease or persistence of airway inflammation 
after smoking cessation (54, 1 52, 1 53) .  Recently, one longitudinal study has shown that 
smoking cessation improves bronchial hyperresponsiveness, but has no association with 
airway inflammation as assessed in sputum ( 1 54). 
Unfortunately, success rates of smoking cessation are rather small ( 1 55). Genetic and 
environmental factors contribute to the success rate of quitting smoking [ 1 56 }. Quit rates are 
larger when patients receive behavioural support and even more when patients are following 
an intense smoking cessation programme ( 1 57). Nicotine replacement therapy doubles quit 
rates compared to placebo and has even more effect when combined with behavioural support 
( 1 58). The antidepressant buproprion has also been shown effective in smoking cessation 
( 1 59) and even larger success rates are being achieved when this is combined with nicotine 
replacement therapy ( 1 60). 
1 .6.2 Inhaled corticosteroids 
The effect of inhaled corticosteroids {!CS) in COPD in the long run has been investigated 
in four large clinical trials ( 1 61 - 1 64), of which none has shown a long-term effect on lung 
function decline. However, a meta-analysis suggests that the use of !CS for more than 2 years 
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slows down the rate of lung function decline by 7. 7 ml per year, especially with a high dose of 
JCS (9. 9 ml per year) ( 1 65) .  Addition of JCS to a long acting bronchodilator improves FEV, as 
compared to bronchodilator therapy alone ( I 66- I 68). Furthermore, discontinuation of !CS is 
associated with a higher recurrence risk of exacerbations and a deterioration of quality of life 
( 1 69, 1 70). Since, JCS reduce the exacerbation frequency in COPD patients in stage GOLD 
III and N and increase quality of life ( 1 62, 1 7 1 ) , the GOLD guidelines recommend JCS in 
a subgroup of patients with repeated exacerbations, which are usually patients with more 
severe COPD (FEV1 <50% predicted}. Some short-term studies have shown anti-inflammatory 
effects of JCS, but most studies did not find this effect ( 1 72, 1 73). Whether these effects are 
associated with long-term beneficial effects on lung function remains to be investigated ( 1 74). 
In conclusion, there are currently no effective anti-inflammatory therapies available for 
patients with COPD to reduce the underlying airway inflammation and/or stop the excess 
decline of lung function and new anti-inflammatory strategies are needed. As outlined in prior 
paragraphs certain cytokines, such as TNF-a, seem to play a key role in the induction and 
maintenance of airway inflammation in COPD. Direct anti-cytokine therapy is therefore an 
interesting therapy to evaluate. 
Aims of the studies 
COPD is one of the leading causes of morbidity and mortality worldwide, and its prevalence 
is still rising. Since chronic smoking is the main risk factor to develop COPD most studies in 
this field have been carried out in chronic (ex} smokers with or without COPD. In order to 
understand the effects of chronic smoking, it is also important to study the very first response 
to cigarette smoke, since repetitive acute smoke effects may cumulate and ultimately lead 
to irreversible damage associated with COPD. In chapter 2 we reviewed the literature and 
identified 1 23 studies investigating the acute effects of cigarette smoking on inflammation 
and oxidative stress in human, animal and in vitro models. We reviewed similarities and 
discrepancies in the smoking response between the three model systems and discussed how 
these results relate to the current insights on the development of COPD. In chapter 3 we 
investigated the acute effects of smoking on inflammation in 16 healthy intermittent smokers 
in an open randomised cross over study. We assessed the time effects of cigarette smoking 
on both the induction and resolution of the inflammatory response in exhaled air, induced 
sputum, blood and urine. We hypothesised that smoking of two cigarettes would induce an 
increase in inflammatory cells and markers within a limited time interval. 
One of the hypotheses in the development of COPD is that tissue repair is disturbed after 
repeated smoke exposure. Fibroblasts are the most important cells in tissue repair in smoking 
induced COPD. Therefore we were interested in the effect of cigarette smoke extract (CSE} 
on human lung fibroblasts, especially in the induction of cell death. Furthermore we w�re 
interested if TGF-�1 and IFN-y, as representatives of the local environment of fibroblasts in 
emphysema lungs, could modulate CSE induced cell death. In chapter 4 we investigated the 
effect of CSE on the induction of cell death (apoptosis and necrosis) of human lung fibroblasts 
in absence and presence of TGF-� I and IFN-y. We hypothesised that CSE would induce 
apoptosis of fibroblasts, to be inhibited by TGF-� I ,  which in general is known to enhance 
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fibroblast function, whereas IFN-y, known to inhibit fibroblast function, would be expected 
to accelerate the process of cell death. 
TNF-a. is thought to play an important role in the induction and maintenance of chronic 
airway inflammation in COPD. No effective anti-inflammatory agents are currently available 
to reduce the underlying airway inflammation and/ or stop the excess decline of lung function. 
The anti-TNF-a.-drug infliximab has shown to be effective in other chronic inflammatory 
diseases such as Crohn's disease and rheumatoid arthritis. In chapter 5 we investigated the 
short-term effect of infliximab on clinical and inflammatory parameters, and also the safety 
and tolerability of this drug in 22 patients with mild to moderate COPD with a randomised 
double blind, placebo-controlled pilot study. We hypothesised that infliximab would attenuate 
neutrophilic inflammation in the airways of COPD and subsequently relief symptoms of cough 
and sputum production. Furthermore, we anticipated that infliximab would decrease resting 
energy expenditure induced by TNF-a.. 
Sputum induction is a safe, non-invasive, and validated technique to assess airway inflammation 
in asthma, COPD and healthy subjects. It is frequently used to monitor inflammation in 
clinical trials, yet some reports have shown a neutrophilic response when it is repeated within 
8 to 24 hours. This 'carry over' effect may limit its repeated use in clinical trials. In 
chapter 6 we investigated the induction and resolution of inflammation generated by 7 
repeated sputum inductions in 16 healthy volunteers. 
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Stage 
0: At Risk 
I: Mild COPD 
II: Moderate COPD 
Ill: Severe COPD 
IV: Very Severe COPD 
Table 1. 
GOLD classification of severity of COPD 
Characteristics 
• normal spirometry 
• chronic symptoms (cough, sputum production) 
• FEV/FVC < 70% 
• FEV1 ;c: 80% predicted 
• with or without chronic symptoms (cough, sputum 
production) 
• FEV/FVC < 70% 
• 50% � FEV1 < 80% predicted 
• with or without chronic symptoms (cough, sputum 
production) 
• FEV/FVC < 70% 
• 30% � FEV1 < 50% predicted 
• with or without chronic symptoms (cough, sputum 
production) 
• FEV1/FVC < 70% 
• FEV1 < 30% predicted or FEV1 < 50% predicted plus 
chronic respiratory failure 
Gold classification of severity of COPD 2005. 
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Figure 1 .  
Side stream and main stream smoke. 
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Figure 2. 
Effect of smoking and smoking cessation on FEV,. Reprinted from Fletcher et al (BMJ 1977) with 
permission from the British Medical Journal. 
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Abstract 
Rationale: Compared with the effects of chronic smoke exposure on lung function and 
airway inflammation, there are few data on acute effects of smoking. 
Methods: A review of the literature identified 1 23 studies investigating the acute effects 
of cigarette smoking on inflammation and oxidative stress in human, animal and in vitro 
models. 
Results: An acute smoking model is a relatively easy and sensitive method of investigating 
the specific effects of cigarette smoke on oxidative stress and inflammation. Acute smoke 
exposure can result in tissue damage, as suggested by increased products of lipid peroxidation 
and degradation products of extra cellular matrix proteins. Acute cigarette smoke has a 
suppressive effect on the number of eosinophils and several inflammatory cytokines, possibly 
due to the anti-inflammatory effect of carbon monoxide. 
Conclusion: An acute smoking model can supplement other ways of studying the effects 
of smoking and is an as yet underinvestigated method for intervention studies in smoking 
related diseases. 
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Introduction 
Chronic obstructive pulmonary disease (COPD) is a world-wide leading cause of morbidity 
and mortality and its prevalence is still rising ( 1 ). It is therefore important to understand the 
development of this disease in order to develop strategies of prevention, treatment, and cure. 
In the past decade research has focussed on the pathophysiological mechanisms underlying 
the development of COPD, yet several questions remain unanswered. 
Most studies investigating the role of smoking in the pathophysiology of COPD have been 
carried out in chronic smokers. The drawback of studying the effects of actual smoke exposure 
in persistent smokers is the likely effect of already developed structural changes in the airways 
on the response to smoke. It is therefore important to study the response to the first smoke 
exposure of a 'naiVe' lung in order to assess the relevant changes that may have a role in the 
first steps of COPD development. In addition, an acute smoking model could be attractive 
for future intervention studies. We hypothesise that an acute smoking model can give clear 
and more specific information about the pathophysiological mechanisms of smoking induced 
lung disease. 
In this paper we review the literature on the acute effects of smoking. We focus on human, 
animal, and in vitro models and systematically describe the effects of acute smoke exposure 
on the cellular response, specifically on oxidative stress and inflammatory mediators. We 
also review similarities and discrepancies in the smoking response between the three model 
systems and will discuss how these results relate to the current insights on the development 
of COPD. 
Methods 
MEDLINE, OLDMEDLINE, Winspirs and Cochcrane library databases were searched from 
their inception until October 2003. The language used was limited to English. Firstly, a 
database including all articles on the effects of smoking on pulmonary status was composed 
(keywords 'cigarette smoke, tobacco smoke' and all subheadings and 'lungs, pulmonary' and 
all subheadings). Secondly, a selection was made of the articles describing the acute effects 
of smoking (keywords 'acute'). Thirdly, all articles describing the acute effects of smoking on 
oxidative stress, inflammatory mediators and inflammatory cells in humans, animals, and in 
vitro models were selected. Fourthly, a specific search was done on oxidative stress (keywords 
'oxidative stress' and all subheadings). Acute smoking was defined as an effect measured 
during 24 hours after smoke exposure. It is explicitly mentioned when articles on chronic 
smoking or COPD have been used. Only studies describing mainstream cigarette smoke were 
included, the number of cigarettes smoked not being a selection criterion. 
Results 
Acute effects of cigarette smoke in humans 
Twenty-five studies examining the acute effects of cigarette smoking (ACS) were identified in 
humans (table 1 ), 16 on inflammation and 9 on oxidative stress. 
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All studies were performed in chronic smokers with normal lung function. In thirteen studies, 
smokers were instructed to refrain from smoking before the acute smoke exposure, varying 
between 7 and 24 hours. Ten studies did not provide information on this issue and in 2 
studies the subjects were not instructed to refrain from smoking. 
Inflammatory cells 
In chronic smoking, the numbers of neutrophils are increased in the blood and broncho­
alveolar-lavage fluid ( BALF) (2-4). With ACS both increased (5) and unchanged numbers 
of neutrophils have been reported in BALF (6) . Acute smoke exposure had no effect on 
the number of monocytes or the total number of leukocytes in BALF (6) . Peripheral blood 
neutrophil granulocytes increased (figure I )  (7-9), whereas peripheral blood eosinophils 
decreased after ACS (8). ACS has different effects on subsets of blood lymphocytes: the 
number of CD 19 positive B-cells (7) and the total number lymphocytes were depressed by 
ACS (8), while the number of CD3 positive cells and the CD4/CD8 ratio did not change (7). 
In capillary blood (finger) the total number of basophils decreased ten minutes after smoking 
2 cigarettes ( 10) and the number of degranulated basophils increased ( 1 1  ) .  
Neutrophil kinetics in the lungs can be examined by measuring the removal of radio labelled­
neutrophils during the first passage through the pulmonary circulation. MacNee et al showed 
increased neutrophil retention in the lungs after ACS using this method (12). This increased 
neutrophil retention was not due to differences in pulmonary hemodynamics ( 13), but may 
result from decreased deformability of leukocytes ( 14) or increased expression of adhesion 
molecules L-selectin on blood neutrophils after ACS ( 1 5) .  
Epithelial permeability as measured by 99m Tc-DTPA lung clearance ( 16) can be used to 
assess the disturbance of the airspace epithelial barrier. ACS increased epithelial permeability 
in chronic smokers after I hour to levels higher than in non-smokers (5). However, Gil et al 
( 17) showed no difference in epithelial permeability 15 minutes after ACS in chronic smokers. 
Endothelial permeability, as measured by radio labelled urea, decreased after ACS (18), but 
could not be detected when measured by PET scanning using radio labelled transferrin [ 19) . 
Oxidative stress 
The acute effects of cigarette smoking on markers of oxidative stress have been analysed in 
exhaled air, BALF and blood. Most studies showed an immediate increase in oxidative stress 
after ACS, but in several studies smoking had no effect (table I ) . 
Five studies have described the effects of ACS on oxidative markers in breath condensate and 
exhaled air. In breath condensate, 8-isoprostane, a lipid peroxidation product, increased 15 
minutes after ACS (figure 2) (20) and hydrogen peroxide increased 30 minutes after smoke 
exposure (21 ) .  Exhaled Nitric Oxide (eNO) increased at I and 10 minutes (22), but decreased 
5 minutes after ACS in another study (23). This inconsistency probably reflects differences 
in eNO measurements and subject characteristics. No difference in eNO was observed at 15 
(23), 30 and 90 minutes (24) after smoking. Breath condensate levels of nitrate increased 30 
minutes after ACS, but nitrite and nitrotyrosine levels did not change (24). 
One study (5) has investigated the effects of smoking on markers of oxidative stress in 
BALF, showing increased superoxide release from BALF leukocytes and an increased trolox 
equivalent anti-oxidant capacity ( TEAC). This latter surprising result can be explained by 
the fact that the subjects studied were all chronic smokers, associated with already high 
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BALF levels of the TEAC. No difference was seen in intracellular reduced glutathione (GSH) 
or oxidised glutathione (GSSG) in leukocytes and in thiobarbituric acid reactive substances 
(TBARS] in BALF and the epithelial lining fluid (ELF] . 
In peripheral blood, nitrate, nitrite and cysteine levels were depressed for a short time after 
smoking only one cigarette (25). No difference was observed in the production of reactive 
oxygen intermediates from neutrophils (7). In contrast to BALF, TBARS in plasma increased 
(26) and TEAC in plasma decreased I hour after smoking (5, 26). Levels of F2-isoprostane, 
another lipid peroxidation product, did not change in plasma (27), possibly because all subjects 
in this study were chronic smokers and already had high F2-isoprostane levels. 
lnjlammato,y mediators 
Six studies have investigated the effects of ACS on inflammatory mediators and generally 
have found increased activity and recruitment of neutrophils and macrophages. In BALF, 
elastase activity increased (6) and leukotriene B4 (LTB4) release from alveolar macrophages 
(AMs) decreased I hour after smoking (28). 
In plasma, neutrophil elastase (NE) was increased immediately (14) and I hour after ACS 
(figure 1 )  (9). Leukotrienes B4, D4 (LTD4) and E4 (LTE4] increased in peripheral blood 
immediately and 20 minutes after ACS and their levels were positively correlated to C3a and 
C5a concentrations (29). LTE4 in urine increased two fold after smoking 6 cigarettes (30). 
Acute effects of cigarette smoke in animal models 
We have identified 37 studies examining the acute effects of cigarette smoke in animal models 
(table 2), 31 on inflammation and six on oxidative stress. 
Most studies have been performed in guinea pigs (n=l l ), mice (n= IO), and rats (n=I 0). 
Five different methods of smoke exposure were used: nose only inhalation, nose and mouth 
inhalation, intratracheal inhalation, inhalation by anaesthesia mask and inhalation via a 
smoking chamber. The cigarette brand differed between the studies as did the amount of 
smoke inhaled, ranging from 3 puffs to 30 cigarettes (table 2). 
lnjlammato,y cells 
ACS predominantly increases AMs and neutrophils in animal lung tissue and BALF (table 2). 
In lung tissue the volume fraction of AMs in the lung parenchyma (31) and the number of 
neutrophils in the airway wall (mucosa and outer adventitia) were increased within 6 hours 
after ACS (31-33). The number of mast cells in the airways was also higher 6 hours after ACS 
(32). The opposite was true for the number of eosinophils, which were decreased 6, 12, and 
24 hours after smoking (32). 
In BALF most studies except three (34-36), showed increased numbers of AMs immediately 
(37-39), 1 hour (37, 38, 40), 6 hours (40), 8 hours (41), and 24 hours after ACS (40, 42, 43). 
The phagocytic capacity of AMs, which is important for host defence, decreased immediately 
after ACS (38, 44, 45) and had returned to normal 12 hours later (38). The viability of AMs in 
BALF also decreased after smoking (46). The number and percentage of neutrophils in BALF 
were increased after I hour (40, 47), 6 (40, 48), 15 (49) and 24 hours (34, 35, 40-43, 50). 
In contrast, 4 studies did not find a smoke effect on polymorphonuclear cells (PMNs) either 
immediately (36, 37, 39), or at 1 hour (37, 49) and 24 hours (49). This discrepancy may be 
explained by differences in animal species, inhalation methods, or cigarette dose. Dhami et 
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al (34) found that the number of neutrophils in mice had returned to normal after 48 hours. 
Both neutrophil and monocyte chemotaxis were reported to be higher I hour after smoke 
exposure than in sham exposed control animals (48). 
All studies but two (51, 52) showed increased epithelial permeability after ACS within 30 
minutes (32, 39, 53-56) and 6 hours (40). In two studies (32, 40) normalisations of epithelial 
permeability were observed after 24 hours. Two different explanations have been put forward 
for the enhanced permeability: damage to the epithelial cell membrane (32, 53, 54, 57) or 
enlargement of the spaces between the epithelial cells (54). The epithelial permeability was 
further increased after Ibuprofen administration (53), suggesting a role for arachidonic acid 
metabolism. 
Oxidative stress 
The acute effects of smoke inhalation on markers of oxidative stress in animals have been 
reported in lung tissue, BALF and blood (table 2). Most studies showed a direct increase in 
oxidative stress after ACS. 
In lung tissue of rats, the amounts of GSH decreased immediately (35, 58) and I hour after 
exposure to smoke (40, 59). After 2 to 6 hours GSH levels had either returned to normal 
(58, 59) or were higher than baseline (35). GSSG increased at I hour, decreased at 6 hours, 
and normalised at 24 hours after ACS (40). ACS did not influence the amount of cysteine, 
an essential amino acid for the synthesis of GSH (59), but it increased several other markers 
of oxidative stress in lung tissue, including 8-OHdG, 4-HNE (35, 60), inducible nitric oxide 
synthase (iNOSl mRNA and endothelial nitric oxide synthase (eNOS) mRNA (6 1 ). 
In BALF extracellular GSH was shown to be reduced either immediately (59), I hour, or 6 
hours after smoke inhalation (40). After 24 hours GSH concentrations returned to baseline 
levels (40). ACS also depleted intracellular GSH concentrations (59). It increased GSSG levels 
(36) and 8-OHdG levels (60), and decreased BALF levels of TEAC (36). 
In blood, no effect from smoke inhalation has been observed on GSH (59). However, ACS 
decreased the anti-oxidants methylumbelliferone glucuronide and ferroxidase (35, 62) and 
increased lipid peroxide and 8-epi-PGF2a, markers of lipid peroxidation in blood (36). 
Inflammatory mediators 
The acute effects of smoke inhalation on inflammatory mediators in animals have been 
described in lung tissue, BALF, and blood (table 2). 
In lung tissue, tumor necrosis factor a (TNF-a), macrophage inflammatory protein 2 (MJP-2) 
and macrophage chemoattractant protein 1 (MCP-1) gene expression increased 2 hours after 
smoke inhalation and normalised 6 hours thereafter (42, 50, 63). Lung TNF-a was increased 
at 2, 6 and 24 hours, and E-selectin was increased at 6 and 24 hours (63). 
In BAU; complement factor 3 increased I hour after ACS (48) and TNF-a release from AMs 
was augmented after 8 hours (41). In contrast, LT B4, another important chemoattractant, 
decreased directly after ACS (53). Pessina et al (64) showed that interleukin (JL)-6 was 
partially degraded after ACS. 
One study showed an increase in the elastase inhibitory capacity (EiC) in BALF after ACS 
(49), but two other studies showed a decrease in the EiC in BALF (65) and plasma (35). 
Furthermore, Churg et al (34, 42, 43, 50) showed a consistent increase in desmosin and 
hydroxyproline, both degradation products of the extra cellular matrix, in BALF of smoke 
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exposed animals after 6 and 24 hours (figure 3). The above findings suggest that acute smoke 
exposure can result in damaging effects on lung tissue. 
Only two studies have been published on effects of smoke exposure on blood inflammatory 
mediators, showing an increase in myeloperoxidase (MPO) (66) but no changes in LTB4 
levels (53). 
The acute effects of cigarette smoke in in 11itro models 
Sixty-two studies examining the acute effects of cigarette smoke in in vitro models were 
identified (table 3), 50 on inflammation and I 2 on oxidative stress. 
Many different cells and cell lines have been used in acute smoke experiments 1 table 3). The 
following cells were most frequently described: AMs [n= 12), type II alveolar epithelial cell 
lines (A549, n= I0) and PMNs (n=I 0). 
The methods of cigarette smoke exposure used were different between the studies. Fifty­
three studies used a cigarette smoke extract (CSE) and 1 4  used whole cigarette smoke (CS). 
The concentration of CSE and the time of exposure differed considerably between the studies 
with concentrations varying between 8- 1 0·5 cigarette/ml to 4 cigarette/ml and exposure 
times varying between I second and 24 hours, respectively. 
Inflammatory cells 
In vitro studies have shown various effects of CS and CSE on different cell characteristics, 
which may provide useful information to enable a better understanding of the effects of 
smoking in vivo. Neutrophil and monocyte chemotactic activity of supernatant of epithelial 
cells and fibroblasts incubated in CSE for 3-24 hours increased (67-69). This increase 
diminished after lipoxygenase inhibitors and arachidonic acid metabolite inhibitors had been 
added (67-69). In contrast, the chemotactic response of blood PMNs exposed directly to 
CS or CSE appeared to be decreased (70) or unchanged (71 ). This suggests that CSE has an 
indirect effect on PMN chemotaxis. 
Adhesion of human PMNs to a type II alveolar epithelial cell line decreased directly after 
exposure to CS (71 ), but adhesion of human PMNs to a primary bovine bronchial epithelial 
cell line (BBEC) increased after incubation in CSE for 24 hours (72). The adhesion of human 
monocytes to human umbilical vein endothelial cells (HUVEC) and human bronchial 
epithelial cells (HBEC) was also increased when incubated in CSE (73, 74). This might result 
from an increased expression of adhesion molecules CD 1 1  b, intercellular adhesion molecule 
I (!CAM- I ), endothelial leukocyte adhesion molecule I (ELAM-I ), and vascular cell adhesion 
molecule I [VCAM-1) (73, 75). The expression of CD 1 8  on human PMNs was increased in 
one study (76) but remained unchanged in another (71 ). Surprisingly, ACS decreased the 
expression of L-selectin on PMNs (76). 
The phagocytic capacity of AMs, peritoneal macrophages (PMs) and PMNs was shown to 
decrease during CS exposure and 30 minutes, 2, and 24 hours after exposure to CS (77-80). 
Increased phagocytic capacity of mice AMs was seen after exposure of only a low dose of CS 
(77). The protein synthesis of rabbit AMs was depressed directly after CSE exposure and was 
restored after 24 hours ( 8 I ,  82). 
ACS can affect the function of fibroblasts in vitro. CSE inhibited the proliferation of human 
fetal lung fibroblasts (HFL-1) (83), decreased fibronectin release (84, 85), viability and protein 
synthesis of fibroblasts (81, 86) and depressed fibroblast collagen mediated gel contraction, a 
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model for wound repair (84, 85). 
The viability of alveolar epithelial cells, AMs and PMs decreased after ACS in a concentration 
and time dependent way (46, 77, 79, 87). Primary murine fibroblasts were less susceptible to 
cell death induced by CSE than murine AMs (46). Six studies have shown that CSE resulted 
in apoptosis within 3-24 hours in different cell types (86, 88-92). However, Wickenden et 
al [93) showed that CSE exposure only induced necrosis. This might partly be explained 
by the fact that different cell types and CSE concentrations were used. Interestingly, two 
studies showed that exposing cells to low concentrations of CSE induced apoptosis while high 
concentrations resulted in necrosis (9 1 ,  92). 
Two studies (94, 95) on epithelial permeability in vitro showed an increase at 20 minutes and 
l hour after exposure to CS and CSE. Gluthatione reduced this effect (95 ), suggesting that 
oxidants contribute to the increase in epithelial permeability. 
Other interesting acute effects of CSE have been found. Firstly, CSE inhibited surfactant 
secretion of alveolar type II cells after 20 minutes of exposure [96). Pinot et al [97) showed 
that surfactant can prevent oxidative stress induced by CSE in vitro. These results have 
clinical relevance since surfactant is important in maintaining alveolar stability and plays 
a role in alveolar clearance and also though less prominently in bronchial clearance. 
Secondly, Takeyama et al (98) showed that CSE increased mucin synthesis by a pulmonary 
mucoepidermoid cell line already within 24 hours. This suggests the possibility of a rapid 
upregulatory mechanism of mucus production in vivo in chronic smokers. A decrease in 
mucus flow on ciliated epithelium was seen within minutes of exposure to CS (99). 
Oxidative stress 
Twelve studies have investigated the effect of ACS on oxidative stress, all showing an increase 
in oxidative stress after exposure to CS. GSSG was released after 30 minutes ( 1 00) and 
intracellular GSH was decreased within 3 hours after ACS exposure (86, 95, l 01 ). When 
measurements were performed 24 hours after exposure, GSH and y-GCS were in fact 
increased, suggesting a protective mechanism of cells against oxidative stress from smoke 
( l 02). Immediately after 6 puffs of smoke, hydrogen peroxide and superoxide molecules from 
CS were detectable along the membranes of epithelial cells ( 1 03), which were prevented 
by anti-oxidants. After 24 hours of incubation with CSE, nitric oxide (NO) was released 
from endothelial cells (88). In contrast, iNOS expression and nitrate release from stimulated 
epithelial cells were decreased after CSE exposure ( 1 04). The pentose phosphate pathway, 
the source of NADPH for the enzyme gluthatione reductase, was activated after incubation of 
endothelial cells with CSE [ 1 00). 
Inflammatory mediators 
All studies but one ( 1 5, 1 05) showed an increased release of IL-8 in various cell types after 
different exposure times to CSE (20 minutes in HBEC ( l 05), 4 and 8 hours in human 
endothelial cells ( 1 06), 6 hours mRNA IL-8 in NCI-H292 [ 1 07), 1 2  hours in HBEC ( 1 08) and 
24 hours in HBEC, and A549 cell line [ l 08, 1 09). The results of the two negative studies 
might be explained by the low concentrations of CSE, the use of CS instead of a CSE, or by 
different cell types used. 
Inconsistent results were also found for IL- I 13, TNF-cx and soluble !CAM (s!CAM): IL- 1 13  and 
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s!CAM were increased in HBEC 20 minutes, I hour and 24 hours after exposure to CS 
(94, 1 05) ,  but were decreased when HBEC were exposed for 3 and 6 hours ( I  05). IL· I �  
and TNF-a release was increased when peripheral blood mononuclear cells (PBMCs) were 
exposed for 5 minutes ( 1 I 0), but decreased after 3 hours of exposure ( 1 1 1  ). TNF-a release 
from AMs was decreased when exposed for I hour at low concentrations ( 1 1 2), but increased 
when exposed 1 8  hours with higher concentrations of CSE (63). CSE had no effect on s!CAM 
release from HUVEC at 24 hours ( I  1 3) .  MRNA expression of IL-8, IL- I �  and s!CAM was 
increased after 30 minutes of incubation of HBEC in CSE ( 1 1 4 ) .  
Cigarette smoke has been shown to have a depressive effect on some other inflammatory 
mediators in vitro. The release of LTB4 from AMs (28) and interferon-y (IFN-y) and IL-2 ( 1 1 1 )  
from human PBMCs was less after incubation in CSE. The activity of both IL-6 and TNF-a 
secreted by AMs was diminished after exposure to CS ( 1 1 5) .  CSE had no direct effect on the 
release of NE from human blood PMNs in vitro ( 1 1 6) .  
Discussion 
Smoking is  the main risk factor for the accelerated decline in  lung function and development 
of COPD. Much is known of the effects of chronic smoke exposure on lung function and 
airway inflammation, but there is a paucity of data on the acute effects of smoking in this 
respect. It seems important to know these effects since repetitive acute smoke effects may 
constitute the underlying causal chain leading to the ultimate chronic effects. 
We identified 1 23 studies investigating the acute effects of CS on inflammatory cells, oxidative 
stress, and inflammatory mediators in humans, animals and in  vitro models. Various cigarette 
brands with and without a filter and different doses have been studied, ranging from I puff to 
30 cigarettes. Different time points and several body compartments in humans and animals 
have been investigated. An extensive collection of information has been acquired, yet of 
various natures. 
One of the problems in the comparison of the various studies is the difference in the way 
human, animal, and in vitro models have been exposed to smoke. Firstly, even though 
animals have a much smaller lung surface than humans, this review shows that animals are 
exposed to a higher number of cigarettes than humans (median of 5 cigarettes (range 0.9-34) 
vs. median of 2 cigarettes (range 1 -24) ) .  Secondly, in vitro studies mainly used CSE, whereas 
all humans and almost all animals were exposed to CS. The composition of CSE and CS has 
important differences regarding the water insoluble substances and free radicals ( I I 7- 1 1 9) .  
Thus, the results of different models cannot simply be compared. 
In this review we have provided data that are of interest and importance to the damaging 
effects of smoke in diseases in general. We have shown that ACS is chemotactic to neutrophils 
and macrophages and activates these cells. Furthermore, acute smoke exposure results in 
tissue damage, as suggested by increased products of lipid peroxidation and matrix degradation 
products. A very intriguing finding was the suppressive effect of ACS on the number of 
eosinophils and several inflammatory cytokines. It may well be that this suppressive effect 
results from the anti-inflammatory carbon monoxide (CO) present in cigarette smoke or as 
produced by inflammatory cells in the lung ( 1 20). 
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Inflammatory cells 
This review shows that neutrophils are already attracted and activated after the first puffs of 
CS in both human and animal studies. In line with this, increased neutrophil chemotactic 
activity of supernatant of epithelial cells exposed to CS was observed in vitro. 
ACS induces increased numbers of AMs in animal lung tissue and BALF, but not in human 
BALE This may be due to the short time interval or the low dose of smoke used. Furthermore, 
increased monocyte chemotactic activity of BALF and supernatant of epithelial cells exposed to 
CS was observed. Eosinophils seem to play a role in a subgroup of patients with stable COPD 
( 1 2 1 )  and in those with exacerbations ( 1 22) . ACS directly increased eosinophil numbers in 
animal BALF (37) . Intriguingly, two other studies (8, 32) have shown a suppressive effect 
of smoke on the number of eosinophils in human blood and in animal tissue. This may be a 
reflection of local shifts in the Th 1 -Th2 type cytokine balance or an anti-inflammatory effect 
of substances in smoke, such as CO ( 1 23, 1 24). 
The effect of ACS on apoptosis and necrosis has mainly been investigated in in vitro studies. 
Interestingly, two studies showed that exposure of cells to low concentrations of CSE induced 
apoptosis, but that high concentrations of CSE resulted in necrosis (9 1 ,  92). Because apoptosis 
of (inflammatory) cells is associated with less damage of the extra cellular matrix, one might 
even hypothesise that smokers who smoke intermittently or only a few cigarettes per day are 
less likely to develop lung damage than those who smoke many cigarettes in a chain. 
ACS increased the air space epithelial permeability in human, animal and in vitro research. 
This increase was shown to occur within an hour after exposure to CS and returned to 
normal within 24 hours. Theoretically, impairment of the epithelial barrier may potentiate the 
damaging effects of noxious agents in the lung. 
ACS also inhibits the function of fibroblasts, which are important in repair processes in the 
lung. Injury and repair processes of airway epithelium have been studied extensively in 
chronic airway disease. It is assumed that these repeated injury and repair processes may 
contribute to the development of airway pathology in chronic inflammatory airway diseases 
( I 25 ). Repetition of acute smoke exposure may lead in this way to irreversible damage, 
especially if fibroblasts are not functioning normally. More studies on this subject should be 
performed to strengthen this hypothesis. 
Summarising, ACS increases local inflammation as reflected by an increase in the number of 
neutrophils and macrophages in the lung. It reduces important qualitative cell characteristics, 
repair mechanisms and the protection of the epithelial barrier. Furthermore, ACS results in 
a decrease in the number of eosinophils indicating a possible local shift in the Th 1 -Th2 type 
cytokine balance or an anti-inflammatory effect of CO. 
Oxidative stress 
ACS increases markers of oxidative stress in all three models (human, animal, and in vitro). 
NO and GSH are the only two parameters that have been investigated in all models. NO 
and its related substances increase within 24 hours after smoke exposure. The GSH/GSSG 
ratio, reflecting the vital balance between oxidants and protecting anti-oxidants, decreased 
following acute smoke exposure in both animal and in vitro studies, but not in the single 
study published in humans. This discrepancy can be explained by differences in species, 
smoke dose or compartment (human BALF versus animal lung homogenate) .  
Interestingly, ACS even results in damage of fatty acids in cell membranes, as measured by 
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an increase in degradation products of lipid peroxidation in humans (exhaled air and plasma) 
(20, 26) and animals (BALF and lung tissue) (35, 60). No in vitro studies investigating the 
acute smoke effects on lipid peroxidation products have been found. 
Because different time points within 24 hours have been studied, it allowed us to observe 
a time response of oxidative stress. In humans all oxidative markers increased within the 
first hour after ACS and most markers normalised within 90 minutes. Exhaled air is the first 
compartment in which an increase in oxidative stress markers can be observed, followed by 
BALF and blood. In animals, most markers of oxidative stress change in the first six hours 
after ACS exposure and return to normal within 24 hours. In all compartments (lung tissue, 
BALF, and blood) GSH or its derivates are depressed in the same time period, suggesting a 
generalised response to ACS. As in humans, only a few time points have been studied in in 
vitro models. The initial depletion of GSH after ACS appeared to be followed by an increase of 
GSH 24 hours later, suggesting a protective mechanism of cells against oxidative stress from 
smoke ( I 02). The importance of the GSH/GSSG balance was shown in several studies. When 
GSH was added to the experiment the oxidative stress and inflammatory response induced by 
cigarette smoke could be prevented. 
In summary, ACS immediately increases markers of oxidative stress in all models and it even 
results in damage of the cell membrane. The GSH/GSSG balance plays an important role in 
the acute protection of the lung against oxidants in CS. 
Inflammatory mediators 
ACS induces a wide range of (pro)inflammatory responses. All three models (human, animal, 
and in vitro) studied the effect of ACS on NE, leukotrienes, and IL-6. Interestingly, NE was 
released only within a few hours after a low dose of CS, both in animals and in humans. In 
contrast, direct exposure of human PMNs in vitro for 4 minutes did not affect the release of 
NE. This suggests that CS does not affect NE release by neutrophils directly, indicating that 
the local microenvironment may have a role in mounting this response. Another explanation 
might be that the in vitro exposure time was too short to activate these cells. 
Inconsistent results have been shown of the effects of ACS on leukotrienes, with increased 
[human, in vitro), decreased (animal, in vitro), or no effects (animal). This could be due to 
differences in cigarette dose, cell type, or species under study (53). 
IL-6, which plays a role in innate and adaptive immunity, was also studied in all models. 
Alveolar macrophage IL-6 activity was decreased after in vitro smoke exposure, and IL-6 
degradation was increased in BALF of rats (64, 1 1 5) .  No effect of ACS was found on human 
blood levels of IL-6 [7), suggesting that ACS may have a depressive effect only locally in the 
bronchial tree or that is compensated for by IL-6 production by other cells. 
In vitro, ACS increased the release of IL-8 from epithelial and endothelial cells and cell lines. 
This is in line with the observed increase in neutrophils after ACS in humans and animals, 
which suggests that IL-8 is a chemoattractant for neutrophils after ACS exposure. 
A suppressive effect of ACS was seen in some inflammatory mediators in vitro (TNF-a, IFN-y, 
LTB4 and IL-2) (28, 1 1 1 ,  1 1 2, 1 1 5) .  This suppressive effect may result from CO from CS or 
CO produced by heme oxygenase- 1 (HO- I )  in inflammatory cells in the lung ( 1 20). 
In summary, ACS can disturb the balance between proteases such as NE and their inhibitors, 
possibly resulting in early tissue damage. In addition, it increases IL-8, which may contribute 
to chemotaxis of neutrophils as found after ACS. Interestingly, ACS has a suppressive effect on 
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some inflammatory mediators, possibly due to the anti-inflammatory effect of CO_ 
Susceptible smoker 
A vital question when investigating the development of COPD is how to pinpoint the 
susceptible smoker. Differences in smoke exposure and genetic factors do not give the 
complete answer. In this review we describe an acute decrease in the GSH/GSSG ratio after 
smoke exposure. This decrease puts the smoker at risk to oxidants of CS soon after the first 
exposure. The extent and velocity to which the GSH/GSSG balance is restored probably 
determines to some extent the degree of susceptibility. The balance between proteases and 
anti-proteases may also have a role, but studies performed to date have shown contradictory 
results. One study showed that NE and EiC in animal BALF increase simultaneously after 
smoke exposure, suggesting a protective mechanism. Yet, acute smoke exposure in three other 
studies showed an increase in the matrix degradation products desmosin and hydroxyproline 
in animal BALE This supports the hypothesis that the ability to maintain the balance between 
proteases and anti-proteases is of vital importance for protecting the lung against proteolysis. 
Finally, a polymorphism in the H0-1 promoter region has been described in patients with 
COPD, resulting in a lower production of HO-I (126). This review shows that ACS decreases 
the number of eosinophils and some inflammatory mediators, which might be caused by the 
anti-inflammatory CO produced locally by H0-1 in the lung. One might hypothesise that, in 
smokers, H0-1 expression is important for the susceptibility to develop COPD. More studies 
on acute smoking with larger groups should be performed to further unravel this complicated 
but very important issue. 
Conclusions 
This review shows that an acute smoking model i s  a relatively easy and sensitive method 
for investigating the specific effects of cigarette smoke on oxidative stress and inflammation. 
We have shown that ACS is chemotactic to neutrophils and macrophages and activates 
these cells. An intriguing finding was the suppressive effect of ACS on the number of 
eosinophils and several inflammatory cytokines, possibly explained by a local shift in the 
Th I -Th2 type cytokine balance or by the anti-inflammatory effect of CO. Importantly, even 
acute smoke exposure might result in tissue damage, as suggested by increased products of 
lipid peroxidation and degradation products of extra cellular matrix proteins. This review 
supports the view that an imbalance between oxidants and anti-oxidants, and between 
proteases and anti-proteases may play an important role in the susceptible smoker, and it 
has become clear that disturbances in effective tissue repair also deserve attention (figure 4). 
It is, however, difficult to draw firm conclusions because of the small sample sizes studied, 
essential differences between human, animal, and in vitro models, and other methodological 
divergences. An acute smoking model is a useful supplement to other methods of studying 
the effects of smoking, and is an as yet underinvestigated method for intervention studies in 
smoking related diseases, such as COPD. 
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5 CS, 5 NS 
7 CS, 7 NS 
23 CS 
11 CS, 11 NS 
24 CS, 6 NS 
12 cs 
8 CS, 8 NS 
8 CS, 4 NS 
25 CS 
27 CS 
5 CS, 5 NS 
4 Female cs 
15 CS, 1 5  NS 
24 cs 
12  CS, 1 0  NS 
17 CS 
14 CS, 7 NS 
10  CS, 1 0  NS 
12 cs 
12 CS, 14 NS 
20 CS 
Acute effects of smoking; human studies. 
Design 
R (hrs); S (no); T (hrs) 
R: 8 S: 8 in 2 hrs T: 0.5, 1 ,  2 
R: 12 S: 2 T: direct 
R : ? S: 6 T: 12 
R : ? S: 1 T: 1 5  min 
R: ? S: 24 in B hrs T: during 
R: no S: 1 T: 30 min 
R: 12 S: 5 T: 0, 20 min 
R : ? S: 2 T: 0.5-1 
R: no S: 3-6 T: during 
R: 12 S:4 T: 10 and 30 min 
R: 12 S: 1 T: 5 min 
R: 7 S: 4 T:1 
R: 12 S :  2 T: 10 min 
R: 1 2  S: 1 -2 T: 10 min 
R : ? S: 1 T: 10 min 
R: 24 S: 12 in 3-4 hrs T: during 
R: ? S: 2 T: 0.5 and 1 .5 
R : ? S: 1 T: 1 , 1 0  min 
R :  10 S: 1 T: 30 min 
R :  8 S: 1 T: 5, 15 min 
R: 12 S: 2 T: 1 
R : 1 0  S: 3 T: 0.5 
R :  12 S: 2 T: 15 min, 5 
R : ? S: 1 T: 1 
R : ? S: 1 T: 5 and 30 min, 1 
Definition of abbreviations: CS: cigarette smokers; NS: non-smokers; R: time refrained from 
cigarette smoking (hrs); S: number of cigarettes smoked ; T: time between smoke inhalation and 
measurements (hrs) 
AMs: alveolar macrophages; BALF: broncho-alveolar lavage fluid; eNO: exhaled nitric oxide; EP: 
epithelial permeability; GSH: reduced gluthatione; GSSG: oxidised gluthatione; IL: interleukin; 
LTB4: leukotrien 84; LTD4: leukotrien 04; LTE4: leukotrien £4; NE: neutrophil elastase; PGE2: 
prostaglandin £2; RBC: red blood cell; ROI: reactive oxygen intermediates; TEAC: trolox equivalent 
anti-oxidant capacity; TBARS: thiobarbituric acid reactive substances. 
48 Chapter 2 
Effect of smoking 
Blood: NE i 1 hr, leukocytes and neutrophils i 1 and 2 hrs 
Blood: Leukocyte deformability J., NE i 
Urine: LTE4 i 
EP· = in CS 
Blood: Granulocytes i, CD19 cells J., CD3 cells =, CD4/CD8 ratio = ,  IL-1 =, IL-6 =, PGE2 =, sCD14 =, ROI = 
Endothelial permeabllityt = 
Blood: LTB4, LTD4 and LTE4 i, correlated positively to C3a en C5a 
BALF: Elastase i, neutrophils =, monocytes =, leukocytes = 
Out wash of neutrophils* J. 
Blood: Granulocyte L-selectin expression i 10  and 30 min 
ABC transit time across the mid and lower part of the lung J. 
BALF: AM release of LTB4 J. 
Blood: Basophils J. 
Blood: Basophilic degranulation i 
Endothelial permeabllity5 i 
Blood: Lymphocytes J., eosinophils J., neutrophils i after 2.5 hrs 
Breath condensate: Nitrate + nitrite i 30 min, 90 min =, nitrite =, peroxynitrite = Exhaled air: ENO = 
Exhaled air: ENO i 
Breath condensate: H202 i 
Exhaled air: ENO J. 5 min, = 15 min 
BALF: Leukocytes 02· i, TBARS =, TEAC i, GSH =, GSSG =, Neutrophils i, Blood: TEAC J.,TBARS i, EP* i 
Blood: F2-isoprostane = 
Breath condensate: 8-isoprostanes i 15 min, = 5 hrs 
Blood: TEAC J., TBARS i 
Blood: Nitrate, nitrite, ascorbic acid, cysteine, methionine, uric acid 5 min J., 30 min = 
* Tc-DTPA-scan 
t PET 
t 111-/n labelled neutrophils 
§ Radioactive Urea 
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Table 2. Acute effects of cigarette smoking; animal studies. 
First author; 
Year of study 
Inflammation 
Abrams WR (1988)(49) 
Bosken CH (1991 )(66) 
Boucher RC (1980)(55) 
Burns AR (1989)(54) 
Churg A (2002)(43) 
Churg A (2002)(42) 
Churg A (2003)(63) 
Daffonchio L (1990)(37) 
Dhami R (2000)(34) 
Holt PG (1973)(46) 
Hulbert WC (1 981 )(32) 
lschizaki T (1996)(35) 
Janoff A (1979)(65) 
Kew RR (1985)(48) 
Kilburn KH (1975)(33) 
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Animals (no) 
Beagle dogs N= 12 
New Zealand White rabbits 
N= 5 CS, 5 NS 
Guinea pigs N= 10-1 5  
Guinea pigs N=  25 
C57BL/6 mice 
N= 4 CS, 4 NS 
C57BL/6 mice 
N= 5 CS, 5 NS 
C57BL/6 mice 
N= 3 CS, 3 NS 
Dunkin-Hartley guinea pigs 
N= ? 
C57BL/6 mice 
N= 5 CS, 5 NS 
C57 black inbred mice N= 10  
Camm Hartley guinea pigs 
N= 30 
Sprague-Dawley rats 
N=103, groups of 6-15 rats 
Sprague-Dawley rats 
N= 21 CS, 16  NS 
Sprague-Dawley rats 
N= 4 CS, 4 NS 
Syrian hamsters N = 3 
Smoke exposure 
S (no); E (hrs); T (hrs) 
S : 1 , 3 or 6 E: ? T: 1 , 4, 15 , 24 
S: 1 2  puffs E: 12 min T: 4, 7, 1 2  min 
S :  5 - 1 00 puffs E: ? T: direct 
S: 15 E: ? T: direct 
S:4 E: ? T: 24 
S: 4 E: ? T: 2, 6, 24 
S: 4 E: 1 T: 2, 6, 24 
S :  ? E: 10 min T: 5, 50 min 
S: 2 E:  ? T: 6, 24 
S :  30 E :  8 min T: direct 
S: 100 puffs E: ? T: 30 min, 1 ,  6 , 12 ,  24 
S: 5 E: 20 min T: 2, 6, 24 
S: 3 or 6 puffs E: ? T: direct 
S: 1 2  puffs E: 4 min T: 1 



















Effect of smoke exposure 
BALF: 3 and 6 cig: PMNs i 15 hrs, = 1 ,  4 and 24 hrs 
3 cig : Elastase/PMN J. 4, 15 hrs, = 24 hrs. 6 cig: EiC i 1 hr. 
Histology: PMNs retention in lungs i, PMNs retention in lowest lung slices i 
Blood: MPO i 4 and 7 min, = 1 2  min, EP" = 
EP1 i after 40 puffs and 100 puffs. EM: 1 00 puffs i intercellular spaces and 
structural changes in tight junctions of tracheal segments 
Lung tissue: Focal disruptions in type I pneumocytes, epithelial desquamation, 
transepithelial FITC-0 penetration, FITC-0 intracellular in type I pneumocytes, EP"i 
Lavage: PMNs, AMs, desmosin and hydroxyproline i 24 hrs 
No effect of smoke in MME knock-out mice, except AMsi 
Lung tissue: a-1 -antitrypsin i 24 hrs 
Lung tissue: TNF-a, MIP-2 and MCP-1 gene expression i 2 hrs, = 6, 24 hrs 
Lavage :  Desmosin, hydroxyproline, PMNs and AMs i 24 hrs 
No smoke effect in TNF-a receptor knock-out mice 
Gene expression 2 hrs: TNF-a i, MCP-1 i, MIP-2 i, 6 hrs: TNF-a = , MCP-1 = , 
MIP-2 i, protein: TNF-a i 2, 6, 24 hrs, E-selectin i 6 and 24 hrs, MMP-1 2 knock­
out mice no effect on gene upregulation, but inhibits effect on TNF-a and E-selectin 
BALF: 5 min: total cells i, neutrophils =, eosinophils i, macrophages i 
50 min : total cells i, neutrophils =, eosinophils =, macrophages i 
BALF: PMNs i 24 hrs, AMs = 24 hrs, desmosin i 6, 24 hrs, hydroxyproline i 6, 
24 hrs, serine and metalloelastase activity l Anti-PMN and a-1 AT: inhibit smoke 
effect on PMNs, desmosin, hydroxyproline and serine elastase activity 
Lavage: Viability AMs J. 
EP1: i 30 min, = 24 hrs . Histology: Exudate i 0.5-1 hr, = 6, 12 ,  24 hrs 
Cells expressed per mm epithelial cells: PMNsi 6 hrs, basal membrane J. 0.5-6 hrs, 
i 24 hrs, goblet cells J. 0.5-12 hrs, plasma cells J., eosinophils J. 6, 12 and 24 hrs, 
mast cells i 6 hrs, = 12 hrs 
Plasma EiC J. 2 hrs, = 6 and 24 hrs, plasma ferroxidase activity J. 2 hrs, = 6 and 24 
hrs, plasma lipid peroxide i 2 and 6 hrs, = 24 hrs 
Lung tissue: Lipid peroxide = 2 hrs, i 6 hrs, = 24 hrs, GSH J. direct, i 2 and 6 hrs, 
J. 24 hrs, GSH/GSSG ratio J. 2, 6 and 24 hrs 
BALF: Total cell count and neutrophils i 24 hrs, AM and lymphocytes = 24 hrs 
BALF: EiC a-1 AT J., after adding reducing agent recovery of 75% of EiC 
BALF: 1 hr: C3 i, PMNs i, monocytes i, leukocyte chemotactic activity i, 
prevented by depletion of complement 
Histology: Ratio PMN/100 epithelial cells time dependent i 6-24 hrs 
The acure effecrs of c13arerre smoke on 111JlanrntaC1on and ox1dauve srress: a review 51  
First author; Animals (no) Smoke exposure 
Year of study S (no); E (hrs); T (hrs) 
Inflammation 
Li xv (1996)(40) Rats N=1 6  S: ? E: 0.2 m l  CSC T: 1 ,  6 ,  24 
Mordelet-Dambrice M Wistar rats N = 28 CS, 28 NS S: 32 puffs E: 8-9 min T:1 5  min 
(1991 )(39) 
Nishikawa M (1990)(51) Hartley guinea pigs S: 5, 1 0  or 20 puffs E: ? T: direct, 5, 24 
N=  46 CS, 18 NS 
Ortega E (1994)(38) Swiss mice IFFA CREDO N= ? S: 1 E: 1 5  min T: direct, 1 ,  12 ,  24 
Ortega E (1993)(45) Mice N= ? S :  1 E: 1 5  min T: 1 
Pessina GP (1 993)(41) Out bred Wistar rats N= 12  S :  3 E :  1 T: 8 ,  24 
Pessina GP (1996)(64) Wistar rats N= 6 CS, ? NS S:3 E: ? T: direct 
Reznik-Schuller HM Syrian hamsters S : 20 puffs E: ? T: 1 
(1980)(57) N= 40 CS, 40 NS 
Simani AS (1974)(52) Guinea pigs N= 67 S :1 or 1 0  E: 24 T: direct 
Vitalls TZ (1998)(31 ) Guinea pigs N=  6 CS, 6 NS S :  5 E: 40 min T: direct 
Walker DC (1988)(1 27) Hartley guinea pigs S :1 5-1 00 puffs E: ? T: direct 
N= 30 CS, 5 NS 
Witten ML (1985)(56) New-Zealand white rabbits S: 5-30 breaths E: ? T: during 
N =12 CS, 6 NS 
Witten ML (1988)(53) Rabbits N= 6 CS, 6 NS S: 5-30 breaths E: ? T: direct 
Wright J (1990)(47) Guinea pigs N= 8 CS, 8 NS S: ? E: 1 5  min T: 15 min, 1 .5 
Wright JL (2002)(50) C57BL/6 mice N= 6 S: 4 E: ? T: 2 
Guinea pigs N=  5 S: 5 E: 3-4 T: 24 
Yamaya M (1989)(44) Mongrel dogs N= 40 S : 1 , 3, 5 or 9 E: ? T: direct, 7, 14 min 



















Effect of smoke exposure 
EP:j:: i 6 hrs, = 24 hrs 
BALF: AMs and PMNs i 1 ,  6 and 24 hrs, GSH j, 1 ,  6 hrs, GSSG i 1 hr, = 24 hrs 
Lung homogenate: GSH J, 1 hr, = 6 hrs, GSSG i 1 hr, J, 6 hrs, = 24 hrs 
EP§: i 1 5  min BALF: AMS i, PMNs = 
EP 11 : =  
Histology: Neutrophils and eosinophils in the trachea = 
Histology: AMs i direct and 1 hr, phagocytic index J, direct and 1 hr, = 12 hrs, % 
activated AMs i direct, phagocytic efficiency J, direct and 1 hr 
Adherence AMs = , chemotaxis AMs = , phagocytosis of Candida Albicans J, 
BALF: AMs i 8 hrs, PMNs i 24 hrs, TNF-a release from AMs i 8 hrs, IFN release 
from AMS = 
BALF: Degradation of IL-6 i 
EM: Haemorrhages, swollen cytoplasm and protrusions in the lumen of type I 
pneumocytes and endothelial cells. Occasionally the cell membrane was ruptured. 
EPt:= after 1 and 10 cigarettes. EM: Tight junctions i after 10 cig 
Lung parenchyma: AMsi Airway wall: PMNs i 
Histology: No increased HRP in epithelial tight junctions of tracheal segments 
EP!:i from 20 breaths. EM: Focal alveolar edema and haemorrhage, no alveolar­
capillary membrane damage 
EP!:i during smoking, Ibuprofen i EP. EM: Focal alveolar edema 
BALF: TxB2 i, 6keto PGF1a i, lymphocytes J,, LTB4 j, 
Blood: LTB4 =, TxB2 = , 6keto PGF1a i 
BALF: 1 .5 hrs: leukocytes =, PMNs i. Blood: 15 min: leukocytes and PMNs i 
Mice: Lung homogenate: MRNA MIP-2, MCP-1, TNF-a i 2 hrs. Plasma: TNF-a i 2 
hrs Guinea pigs: BALF: PMNs, desmosin, hydroxyproline i 24 hrs 
Neutrophil elastase inhibitor prevented smoke effects, except on TNF-a mRNA 
BALF: Cytoplasmic motility AMs i direct, = 7 min after 1 ,  3 or 5 cig 
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First author; Animals (no) 
Year of study 
Oxidative stress 
Aoshiba K (2003)(60) C57BL/6 mice N=6 
Bilimoria MH (1992)(58) Sprague-Dawley rats N=8 
Hartley guinea pigs N=? 
Cavarra E (2001)(36) C578L/6J mice 
N=35 CS, 70 NS 
Cotgreave IA (1987)(59) Sprague-Dawley rats N= ? 
Uotila P (1982)(62) Syrian hamsters N = ? 
Wright JL (1999)(61) Rats N= ? 
Table 2. 
Acute effects of cigarette smoking; animal studies. 
Definition of abbreviations: 
Smoke exposure 
S (no); E (hrs); T (hrs) 
S: 10 E: 1 T: 1, 3, 16,  24 
S: 40, 1 20, 240 puffs E: ? T: direct and : 
S: 5 E: 20 min T: direct, 20, 60 min 
S: 10 E: 1 T: direct 
Experiment 1 1: S: 5 E: 1 T: 20 
Experiment r: S: 12 E: 2 T: during 
S: 7 E: 2 T: 24 
S: number of cigarettes exposed (no); E: exposure time (hrs); T: time between smoke exposure 
and measurement (hrs); AM: anesthesia mask; IT: intra tracheal inhalation; N: nose-only 
inhalation; N&M: nose and mouth inhalation; SC: smoking chamber; SM: smoking machine. 
a-1 AT: a-1 antitrypsin; BALF: broncho-alveolar lavage fluid; CS: cigarette smoking animals; 
CSC: cigarette smoke condensate; EiC: elastase inhibitory capacity; EM: electron microscopy; 
EP: epithelial permeability; FITC-D: fluorescein isothiocyanate-dextran; GSH: reduced gluthatione; 
HRP: horseradish peroxidase; 1251-BSA= 125lodine labelled bovine serum albumin; IFN: 
interferon; MME: macrophage metalloelastase; NOS: nitric oxide synthase; 6keto PGF1a: stable 
metabolite of prostacycline, prostaglandin P; MCP-1: macrophage chemoattractant protein-1; 
MIP-2: macrophage inhibitory protein-2; MPO: myeloperoxidase; MUG: 4-methylumbelliferone 
glucuronide; NS:non-smoking animals; PMNs: polymorphonuclear cells; SLPI: secretory 
leukoprotease inhibitor; Tx82: stable metabolite of tromboxane A2 
54 Chapter Z 
Route of 
administration 







Lung tissue: 8-0HdG and 4-HNE i 1 hr in bronchial epithelial cells and type I I  
alveolar cells, cellularity i 1-1 6  hrs. BALF: 8-0HdG levels i 1 hr, = 24 hrs 
Lung homogenate: GSH .J, direct, = 3 hrs, Ascorbic acid = direct 
BALF: TEAC .J, direct, = 20 min. BALF: direct: GSSG i, ascorbic acid .J,, protein 
thiols .J,, total gluthatione = , vitamin E = , 8-epi-PGF2a i, all prevented by NAG 
Plasma: 8-epi-PGF2a i direct, 20 and 60 min. Total cell count, AMs, PMNs and 
lymphocytes = . Inactivation of human SLPI 
BALF: Intracellular GSH .L, free GSH in lavage fluid .J, 
Blood: GSH = , cysteine i. Lung tissue: Cysteine =, intracellular GSH 
Experiment 1 :  Blood: MUG i 20 hrs 
Experiment 2: Blood: MUG .L during smoking 
Lung homogenate: 24 hrs: cNOS mRNA and protein = , iNOS mRNA i, protein =, 
eNOS mRNA i, protein = 
* Measured by FITC-0 inhalation 
t Measured by HRP 
:t Measured by 1251-BSA 
§ Measured by 99mTcDTPA 
II Measured by wash out of Evans Blue 
1/ Lungs were isolated, ventilated with cigarette smoke and thereafter perfused with MUG 
** Isolated lungs were simultaneously ventilated with cigarette smoke and perfused with MUG 
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Table 3. Acute effects of cigarette smoke exposure; in vitro studies. 
First author; Cell types Smoke exposure 
Year of study S (cig/ml); E (hrs); T (hrs) 
Inflammation 
Aoshiba K (2001)(90) Murine, rat and human AMs CSE: S: 0.1 E: 4-24 T: 4-24 
Brown GM (1991)(1 16) Human PMNs CSE: S: 1 cig E: 4 min T: 4 min 
Bridges RB (1977)(70) Human PMNs CSE: S: ? E: ? T: ? 
Cantral DE (1995)(128) BBEC CSE: S: 0.01 E: 2, 6, 24 T: 2, 6, 24 
Carnevali S (1998)(84) HFL-1 CSE: 0.001 6-0.0024 E: 24 T: 24 
Carnevali S (2003)(86) HFL-1 CSE: S: 0.002-0.004 E: 3 T: 3 
Churg A (2003)(63) Mice AMs CSE: S: 0.3 E: 18 T: 18 
Drost EM (1992)(129) Human PMNs CS: S: 1 ,  3, 5 puffs E: 4 min T: 4 min 
Dubar V (1993)(115) Guinea pig and human AMs CS: S: 2 E: ? T: ? 
Falk HL (1959)(99) Ciliated epithelium from dog, rat CS: S: 50 ml E: 2 sec T: 1 ,  16, 46 min 
and rabbit trachea CSE: S:0.5 E: 2-30 sec T: 1 ,  16, 46 min 
Floreani AA (2003)(74) Primary HBECs CSE: S: 0.02 E: 1 T: 1 
BEAS-2B 
Green GM (1967)(78) Rabbit AMs monolayer CSE: S: 1 -4 ml E: ? T: 2 
Higashimoto Y Mice AMs CSE: S: 0.04-0.001 E: 1 T: 1 
(1991 )(1 12) 
Hellerman GR HBEC CSE: S: ? E: 30 min T: 30 min 
(2002)(1 14) 
Holt PG (1972)(81) Rabbit AMS, murine PMS, CS: S: 0.5-2 puffs E: 4 sec T: 30 min-24 
secondary cultured murine CSE: S: 35 ml smoke E: 70 min T: 70 mi 
embryonic fibroblasts 
Holt PG (1973)(46) Primary cultured mice AMs, CS: S: ? E: 60 sec T: 30 min, 24 
PMs, fibroblasts 
Hoshino Y (2001 )(87) A549 cell line CSE: S: 0.008-0.01 E: 3, 12, 24 
T: 3, 12,  24 
Ishii T (2001 )(89) HFL-1 CSE: S: 1 E: 4, 8, 12, 16, 20, 24 
T: 4, 8, 1 2, 16, 20, 24 
Kalra VKE (1 994)(73) Human monocytes, CSE: S: 10-60 1,19/ml E: 5-90 min 
HUVEC T: 5-90 min, 2-24 hrs 
Kim HJ (2002)(85) HFL-1 CSE: S: 0.0004 E: 24 T: 24 
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Effect of smoke exposure 
24 hrs: 93% of AMs in apoptosis", inhibition by anti-oxidants 
NE = 4 min. PMNs: Extensive blebbing of cell membranes 
Chemotaxis of PMNs J. concentration dependent 
2 and 6 hrs exposure: attachmentt of BBEC J., cell migration 2, 6 and 24 hrs = 
24 hrs exposure: attachmentt of BBEC i 
Fibroblast-mediated collagen gel contraction J. 
PGE2 release =, a2�1 integrin expression =, fibronectin release J. 
Intracellular H2DCFDA i, apoptosis* i, prevented by NAG, intracellular GSH J., inhibited by 
NAG 
DNA fragmentation i, inhibited by NAG 
TNF-a release i 
PMN filtration pressure i after 1 ,  3, or 5 puffs, no effect of anti-CD18, inhibited by anti­
oxidants and actin filaments cytoskeletal inhibitors, release HzD2 J. 
Activity of IL-6 and TNF-a J. 
Mucus flow along epithelium J. 1 -46 min 
Adhesion THP-1 monocytes to HBEC i, Inhibited by antl-TNF-a, ICAM-1 expression HBEC i 
Adhesion AMs, THP-1 , peripheral blood monocytes to BEAS-2Bi 
Phagocytosis staphylococcus albus J. dose dependent 
TNF-aJ. 
mRNA of IL-1 �. IL-8, IL-6, GM-CSF, ICAM-1 , RANTES i 
CS: AMs and PMs: 30 min viability J. and 3H-protein synthesis J., 24 hrs = 
Fibroblasts: 30 min viability =, 3H-protein synthesis 30 min and 24 hrs J. 
CSE: macrophages and fibroblasts: 3H-proteln synthesis decreased dose dependent 
30 min: viability AMs and PMs J., fibroblasts = 
24 hrs: viability PMs and fibroblasts J., RNA synthesis of survivors i 
Cell viability J. time and dose dependent 
3 hrs 0.8% CSE: i oxidative activity in cells, inhibited by NAG 
10-25% CSE: Apoptosis* 20, 24 hrs 
50-100% CSE: Necrosiss 4-48 hrs. GSTP1 sense vector J.: necrosis 20, 24 hrs, apoptosls = 
GSTP1 anti-sense vector i: necrosis 4-48 hrs, apoptosis = 
CD11 b  expression monocytes i time dependent, optimum after 25 min exposure 
Adhesion monocytes to HUVEC i, 30 min exposure 
HUVEC: ICAM-1 and ELAM-1 i 8, 24 hrs (60 min exposure) 
Collagen gel contraction J. Fibronectin release J., prevented by NAG. Intracellular GSH J., 
prevented and repleted by NAG EIIIA and B fibronectin mRNA J. 
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First author; Cell types Smoke exposure 
Year of study S (clg/ml); E (hrs); T (hrs) 
Inflammation 
Koyama S (1991 )(68) Bronchial epithelial cell CSE: S: 0.004 E: 2, 6, 24 T: 2, 6, 24 
monolayers 
Lannan S (1992)(130) Human PMNs CSE: S: 4 puffs E: 4 min T: 4 min 
Lannan S (1994)(131) A549 cell line CS: S :  1 cig E: 5 min T: 5 min 
CSE: S: 1 E: during smoke exposure 
T: during smoke exposure 
Marwick JA (2002)(132) A549 cell line CSE: S :  1 0% E :  4, 24 T: 4, 20, 24 
Masubuchi T (1998)(133) A549 cell line CSE: S: 0.002 E: 12, 24 T: 12, 24 
Mio TD (1997)(108) HBEC CSE: S: 0.004 E: 1 2-24 T: 1 2-24 
Nakamura Y (1995)(83) HFL-1 CSE: S: 0.002 E: 1 -24 T: 1 -24 
Niki E (1993)(134) Rabbit erythrocytes CSE: S: ? E: ? T: ? 
Ouyang Y (2002)(1 13) HUVEC CSE: S: ? E: 24 T: 24 
Richter A (2002)(107) NCI-H292 CSE: S: 0.002 E: 6, 24 T: 6, 24 
Robbins RA (1992)(72) BBEC, human PMNs, CSE: S: 0.004 E: 24 T: 24 
mononuclear cells 
Rusznak C (2000)(94) HBEC from HS, CS and COPD CS: S :  4 E: 20 min T: 20 min 
patients 
Rusznak C (2001 )(105) HBEC CS: S: ? E: 20 min, 1, 3, 6; T: 20 min, 1 ,  3 
Ryder Ml (1998)(76) Human blood neutrophils CS: S : ? E:  1 -5 min T: 1-5 min 
Ryder Ml (2002)(1 10) PBMCs from 8 CS and 8 NS CS: S:? E :  1 ,  2, 5 min T: 1 ,  2, 5 min 
Sato E (1999)(67) HFL-1 CSE: S: 0.004 E: 6, 12, 24 T: 6, 24 
Selby C (1992)(71) Human PMNs CS: S :  1 -4 cig E: 4 min T: 4 min 
Shen Y (1996)(75) HUVEC CSE: S: 25 µg/ml E: 30 min-8 T: 30 mir 
Shoij S (1995)(69) Bovine epithelial cells CSE: S: 0.04 E:3, 6, 12, 24 T: 
3, 6, 1 2, 24 
Takeyama K (2001 )(98) NCI-H292 CSE: S: 0.5 puff/ml E :  15 T: 6, 12, 24 
Tardiff J (1990)(28) Human AMs CSE: S: 0.04 E: 1 T: 1 
Thomas WR (1977)(77) Murine PMs CS: S: 0.5-2 puffs E: ? T: 
30 min, 2, 3, 5, 24 
Vayssier M (1998)(92) U-937 cell line CSE: S: 0.003-0.1 E: 4-16 T: direct 
Vayssier-Taussat M Human PBMCs CSE: S: 0.3-2.4 E: 4, 16 T: 4, 1 6  
(2001 )(91 ) TrHBMECs 
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Effect of smoke exposure 
MCA i dose dependent. MCA i after 2 hrs, time dependent 
Arachidonic metabolites inhibitors: J.. MCA 
Diameter and circumference of neutrophils i. Surface membrane blabbing i 
CS: Attachment' J.. 45 min-24 hrs, prevented by GSH. CSE: Detachment' i, prevented by 
GSH, augmented by depleting GSH. CSE: Proliferation J.., prevented by GSH 
P21waf1/cip1 mRNA = 4 hrs, i 24 hrs. HDAC mRNA = 4, 24 hrs. HDAC-2 protein J.. 20 hrs 
NCA = 1 2, 24 hrs 
IL-8 release i concentration dependent. IL-8 release i time dependent, 1 2-48 hrs. 
mRNA IL-8 i 12 hrs 
Proliferation fibroblast= 1 hr, J.. 24 hrs 
Haemolysis rabbit erythrocytes, anti-oxidants no protection 
slCAM = 
6 hrs: IL-8 mRNA i, TGF-a mRNA =, AR mRNA i, HB-EGF mRNAi. 24 hrs: HB-EGF mRNA i 
Adherence of PMNs to BBEC i 
EP i in all groups, COPD> HS> CS 
11-1 � and slCAM i 24 hrs 
20 min: IL-8 i, slCAM i, IL-1 � i. 1 hr: IL-8 J.., IL-1 � i. 3 and 6 hrs: IL-1� J.., IL-8 J.., slCAM J.. 
CD18 expression i after 5 min. L-selectin expression J.. 1-5 min 
IL-1 � i 5 min in NS group, TNF-a. =, TGF-� = 
MCA and NCA 24 hrs i, both inhibited by lipoxygenase inhibitors, anti-GM-CSF and anti­
LTB4; NCA inhibited by anti-lL-8, MCA inhibited by anti-MCP-1 
mRNA IL-8, GM-CSF and MCP-1 i 6 hrs 
Basal adherence' J.., CD18 expression = ,  no effect of GSH 
Neutrophil chemokinesis J.., chemotaxis = 
ICAM-1 , ELAM-1 , VCAM-1 i 
Dose and time dependent i NCA from 3 hrs, inhibition by lipoxygenase inhibitors 
EGFR mRNA and MUC5AC mRNA i 6-12 hrs 
MUC5AC protein i 24 hrs dose dependent, inhibition by anti-oxidants 
Unstimulated AMs: LTB4 =. PMA stimulated AMs: LTB4 J.. 
Dose dependent J.. of viability and phagocytosis of Pseudomonas aeruginosa 
2 puffs: phagocytic activity J.. 30 minutes and 24 hrs 
1 puff: phagocytic activity J.. at 2 hrs,i 5 hrs 
Low CSE: apoptosis* 1 6  hrs. High CSE: necrosis 1 6  hrs 
HSP70 expression i dose dependent. BCL-2 expression i dose dependent 
Low CSE: 4hrs: HSP70 and H0-1 expression i, 16 hrs apoptosis:t:, inhibited by NAC 
High CSE: H0-1 expression J.., 1 6  hrs: necrosis, inhibited by NAC 
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First author; Cell types Smoke exposure 
Year of study S (cig/ml); E (hrs); T (hrs) 
Inflammation 
Voisin C (1985)(79) Guinea pig AMs CS: S: 1 -5 cig E: ? T: direct-3 
Wang HY (2000)(106) ECV304 CSE: S: ? E: 2, 4, 8 T: 2, 4, 8 
Witherden IR (1997)(109) Primary human alveolar type CSE: S: 0.01 -0.05 E: 24 T: 24 
II cells 
Wirtz HR (1996)(96) Rat alveolar type I I  cells CSE: S: 0.04 E: 0-1 T: 0-5 
Yeager H (1968)(82) Rabbit AMs CSE: S : ? E: 20-120 min T: 20-120 min 
York GK (1973)(135) Sheep AMs CSE: S: 0.1 E: ? T: ? 
Zappacosta B (2001)(80) Human PMNs CSE: S :  ? E :  40 min T: during exposure 
Zhang X (2000)(1 1 1 )  Human PBMCs CSE: S: 1 E: 3 T: 3 
Oxidative stress 
Bridgeman M (1991 )(101)  Erythrocytes, neutrophils, A549 CS: S: 1 ,  3, 5 puffs E: ? T: ? 
cell line 
Hobson J (1991 )(103) Rat tracheal explants CS: S: 1 ,  3, 6 puffs E: 10 min T: 40 min 
Hoyt JC (2003)(104) LA-4 CSE: S: 0.0004-0.0008 E: 4, 24 T: 4, 24 
A549 cell line 
HBEC 
Kayyal i  US (2003)(136) RPEMC CSE: S: 20 µg/ml E: 4, 24 T: 4,24 
Li xv (1994)(95) A549 cell line CSE: S: 1 E: 1-6 T: 
1 ,  4, 6 and 24 hrs after wash 
Noronha-Dutra A HUVEC CSE: S: 0.5 E: 30 min T: 30 min 
(1993)(100) 
Pinot F (1999)(97) Human peripheral blood CSE: S :0.006-0.024 E: 
monocytes overnight T: direct after 
Powell GM (1971 )(1 37) Rabbit AMs CSE: S: ? E: ? T: ? 
Rahman I (1996)(102) A549 cell line CSE: S: 1 puff/3 ml E: 4 T: 16-28 
Tsuchiya MD (1992)(138) Rat PMNs CSE: S :  1 cig E: 20 min T: 20 min 
Tuder RM (2000)(88) Bovine artery endothelial cells, CSE: S: 1 0% E: 24 T: 24 
Monocytic U937, Hep G2, 
A549 cell line 
Wickenden JA A549 cell line, CSE: S: 0.05-0.1 E: 24 T: 24 
(2003)(93) HUVEC, Jurkat cell 
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Effect of smoke exposure 
Viability AMs J. dose dependent, inhibited by NAC 
Bactericidal activity of AMs J., inhibited by NAC 
Time and dose dependent i IL-8 secretion 4-8 hrs 
1 .01 cig/ml: IL-8 release i 
0.05 cig/ml: cytotoxity 
Surfactant secretion dose and time dependent J. from 20 min, no effect anti-oxidants 
Protein synthesis J. dose and time dependent 
Dose dependent J. of 02 consumption. Cell viability J. 
Phagocytic capacity J. 
TNF-a, IL-1 �. IL-2 and IFN-y J. dose dependent 
Intracellular GSH J., no effect reducing agents 
H202 and 0
2 i along epithelial cell membranes, prevented by SOD 
3 and 6 puffs: cell separation, focal membrane blebbing, loss of cilia, cell disintegration. 
Cells were stimulated for increased iNOS expression: 
Nitrate J. 4 and 24 hrs in all cell types. iNOS positive LA-4 cells J. 24 hrs. 
iNOS mRNA J., eNOS and nNOS mRNA = in LA-4 cells 24 hrs, eNOS in A549 cells = 24 hrs 
XO activity i 4 and 24 hrs. mRNA XO i 6 hrs 
EP:i 1 hr, prevented by GSH, = 24 hrs after wash 
GSH intracellular J., = 24 hrs after wash 
Pentose phosphate pathway activated 
GSSG release i 
02• production =, HSP70 i 
Membrane pseudopodes J., submembrane vacuoles i. Surfactant prevents effects CSE 
G3PD activity in AMs J., prevented by cysteine. G6PD and LDH in AMs = 
24 hrs after CSE intracellular: GSH i, GSSG =, yGCS activity i, yGCS-HS mRNA i 
ROS production from PMNs J., prevented by SOD. 02 consumption from PMNs i 
Ali cells: NO production i 
All cells, except A549 cell line: VEGF J. protein and mRNA 
Apoptosis i bovine artery endothelial cells 
Necrosis i, no apoptosis* 
GSH inhibits necrosis and apoptosis (Jurkat cell). GSH/GSSG J. intracellularly 
Inhibition caspase-3 activation (Jurkat cell) 
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Table 3. 
Acute effects of cigarette smoke exposure; in vitro studies. 
Definition of abbreviations: 
S: dose of smoke exposure (cig/ml). When possible, in order to compare cigarette smoke 
exposure between studies, the number of cigarettes per ml was calculated; E: time of smoke 
exposure (hrs); T: time between start of smoke exposure and measurement (hrs). 
AMs: alveolar macrophages; AP-1: activator protein-1; AR: amphiregulin; BEAS-28: human 
bronchial epithelial cell line; BBEC: bovine bronchial epithelial cells; CS: cigarette smoke (gas 
phase); CSE: cigarette smoke extract; ECV304: human endothelial cell line; EGFR: epidermal 
growth factor receptor; ELAM-1: endothelial leukocyte adhesion molecule; EP: epithelial 
permeability; G3PD: g/yceraldehydes 3-phosphate dehydrogenase; G6PD: glucose-6 phosphate 
dehydrogenase; y-GCS: y-glutamylcysteine synthetase; y-GCS-HS: y-glutamylcysteine synthetase 
heavy subunit; GM-CSF: granulocyte-macrophage colony-stimulating factor; GSH: reduced 
gluthatione; GSSG: oxidised gluthatione; GSTP1: gluthatione S-transferase P1; HOAG: histone 
deacetylase; HBEC: human bronchial epithelial cell; HB-EGF: heparin-binding EGF like growth 
factor; trHBMECs: transfected human bone marrow endothelial cells; HFL-1: human fetal lung 
fibroblasts; HSP 70: heat shock protein 70; HUVEC: human umbilical vein endothelial cells; 
ICAM-1: intercel/ular adhesion molecule 1; IFN-y: interferon-y; IL: interleukin; l.A-4: murine lung 
epithelial cell line; LOH: lactate dehydrogenase; LTB4: leukotrien 84; MCA: monocyte chemotactic 
activity; NAG: N-acetylcysteine; NGA: neutrophil chemotactic activity; NCI-H292: human 
pulmonary mucoepidermoid carcinoma cell line; NE: neutrophil elastase; NO: nitric oxide; PBMCs: 
peripheral blood mononuclear cells; PMs: peritoneal macrophages; PMNs: polymorphonuclear 
cells; RANTES: regulated on activation normal T-ce/1 expressed and presumably secreted; ROS: 
radical oxidant scavengers; RPMEC: rat pulmonary micro vascular endothelial cells; slCAM: 
soluble intercellular adhesion molecule; SOD: superoxide dismutase; TGF-�: transforming growth 
factor-�; TNF-a: tumor necrosis factor-a; TrHBMECs: human bonemarrow micriovascular 
endothelial line; TIJNEL: terminal deoxynucleotidyl transferase-mediated dUTP nick end labelling; 
U-937: premonocyte cell line; VCAM-1: vascular cell adhesion molecule 1; VEGF: vascular 
endothelial growth factor; XO: xanthine oxidase. 
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• Light microscopy, TUNEL and EM 
t Attachment and migration to fibronectin-coated dishes 
t Annexin V 
§7-AAD uptake 
II Attachment/detachment to plastic 
,i Functional adherence to A549 cell line 
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Increase in plasma elastase levels at 1 hour and blood neutrophil counts at 1 and 2 hours after 
smoking B cigarettes in 2 hours compared with non-smoking. Reprinted from Abboud et al (9) 
with permission from Elsevier. 
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8-isoprostane concentrations in breath condensate in healthy smokers before smoking and after 
15 minutes and 5 hours after smoking. Reprinted from Montuschi et al AJRCCM 2000 (20), with 
pennission from the American Thoracic Society. 































Desmosin and hydroxyproline increased in bronchoalveolar lavage fluid of mice 6 and 24 hours 
after acute cigarette smoking. Reprinted from Dhami et al (34) with permission from the American 
Thoracic Society. 






















Summary of the acute effects of cigarette smoking. Data extracted from human, animal and in 
vitro studies. ECM: extracellular matrix. 
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Abstract 
Rationale: Chronic smoking is the main risk factor for chronic obstructive pulmonary disease. 
Knowledge on the response to the initial smoke exposures might enhance the understanding 
of changes due to chronic smoking, since repetitive acute smoke effects may cumulate and 
lead to irreversible lung damage. 
Methods: We investigated acute effects of smoking on inflammation in 1 6  healthy intermittent 
smokers in an open randomised cross-over study. We compared effects of smoking of two 
cigarettes on inflammatory markers in exhaled air, induced sputum, blood and urine at 0, 1 ,  
3, 6, 12, 24, 48, 96 and 192 hours and outcomes without smoking. All sputum and blood 
parameters were log transformed and analysed using a linear mixed effect model. 
Results: Significant findings were: smoking increased exhaled carbon monoxide between 
0 and 1 hour, and induced a greater decrease in blood eosinophils and sputum lymphocytes 
between O and 3 hours compared to non-smoking. Compared to non-smoking, smoking 
induced a greater interleukin-8 release from stimulated blood cells between O and 3 hours, 
and a greater increase in sputum lymphocytes and neutrophils between 3 and 12 hours. 
Conclusion: We conclude that besides an increase in inflammation, as known from chronic 




Chronic obstructive pulmonary disease (COPD) is one of the leading causes of morbidity and 
mortality world-wide, and its prevalence is still rising ( I ). In order to develop strategies for 
its prevention and treatment, it is important to understand the underlying pathophysiologic 
mechanisms of this disease. Since chronic smoking is the main risk factor to develop COPD 
most studies in this field have been carried outin chronic (ex) smokers with or without COPD. 
It is also important to study the initial response to cigarette smoke to better understand the 
effects of chronic smoking, since repetitive acute smoke effects may cumulate and ultimately 
lead to irreversible tung damage associated with COPD. In addition, to appropriately evaluate 
the impact of chronic smoking, the 'back-ground' effects of acute smoking should be 
determined. 
Until now, only a few studies have investigated acute effects of smoking in humans (2). 
Unfortunately, these studies investigated only a small number of time points after smoking, 
hence little information is available on the time course and resolution of smoking induced 
changes. Furthermore, all studies assessed acute effects of smoking in chronic smokers who 
refrained from smoking for maximally 24 hours. It is unknown whether this is sufficiently 
tong to exclude the influence of previous smoking on the acute smoke results. Finally, no 
study so far investigated acute smoke effects in sputum. 
In the present study we investigated acute effects of smoking of two cigarettes by healthy 
intermittent smokers who refrained from smoking nine days before the study period. In this 
way, temporary effects on the airways due to chronic smoking will probably not affect the 
acute response to smoke. We assessed the time effects of cigarette smoking on both induction 
and resolution of the inflammatory response in exhaled air, induced sputum, blood and urine. 
We hypothesised that smoking of two cigarettes would induce an increase in inflammatory 
cells and markers within a limited time interval. 
Methods 
Design of the study 
We performed a randomised, two-period cross-over, pilot study. Subjects were randomised 
into smoking two cigarettes or no smoking. Subjects refrained from smoking during nine days 
before each study period, verified by exhaled carbon monoxide (CO < 6 ppm) and urinary 
cotinine (< 25 ng/ml). The time interval between the two study periods varied between 9 
to 20 days. Measurements of exhaled CO, exhaled Nitric Oxide (NO), blood sampling and 
Forced Expiratory Volume in I second (FEV1) were performed immediately before (baseline} 
and I ,  3, 6, 1 2, 24, 48, 96 and 192 hours after smoking and at the same time points in the 
no smoking period. Sputum was induced at 3, 6, 1 2, 24, 48, 96 and 192 hours after smoking 
and no smoking. All subjects smoked two cigarettes from the same brand within 30 minutes 
and were encouraged to inhale deeply (Caballero unfiltered cigarettes, tar 1 2  mg, nicotine 
1 .0 mg, commercially obtained, no gifts). Adequacy of smoke inhalation was verified by the 
investigator. The working group sputum induction from the ERS stated recently that sputum 
inductions should not be repeated within 48 hours to avoid 'carry over' effects (3). Taking this 
into account, we used a cross-over design (including no smoking) in this study to correct for 
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this 'carry over' effect. We have analysed the results of the control arm as a separate study in 
order to investigate the induction and resolution of the inflammatory response generated by 
repeated sputum inductions (4). 
Subjects 
Sixteen healthy intermittent smokers were recruited by advertisements in the local newspaper. 
Intermittent smoking was defined as smoking more than one cigarette a month, but not daily, 
during the last 6 months. We chose to investigate intermittent smokers because they are able 
to refrain from smoking for a certain time period (in contrast to most current smokers) and 
they are used to inhale smoke (in contrast to non-smokers). Included were subjects older than 
40 years, with normal lung function (prebronchodilator FEV/NC [Inspiratory Vital Capacity] 
> 89% of predicted for women and > 88% of predicted for men (5) and a prebronchodilator 
FEV 1 > 1 litre). Excluded were subjects with: 1) a history of asthma, allergic rhinitis, or 
allergic eczema; 2) atopy, confirmed by a positive skin prick test; 3) any current respiratory 
disease, symptoms of cough or sputum production; 4) a respiratory tract infection within 
the preceding 8 weeks or a nasal infection within the preceding 4 weeks; 5) treatment with 
glucocorticosteroids within the preceding 8 weeks; 6) use of aspirin, NSA!Ds, paracetamol or 
antihistamines within the preceding 4 weeks. Subjects were asked to avoid places with high 
environmental tobacco smoke exposure during the study periods. The study was approved by 
the medical ethics committee of the University Medical Center Groningen, the Netherlands. 
Written informed consent was obtained from all subjects. 
Pulmonary function, exhaled NO and CO 
FEV 1 and NC were measured according to the guidelines of the European Respiratory Society 
(5), using a pneumotachograph (Jaeger, Wurzberg, Germany). Exhaled NO levels were 
determined according to the guidelines of the American Thoracic Society (6), exhaling with a 
flow of 100 ml/sec against a resistance between 5 and 20 cm Hp, using a chemiluminescence 
analyser (CLO 700 AL, Ecophysics , Durnten, Switzerland] . Exhaled CO levels were measured 
using an infrared CO analyser (UNOR 6N, Maihak AG, Hamburg, Germany) (7). 
Blood analyses 
Blood differential cell counts were analysed automatically with a haematology flow cytometer 
(Coulter-STKS, Beckman Coulter, Miami, USA). Row cytometric analysis was performed 
on blood cells using peridinin chlorophyll protein (PerCP) labelled anti-human leukocyte 
antigen (HLA)-DR, phycoerythrin (PE) labelled anti-CO i l b, allophycocyanin (APC) labelled 
CD 14 and fluorescein-isothiocyanate (FITC) labelled CD63 monoclonal antibodies (Becton 
Dickinson, Franklin Lakes, NJ, USA). HLA-DR, CD63 and CDI l b  are activation markers 
for respectively monocytes and granulocytes. CD 14 is used to discern between monocytes 
and granulocytes. Functional assays were performed on unstimulated and lipopolysacharide 
(LPS, 1 ng/ml, BioWhittaker, Walkerville, USA) stimulated blood cells, measuring tumor 
necrosis factor (TNF)·a, interleukin (IL)- I�. IL-8 and IL- 10 by ELISA (Sanquin, Amsterdam, 
the Netherlands). 
Sputum induction and processing 
Sputum was induced according to a modified standard technique (8), using 4.5% hypertonic 
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saline. Whole sputum was processed within 120 minutes according to the modified method 
of Rutgers and colleagues (8). The cell-free supernatant was collected and stored in aliquots 
at -80°C pending analysis of soluble mediators. 
Sputum analyses 
Flow cytometric analysis was performed on sputum cells using PerCP labelled anti-HLA-DR, 
PE labelled anti-CD! l b, APC labelled CD14 and FITC labelled CD63 monoclonal antibodies 
(Becton Dickinson, Franklin Lakes, NJ, USA). lmmunocytology was performed to quantify the 
percentage of inducible NO synthase (iNOS) positive macrophages. Cytospins were double 
stained with a monoclonal antibody against CD68 (lgG I isotype, Dako, Glostrup, Danmark) 
as a marker for macrophages and rabbit polyclonal antiserum against iNOS (Transduction 
Laboratories, Lexington, KY, USA). The following soluble mediators were measured in sputum 
supernatant. NO2 /NO3 was measured using the Griess reaction, eosinophilic cationic protein 
(ECP) using the fluorenzyme immunoassay UniCAP ECP (Pharmacia, Uppsala, Sweden). IL-8 
and leukotriene B4 (LTB4) were measured by a commercial ELISA (IL-8: Sanquin, Amsterdam, 
the Netherlands; LTB4: Amersham Biosciences, UK). Matrix metalloproteinase (MMP)-9 was 
measured by gelatine zymography (9), and tissue inhibitor of metalloproteinase (TIMP)-1 by 
ELISA (R&D, Abingdon, UK). Neutrophil elastase (NE) activity was measured by chromogenic 
substrate assay (Nmethoxysuccinyl-ala-ala-pro-val-p-nitoanilide, Sigma, UK) ( I 0). 
Urinary measurements 
Before inhalation of smoke (or control), a urine portion was collected to measure urine 
cotinine. Cotinine was measured by gaschromatography-mass-spectrometry (Pharmacy 
Department, Groningen, the Netherlands). Furthermore, urine was collected over 24 hours 
in five consecutive fractions: 0- 1 hour, 1-3 hours, 3-6 hours, 6-12 hours and 12-24 hours from 
all subjects to assess leukotriene E4 levels (ELISA, Amersham Biosciences, UK). 
Statistical analyses 
Since the start and duration of the acute effects of smoking of two cigarettes on our parameters 
were unknown, time series of all variables were plotted. Based on visual inspection of these 
plots the time intervals to be analysed were selected. The slopes of parameters were estimated 
using linear mixed effect models (II) by including the variables time (hours), smoking (yes 
or no) and their interaction. For the sputum parameters no baseline values were present, 
therefore time point 192 hours was used as baseline value. After log-transformation of all 
blood and sputum variables, the residuals of the models were normally distributed. All 
analyses were performed in S-plus 2000 (Insightful Corporation, Seattle, WA, USA). A p value 
<0.05 was considered statistically significant. 
Results 
Subjects 
Clinical characteristics of the 16 subjects are listed in table 1. Fifteen subjects successfully 
refrained from smoking for nine days. One subject smoked one cigarette five days before the 
start of the study, but the urinary cotinine and exhaled CO levels were within the required 
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range. The analyses are performed on data from all 1 6  subjects. 
Exhaled NO and CO and FEV1 
Exhaled CO increased significantly more with smoking than without between O and I hour 
and subsequently decreased significantly more between I and 1 2  hours table 2 and figure 1 ) . 
Smoking had no significant effect on exhaled NO (data not shown) or FEV
1 (table 2) . 
Blood 
The number of blood eosinophils decreased more with smoking than without between O and 
3 hours (table 3 and figure 2) . Smoking had no significant effect on the number of other blood 
cells (table 3 and table 4) . IL-8 release from LPS stimulated blood cells increased more with 
smoking than without between O and 3 hours (table 3) . Smoking had no significant effect on 
TNF-a, IL· I O  and IL· I �  release compared with no smoking (table 5 ) . There was no significant 
difference in the expression of CD 1 1  b, CD63 and H1A-DR on CD 1 4  high and CD 1 4  low cells 
between smoking and no smoking (data not shown}. 
Sputum 
The total number and percentage of sputum cells within the first 24 hours after smoking 
and no smoking are shown in table 6. The number of neutrophils increased significantly 
more with smoking than without between 3 and I 2 hours (table 7, figure 3) . The number 
of sputum lymphocytes decreased more with smoking than without between O and 3 hours 
(table 7, figure 4) . Subsequently, however, the percentage and number of sputum lymphocytes 
increased more with smoking than without between 3 and 1 2  hours (table 7, figure 4) . 
Smoking had no significant effect on the percentage and number of sputum eosinophils (table 
7, figure 5) and macrophages (table 7) . Smoking had also no significant effect on the levels of 
inflammatory mediators in sputum (table 8 and the expression of CO i l b, CD63 and H1A· 
DR on CD14 high and CD 1 4  low cells and the number of iNOS positive macrophages (data 
not shown). 
Urine 
Smoking had no significant effect on leukotriene E4 levels in urine compared to no smoking 
[data not shown). 
Discussion 
In order to better understand the effects of chronic smoking, i t  is  important to study the 
initial (acute) response to cigarette smoke, since repetitive acute smoke effects may cumulate 
and ultimately lead to irreversible damage. We therefore investigated the acute effects of 
cigarette smoking on both induction and resolution of the inflammatory response in healthy 
intermittent smokers. This study shows that smoking of two cigarettes acutely suppresses 
blood eosinophils. Furthermore, smoking induces a biphasic response in sputum lymphocytes, 
after an initial smoke-related suppression, the cells increase more with smoking than without. 
Finally, smoking increases sputum neutrophils and the release of IL-8 from whole blood 
cells. 
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A remarkable finding in our study is that smoking of two cigarettes decreases eosinophils 
in blood. Three other studies have reported similar results: eosinophils decreased in blood 
from healthy female smokers within two hours after smoking 1 2  cigarettes ( 1 2), in lung 
tissue of rats within 6 hours after smoke exposure ( 1 3), and in lung lavage fluid of ovalbumin 
sensitised mice after 3 weeks smoke exposure ( 1 4). A decrease in eosinophils may be due to 
a direct (apoptotic) effect by toxic substances in cigarette smoke ( 15), or to anti-inflammatory 
substances in cigarette smoke, like CO ( 16, 17). Smoking did not show a significant suppressive 
effect on sputum eosinophils in our study, although the figures show that sputum eosinophils 
are decreasing more from 3 hours onwards with smoking than without. The reason for this 
is probably a lack of study power, due to the lower number of successful measurements in 
sputum than in blood, or due to the low baseline levels of sputum eosinophils in our healthy 
non-atopic subjects. One has to realise that the decrease in eosinophils in blood in our study 
is significant but relatively small. 
This study is the first to report that sputum can be used to study acute smoke effects. The 
number of sputum neutrophils increased between 3 and 12 hours after smoking. In line with 
this, we demonstrated a higher release of IL-8 by LPS stimulated blood cells after smoking, 
which may have contributed to increased neutrophil chemotaxis. The rise in neutrophils is in 
line with two studies on acute effects of smoking in humans, showing increased neutrophils 
in broncho-alveolar lavage fluid I hour after smoking ( 18) and increased neutrophil retention 
in the lung during smoke exposure ( 1 9). The fast increase in neutrophils in sputum might 
result from detachment of neutrophils from the pulmonary vascular endothelium (the so­
called marginated pool) (20) or from recruitment from the bone marrow (2 1 ,  22). 
Smoking also shortly suppressed the number of lymphocytes in sputum. Thereafter sputum 
lymphocytes increased more with smoking than without. The initial decrease might result 
from increased adherence of lymphocytes in the lung tissue due to the fast upregulation 
of adhesion molecules after smoking (23) or may also be caused by the suppressive CO as 
mentioned in the prior paragraph ( 16 ). The subsequent increase in sputum lymphocytes may 
reflect the outwash of lymphocytes from the tissue into the sputum, which can be regarded 
as the 'waste bin' of lung inflammatory cells. 
Smoking did not affect all inflammatory markers we investigated. A few factors may contribute 
to this lack of response. First, the number of subjects and the number of cigarettes (n=2) 
might have been too low. Second, we may have included a heterogeneous group of subjects 
regarding their response to cigarette smoke. We know that approximately 80% of all smokers 
never develop COPD. Therefore it is conceivable that a part of our healthy smokers does not 
respond to cigarette smoking. Third, we included subjects with a broad range in current and 
past smoking. Fourth, sputum may reflect only a part of the acute inflammatory changes of the 
airway wall (8). It would be interesting to study the acute effects of smoking on lung tissue. 
Finally, CO in cigarette smoke may have dampened the inflammatory response, especially in 
the early phase. After continuous smoking the damaging and irritating effects may prevail, 
giving rise to more pronounced inflammation. 
Studying the acute effects of smoking in intermittent healthy smokers has both advantages and 
disadvantages. We choose the presented model for a number of reasons. First, intermittent 
smokers can refrain from smoking for three weeks in contrast to most current smokers. 
Second, intermittent smokers have a normal lung function (in contrast to COPD), and likely 
(nearly) no structural airway changes, which may affect a normal response to cigarette smoke. 
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Third, we assumed that detecting an acute inflammatory response to cigarette smoking after 
an abstinence period of 9 days would be easier than detecting a response on top of chronic 
smoke exposure. Finally, intermittent smokers are used to inhale cigarette smoke (in contrast 
to non-smokers) .  We realise that our model has the disadvantage that the results of our 
study cannot easily be extrapolated to the chronic effects of smoking or COPD development. 
Nevertheless, when comparing the airway inflammation of our subjects with that of smoking 
COPD patients, both show increased levels of neutrophils, lymphocytes and IL-8 in sputum. 
However, in COPD patients after quitting smoking lymphocytes and neutrophils do not 
normalise (24), in contrast to the short-lived acute effects of smoking in this study. This 
suggests that not smoke but structural changes in the airways are responsible for the ongoing 
inflammation in COPD. Despite above limitations we think that knowledge on both the acute 
and chronic effects of smoking will help to better understand the mechanisms of cigarette 
smoke induced inflammation, which may underlie the development of COPD. 
Conclusion 
We conclude that besides an  increase in  inflammation, as known from chronic smoking, 
there is also a suppressive effect of smoking of two cigarettes on particular inflammatory 
parameters. Although this seems beneficial, it may disturb physiologic responses, like repair 
processes, in which inflammatory cells play a role. 
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Smoked cigarettes per month 
FEV" % predicted 
FEV/ IVC, % 
Table 1 .  





1 19  (68-144) 
77.6 (68.1-87.0) 
Values expressed as medians (ranges). FEV1: Forced Expiratory Volume in 1 second, IVG: 
lnspiratory Vital Capacity. 
Independent variable Time interval B 95% CI p value 
CO, ppm 0- 1 hour 3.61 2.67-4.54 <0.0001 
1 -1 2  hours -0.29 -0.38- -0.21 <0.0001 
FEV, ,  Lisee 0-1 hour 0.06 -0.07-0.20 0.38 
Table 2. 
Linear mixed effect models: CO and FEV1• 
The time intervals of the above parameters were selected based on visual inspection of the plots. 
The slopes of the parameters were estimated using linear mixed effect models (11) by including 
the variables time (hours), smoking (yes or no) and their interaction. 8: regression coefficient for 
the variable time (for further information see the method section). CO: carbon monoxide, FEV1: 
Forced Expiratory Volume in 1 second. 
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Independent variable Time interval B 95% CI p value 
Log (leucocytes, 109/L) 0-12 hours 0.00 -0.01-0.01 0.44 
Log (neutrophils, 109/L) 0-12 hours 0.00 -0.01 -0.02 0.58 
Log (monocytes, 109/L) 0-1 hour 0.04 -0.10-0.19 0.55 
Log (eosinophils, 1 09/L) 0- 3 hours -0.1 1 -0.18- -0.03 0.01 
Log (lymphocytes, 1 09/L) 0-12 hours -0.00 -0.01-0.01 0.65 
Log (IL-8, pg/ml)* 0-3 hours 0.09 0.04-0.14 0.001 
Log (TNF-a, pg/ml)** 0-3 hours 0.02 -0.08-0.12 0.75 
Table 3. 
Linear mixed effect models: blood cells, IL-8 and TNF-a. 
The time intervals of the above parameters were selected based on visual inspection of the plots. 
The slopes of the parameters were estimated using linear mixed effect models (11) by including 
the variables time (hours), smoking (yes or no) and their interaction. B: regression coefficient for 
the variable time (for further information see the method section). * Release from whole blood cells 
after lipopolysacharide (LPS) stimulation. ** Spontaneous release from whole blood cells. 
IL: interleukin, TNF-a: tumor necrosis factor-a. 

















































(2.8-6.7) (2.6-1 0.2) 
1 .9 1 .8 









(1 .9-5.3) (2.0-5.9) 
1 .9 2.0 





Number of blood cells (109/L) after smoking and no smoking. 
Values are expressed as medians (ranges). 
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1 2  hours 
7.1 5.5 
(4.4-1 1 . 9) (4.1 -8.6) 
4.1 3.2 
(2.3-8.3) (1 .9-6.0) 
2.3 1 .7 
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Chapter 3 
o hours 3 hours 24 hours 
smoking 
IL-1 P 15.0 13.9 19.3 
(0.9-133) (1 .6-1 12) (1.1 -274) 
LPS induced IL-1P 1435 2400 2392 
(752-2970) (474-4784) (723-4020) 
IL-10 2.3 2.9 2.3 
(0.3-73.4) (0.3-62.1) (0.2-97.7) 
LPS induced IL-10 22.6 32.5 38.7 
(5.1 -1 31) (5.5-161) (13.7-183) 
IL-8 328 343 352 
(22.8-1710) (25.3-2893) (1 1 .5-2457) 
LPS induced IL-8 4066 6031 6736 
(1276-7714) (1844-13162) (2284-13533) 
TNF-a 10.3 10.0 14.0 
(2.6-39.9) (1 .3-35.8) (2.1-63.3) 
LPS induced TNF-a 201 1 2323 1957 
(564-4470) (516-4298) (827-4701) 
no smoking 
IL-1 P 29.3 13.0 15.6 
(1 .7-1 27) (3.7-127) (2.6-148) 
LPS induced IL-1 p 1993 2387 1746 
(480-5569) (471-6979) (571 -4439) 
IL-1 0 1 .7 2.9 1 .4 
(0.3-75.8) (0.6-70.9) (0.2-78.4) 
LPS induced IL-10 24.9 22.3 32.8 
(7.8-131) (7.1 -164) (7.4-141 ) 
IL-8 192 266 287 
(15.8-1537) (71 .0-1730) (84.2-1082) 
LPS induced IL-8 4631 5368 4592 
(869-121 13) (1099-1 0328) (2268-17671) 
TNF-a 12.2 10.4 12.4 
(3.7-68.6) (5.2-41 .2) (1 .7-33.1) 
LPS induced TNF-a 2035 2021 2167 
(749-6822) (917-5487) (636-5705) 
Table 5. 
Release of IL-1P, IL-10, IL-8 and TNF-a from blood cells after smoking and no smoking. 
Spontaneous and LPS (1 ng/ml) stimulated release of IL-1P, IL-10, IL-8 and TNF-a (pg/ml) from 
whole blood cells after smoking and no smoking. Values are expressed as medians (ranges). IL: 
interleukin, LPS: lipopolysacharide, TNF-a: tumor necrosis factor-a. 
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Baseline 3 hours 6 hours 1 2  hours 24 hours 
(192 hours) 
smoking 
Sputum cells, 1 06/ml 1 .8 2.0 2.4 2.4 2.6 
(0.1 -16.3) (0.3-6.6) (0.1 -7.3) (0.5-6.6) (0.0-9.0) 
Neutrophils, % 56.9 56.4 83.2 77.5 67.3 
(22.0-97.3) (4.0-96.0) (13.7-97.3) (32.2-98.3) (39.0-84.3) 
Macrophages, % 37.9 42.2 13.8 16.8 27.4 
(2.5-74.5) (3.7-84.8) (2.5-68.5) (1 .7-61 .7) (14.8-57.7) 
Eosinophils, % 0.1 0.5 0.0 1 .1 1 . 0  
(0.0-6.2) (0.0-5.2) (0.0-0.3) (0.0-8.3) (0.0-5.2) 
Lymphocytes, % 1 .1 0.4 1 .0 1 .2 0.4 
(0.0-3.8) (0.0-1.7) (0.0-2.0) (0.0-7.3) (0.0-1.8) 
no smoking 
Sputum cells, 1 06/ml 2.8 3.1 2.0 2.1 2.1 
(0.8-23.8) (0.1 -20.4) (0.7-7.9) (0.4-6.2) (0.6-9.5) 
Neutrophils, % 50.9 58.9 73.2 83.2 64.5 
(20.3-84.8) (31 .8-94.2) (22.8-94.7) (26.7-98.3) (29.0-80.3) 
Macrophages, % 46.9 38.5 20.8 1 0.3 28.7 
(1 5.0-77.7) (4.2-64.0) (4.5-71.2) (1 .7-67.8) (16.0-66.5) 
Eosinophils, % 0.2 0.3 0.2 1 .7 2.2 
(0.0-3.2) (0.0-1 .2) (0.0-4.2) (0.0-15.5) (0.5-12.5) 
Lymphocytes, % 0.7 0.9 0.4 0.2 0.9 
(0.0-4.0) (0.0-2.8) (0.0-3.5) (0.0-3.7) (0.0-1.5) 
Table 6. 
Inflammatory cells in sputum after smoking and no smoking. 
Values are expressed as medians (ranges). 
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Independent variable 
Log (total cells, 1 06/ml) 
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Time interval B 
0-3 hours 0.075 
0-3 hours -0.17 
0-3 hours -0.22 
3-12 hours 0.03 
3-12 hours 0.13 
0-3 hours 0.12 
0-3 hours 0.13 
0-6 hours -0.22 
0-6 hours -0.1 2 
3-6 hours -0.84 
3-6 hours -0.31 
0-3 hours -0.28 
0-3 hours -0.26 
3-12 hours 0.19 
3-12 hours 0.23 
Linear mixed effect models of sputum cells. 
95% CI p value 
-0.15-0.30 0.52 
-0.34- -0.00 0.07 
-0.49-0.30 0.1 1 
-0.02-0.07 0.27 
0.04-0.22 0.007 
-0.01 -0.25 0.08 
-0.1 1 -0.36 0.31 
-0.71-0.28 0.39 
-0.30-0.06 0.20 
-3.63-1 .96 0.57 
-1 .35-0.73 0.57 
-0.59-0.02 0.08 
-0.42- -0.11 0.004 
0.06-0.31 0.006 
0.09-0.36 0.002 
The time intervals of the above parameters were selected based on visual inspection of the plots. 
The slopes of the parameters were estimated using linear mixed effect models (11) by including 
the variables time (hours), smoking (yes or no) and their interaction. B: regression coefficient for 
the variable time (for further information see the method section). 
Acure ef ecrs of n3arerre smokin3 on uif!ammanon m healrlry mrernurrenr smokers 91 
Baseline 3 hours 6 hours 1 2  hours 24 hours 
(192 hours) 
smoking 
IL-8, pg/ml 1813 1635 1 152 2034 1591 
(590-16230) (539-6392) (420-4576) (596-6134) (426-13180) 
ECP, ng/ml 77.9 37.8 29.6 76.4 54.6 
(12.9-264) (12.8-304) (5.1-179) (13.2-392) (5.6-614) 
LTB4, nM 3.3 2.6 2.6 3.1 2.9 
(0.8-25.4) (0.8-8.3) (0.6-22.9) (0.7-15.4) (0.7-8.9) 
MMP-9, nM 2.0 2.6 2.8 4.8 4.5 
(0.1 -45.1) (0.2-44.0) (0.0-30.9) (0.1 -52.0) (0.0-58.3) 
TIMP-1 , nM 5.3 4.0 5.4 5.9 3.7 
(0.3-8.4) (1 .6-10.5) (0.3-13.2) (0.5-16.3) (0.4-10.7) 
Nitrite/nitrate, µM 175 161 226 242 155 
(86.0-525) (79.0-318) (73.0-1023) (61.0-1360) (67.0-1202) 
no smoking 
IL-8, pg/ml 1766 1553 1216 1384 1628 
(614-26524) (462-81 92) (241-3478) (379-12966) (429-22476) 
ECP, ng/ml 72.1 75.1 43.0 46.3 73.4 
(16.6-14040) (12.1-346) (15.5-346) (13.0-386) (8.0-804) 
LTB4, nM 4.1 3.6 2.6 3 .2  3.4 
(1 .1-17.7) (1 .0-14.4) (0.6-10.3) (0.7-13.4) (0.7-15.3) 
MMP-9, nM 3.3 2.7 1 .6 2.1 1 .2 
(0.5-59.3) (0.1-75.1) (0.0-30.6) (0.0-69.1) (0.1-75.5) 
TIMP-1 , nM 5.9 5.5 4.7 4.6 4.2 
(0.6-10.8) (2.1-16.0) (2.2-14.3) (1 .3-12.0) (0.8-14.4) 
Nitrite/nitrate, µM 150 149 1 69 254 150 
(54.0-451) (66.4-403) (76.0-1324) (65.0-1 279) (78.0-618) 
Table 8. 
Inflammatory mediators in sputum after smoking and no smoking. 
Values are expressed as medians (ranges). IL· interleukin, ECP: eosinophilic cationic 
protein, LIB4: leukotriene 84, MMP-9: matrix metal/oproteinase-9, nMP-1: tissue 
inhibitor of metal/oproteinase-1, 
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Black circles represent the values after smoking two cigarettes and grey circles represent the 
values of the control period. 
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Figure 4. 
Time course of smoking of two cigarettes on sputum lymphocytes. 
Black circles represent the values after smoking two cigarettes and grey circles represent the 
values of the control period. 
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Black circles represent the values after smoking two cigarettes and grey circles represent the 
values of the control period. 
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Abstract 
Rationale: Hampered tissue repair, in which fibroblasts are the main regulatory cells, may be 
important in the development of smoking induced emphysema. 
Methods: Therefore we investigated the induction of apoptosis and necrosis of human lung 
fibroblasts (MRC-5) by cigarette smoke extract (CSE). Furthermore, we were interested if 
transforming growth factor (TGF)·� 1 and interferon (IFN)-y, as main constituents of the local 
microenvironment in emphysema lungs, could modulate CSE induced cell death. MRC-5 
cells were exposed to 2, 5 and 12.5% CSE for 24 hours with and without preincubation with 
TGF·� 1 and IFN-y. This was compared with generally accepted stimuli of cell death: UVB and 
anti-Fas. The percentage of apoptotic cells (DiOC6 low and propidium iodide (PI) low) and 
necrotic cells (Pl high) were assessed by FACS. 
Results: We showed that 12.5% CSE increased the percentage of apoptotic cells within the 
non-necrotic PI low cells significantly, but even more increased the percentage of necrotic 
cells. TGF-�l increased and IFN-y diminished the percentage of necrotic cells significantly 
after CSE exposure, with limited effect on apoptosis. 
Conclusion: CSE exposure mainly induces necrosis of human lung fibroblasts, which is 
enhanced by TGF-�l . In emphysema lungs this may contribute to increased tissue damage 
and enhanced local inflammation. 
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Introduction 
Emphysema is a progressive lung disease characterised by enlargement of distal airspaces and 
destruction of alveolar walls. Cigarette smoking is its main risk factor, but only 15-20% of the 
smokers develops emphysema. Current concepts about the pathogenesis of emphysema are 
mainly based on an imbalance between oxidants and anti-oxidants, and proteases and anti­
proteases in the lung ( I ,  2). More recently it has become likely that disturbances in tissue 
repair may be important as well (3, 4). 
Since fibroblasts play a pivotal role in tissue repair, altered fibroblast function could be 
responsible for insufficient tissue repair in emphysema. Noordhoek et al (5) have shown 
that fibroblasts from emphysema patients have decreased proliferative capacity. Furthermore, 
cigarette smoke can directly impair fibroblast function and can induce fibroblast cell death 
(6-9). 
In general there are two principle forms of cell death, apoptosis and necrosis ( I 0). Necrosis 
is pathological cell death due to extreme stimuli. This pathway of cell death may result in 
considerable local tissue damage. Apoptosis is physiological cell death that occurs as a result 
of an internally controlled 'suicide' program, after which the dead cells are removed with 
minimal interruption of the surrounding tissue. Two main pathways are involved in the 
induction of apoptosis. Firstly, the receptor-mediated apoptosis, which is initiated by binding 
death receptors, like Fas and tumor necrosis factor and works via the activation of the caspase 
cascade, which ultimately activates the effector caspase-3. Secondly, the mitochondria 
mediated apoptosis, which is initiated by stimuli as oxidative stress and ultra violet (UV)B 
radiation, resulting in depolarisation of the mitochondrial membrane and ultimately in 
activation of the effector caspase-3. 
Tissue repair consists of a series of co-ordinated events involving cell division, migration, cell 
differentiation, and extra cellular matrix production, which all are strictly regulated by locally 
released mediators. One of the most important cytokines in tissue repair is transforming growth 
factor (TGF)-� I ,  which enhances fibroblast proliferation, fibroblast survival and extra cellular 
matrix deposition ( I 1- I 4). TGF-� I expression is increased in the alveolar and bronchial 
epithelial cells in patients with COPD and the latter correlates negatively with the forced 
expiratory volume in I second (FEV 1 ) (15). T cells are increased in the lung parenchyma of 
emphysema patients ( 1 6) and are associated with increased tissue destruction ( 17). Interferon 
(IFN)-y, a major cytokine of T cells has been shown to decrease fibroblast proliferation (5) 
and in a mouse model IFN-y induced emphysema (18). We were interested if TGF-�1 and 
IFN-y, as important constituents of the local microenvironment of fibroblasts in emphysema, 
can modulate cigarette smoke extract (CSE) induced cell death and in this way play a role in 
disturbed tissue repair. 
In this study we investigated the effect of CSE on the induction of cell death (apoptosis 
and necrosis) of human lung fibroblasts and compared it with generally accepted stimuli 
of cell death: 1JVB radiation and anti-Fas. Furthermore, we investigated the influence of 
TGF-�l and IFN-y on the induction of cell death. We hypothesised that CSE would induce 
apoptosis of fibroblasts, to be inhibited by TGF-� 1 ,  which in general is known to enhance 
fibroblast function, whereas IFN-y, known to inhibit fibroblast function, would be expected 
to accelerate the process of cell death. 
Trnnsformin33rowrhfactor-fll increases n3arme smoke mduced cell death 
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Material  and rnethods 
Culture of fibroblasts 
Normal diploid MRC-5 cells derived from human fetal lung fibroblast ( 19) were obtained 
from the American Tissue Culture Collection (ATCC CCL-171, Rockville, MD, USA). MRC-5 
from confluent cultures were seeded in 25 cm2 culture flasks (Cambrex BioScience, Verviers, 
Belgium) in 'complete medium' (Ham's F l2  medium, Cambrex BioScience) supplemented 
with 10% fetal calf serum (FCS, PAA laboratories, Linz, Austria), 2 mM L-glutamin, 100 
µg/ml streptomycin and 100 U/ml penicillin ( Cambrex BioScience) and grown to confluency 
at 37°C in humidified air containing 5% COz- Culture medium was changed once a week. 
MRC-5 cultures were grown until confluence before experiments were performed. Passages 
6-9 were used in all experiments. 
Apoptosis induction 
In vitro fibroblast apoptosis was induced by addition of anti-Fas antibody (receptor dependent), 
UVB exposure (receptor independent) and exposure to CSE. 
Anti Fas induced apoptosis: to examine the concentration of anti-Fas induced fibroblast 
apoptosis MRC-5 was incubated with different concentrations (0, 0.01, 0.03, 0.08 µg/ml) of 
anti-Fas monoclonal antibody (7c l 1, Immunotech, Marseille, France) for 24 hours. 
UVB exposure induced apoptosis: MRC-5 cultures were exposed for 90 minutes to UV B 
radiation (TL! 2 lamp, Philips, 20 W, UV B 260-360 nm, 90 minutes exposure equals a dose 
of 1.8 KJ/m2) and apoptosis was measured after 24 hours. 
CSE: the smoke of four cigarettes (reference 2R I, University of Kentucky, USA) without filters 
was smoked continuously by a pump-smoke machine (smoke exposure system of the Tobacco 
and Health research institute of the university of Kentucky (20)) through 50 ml of Ham's F l 2  
supplemented with 0.5% FCS. The CSE was adjusted to pH  7.4 and filtered through a 0.22 
µm pore filter to remove bacteria and large particles. The resulting solution was considered 
I 00% CSE. CSE was stored at -80°C until use. To examine the effects of CSE on fibroblast 
apoptosis MRC-5 were incubated with different concentrations (0, 2, 5, 12.5%) of CSE for 
24 hours. 
Preincubation with TGF-� and IFN-y 
Culture medium was replaced with fresh 'complete' medium. After one day TGF-�l 
(320 U/ml, R&  D Systems Europe Ltd, Abingdon, England) or IFN-y ( 100 U/ml, R & D Systems 
Europe Ltd) or medium was added for 24 hours. The effects of different concentrations of 
IFN-y and TGF-�l on apoptosis induction were determined and respectively 100 U/ml and 
320 U/ml appeared optimal. 
Analysis of apoptosis and necrosis 
DiOC6 staining: DiOC6 (3,3-dihexyloxacarbocyanine iodide, Molecular probes, Leiden, 
the Netherlands) is a fluorescent cationic lipophilic dye which binds to the mitochondrial 
membrane (21 ). Upon apoptosis and necrosis cells lose their mitochondrial membrane 
potential, which can be demonstrated by a decrease in DiOC6 fluorescence. Apoptotic cells 
can be distinguished from necrotic cells when DiOC6 is used in combination with propidium 
iodide (Pl). As a result of this staining, necrotic cells are characterised by a high PI fluorescence, 
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whereas apoptotic cells are characterised by a low DiOC6 staining in combination with a low 
or absent PI staining. 
MRC-5 cells were harvested by trypsinization and washed twice with Ham's F l 2  solution. 
MRC-5 cells were incubated with a freshly made solution of 50 mM DiOC6 for 45 minutes 
at 33°C. After washing, the cells were resuspended in 250 µl Hank's Balanced Salt Solution 
(HBSS) without Calcium and Magnesium (Cambrex BioScience) and, 1 2  µl of a 10 µg/ml PI 
solution was added. Subsequently cells were put on ice and in the dark until flow cytometric 
analysis, which was performed within 1 5  minutes. Flow cytometric analysis was performed 
on a Coulter Epics ELITE flow cytometer (Coulter, Hialeah, Florida, USA). Data were analysed 
using Winlist-3D software, and expressed as: I )  apoptotic cells, as defined by the ratio of cells 
with a low DiOC6 staining in combination with a low PI staining divided by all PI low (non­
necrotic) cells, 2) necrotic cells, as defined by the ratio of all PI high cells divided by all cells 
(figure I ) . Experiments were performed in triplo (8). 
Statistical analyses 
Results are presented as medians with ranges. Differences in the percentage of necrotic and 
apoptotic cells after different exposures were tested with a Kruskal-Wallis test and when 
appropriate followed by a Mann-Whitney test. A p value of :,; 0.050 was considered statistically 
significant. 
Results 
CSE, UVB and anti-Fas effects on apoptosis and necrosis induction in human lung 
fibroblasts 
The effects of anti-Fas, UVB and CSE on MRC-5 cells are shown in figure 2 . Anti-Fas exposure 
significantly increased the percentage of necrotic cells at a concentration of0.08 µg/ml. Within 
the non-necrotic PI low cells the percentage of apoptotic cells increased dose dependent after 
stimulation with anti-Fas (p=0.02, figures 2A and 2D). UVB exposure had no significant effect 
on the percentage necrotic cells, but within the non-necrotic PI low cells UVB increased the 
percentage of apoptotic cells significantly (figures 2B and 2E) . At a concentration of 1 2.5%, 
CSE significantly increased the percentage of necrotic cells and within the non-necrotic PI 
low cells also the percentage of apoptotic cells (figures 2C and 2F) . 
TGF-� 1 and IFN-y effects on apoptosis and necrosis induction of human lung 
fibroblasts 
The results of preincubation with TGF-� I and IFN-y are shown in figure 3. At basal conditions 
TGF-� I significantly increased the percentage of necrotic cells, but TGF-� I had no significant 
effect on the percentage of apoptotic cells within the non-necrotic PI low cells (figures 3A, 3E) . 
Preincubation with TGF-� l prior to anti-Fas exposure increased the percentage of necrotic 
cells (p=0.02). Preincubation with TGF-� I prior to 0.08 µg/ml anti-Fas significantly increased 
the percentage of apoptotic cells within the remaining non-necrotic PI low cells (figures 3B, 
1 • Preincubation with TGF-� 1 had no significant effect on the percentage of apoptotic and 
necrotic cells after UVB exposure (figures 3C, 3G). Preincubation with TGF-� l prior to 5% 
CSE exposure significantly increased the percentage of necrotic cells and the percentage of 
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apoptotic cells within the remaining non-necrotic PI low cells (figures 3D, 3H). 
Preincubation with IFN-y had no significant effect on the percentage of apoptotic or necrotic 
cells at basal conditions, after anti-Fas and after UVB exposure. IFN-y significantly decreased 
the percentage of necrotic cells after 2 and 5% CSE exposure [figure 3D). Preincubation with 
IFN-y had no significant effect on the percentage of apoptotic cells within the non-necrotic PI 
low cells after CSE exposure (figures 3H). 
Discussion 
Fibroblast cell death may contribute to insufficient repair of lung parenchyma in patients 
with emphysema. In this study we investigated the effect of CSE on the induction of cell 
death of human lung fibroblasts. Furthermore, we were interested if TGF-Pl and IFN-y, as 
important constituents of the local microenvironment of fibroblasts in emphysema lungs, 
could modulate CSE induced cell death. This study shows that high concentrations of CSE 
predominantly cause necrosis of human lung fibroblasts, whereas a less pronounced effect 
is seen with respect to induction of apoptosis. Rather unexpectedly, TGF-P 1 increases and 
IFN-y diminishes the percentage of necrotic cells after CSE exposure. Both anti-Fas and UVB 
exposure induce apoptosis, but preincubation with TGF-Pl only increases the percentage of 
necrotic and apoptotic cells after anti-Fas exposure. 
We have shown that a high concentration of CSE induces apoptosis, but mainly necrosis 
in human lung fibroblasts. This is in line with the study of Ishii et al (8), who also showed 
induction of both forms of cell death after CSE exposure. However, in the study of Carnevali 
et al (6) CSE only induced apoptosis in human lung fibroblasts. This might be due to a lower 
concentration of CSE and a shorter exposure time. Moreover, Ishii et al (8) showed that 
lower concentrations of CSE induced apoptosis and higher concentrations induced necrosis. 
Contradictory results have also been published by studies investigating CSE induced cell 
death in other cell types, showing either apoptosis or necrosis or both (22-26). Different 
measurements of cell death and different preparations of cigarette smoke extract may be 
responsible for these inconsistent results. 
Since TGF-P 1 and IFN-y can influence fibroblast function, we were interested if these 
cytokines could modulate CSE induced fibroblast cell death and in this way play a role in 
disturbed tissue repair or breakdown. Unexpectedly, preincubation with TGF-Pl increased 
the percentage of necrotic cells at basal conditions and after CSE exposure, whereas this 
cytokine is known to enhance fibroblasts function. TGF-Pl also increased the percentage of 
apoptotic cells in the remaining non-necrotic fibroblasts, but only after exposure of 5% CSE. 
An explanation for this result may be found in the study of Aoshiba et al (27), who observed 
that actively repopulating fibroblasts are more sensitive to go into apoptosis after anti-oxidant 
depletion than quiescent fibroblasts. Since TGF·P 1 induces proliferation of fibroblasts, these 
cells might be more vulnerable to die after CSE exposure (oxidants) than non-proliferating 
fibroblasts. Moreover, Liu et al have shown that TGF·Pl decreases intracellular glutathione 
in fibroblasts, which may explain the increased vulnerability to oxidants from smoke in our 
study (28). Overall, this suggests that TGF-P 1, that is increased in the lungs of emphysema 
patients (15), might increase the vulnerability of fibroblasts to die when exposed to cigarette 
smoke. 
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In contrast to our expectations knowing that IFN-y is able to cause emphysema, IFN-y 
decreased the necrosis induction of human lung fibroblasts after CSE exposure, opposed to the 
effect of TGF-P I .  As we discussed in the previous paragraph, fibroblasts that are proliferating 
might be more vulnerable for CSE induced cell death than fibroblasts that are in a resting 
phase. Since, IFN-y predominantly inhibits, and TGF-P I enhances fibroblast proliferation ( 1 3, 
29), this might explain the opposed effects on necrosis induction. 
In this study we were also interested which route of apoptosis induction occurs during 
cigarette smoke induced apoptosis. Therefore we compared the apoptosis induction by 
anti-Fas (receptor mediated) and UVB (mitochondrial mediated) to the apoptosis induction 
by CSE. Only some interesting resemblance was seen between CSE and anti-Fas induced 
apoptosis, in that TGF·P I increased apoptosis both after anti-Fas and after CSE, but not after 
UVB exposure. This suggests that the CSE effect likely does not involve the mitochondrial 
mediated pathway. 
Disturbances in tissue turnover by inadequate repair or increased breakdown may play a role in 
the pathogenesis of emphysema (3, 4). With this study we support this hypothesis by showing 
that fibroblasts die due to CSE exposure, either by apoptosis or necrosis. Decreased numbers 
of fibroblasts in the lung may delay or impair repair of tissue damaged by cigarette smoke 
and contribute to the impairment of the parenchymal structure. Furthermore, CSE induced 
necrosis of fibroblasts may even enhance local inflammation by recruitment of macrophages 
and other inflammatory cells and in this way contribute to the ongoing destruction of the 
alveolar walls. 
In conclusion, CSE exposure induces mainly necrosis of human lung fibroblasts, which in 
vivo may contribute to decreased tissue repair and impaired tissue structure, and which may 
stimulate local inflammation. Surprisingly, TGF·P 1 enhances fibroblast necrosis after CSE 
exposure. This suggests that increased TGF·P l levels in the lungs of emphysema patients 
might increase the vulnerability of fibroblasts to die when exposed to cigarette smoke. 
Abbreviations 
COPD: chronic obstructive pulmonary disease, CSE: cigarette smoke extract, IFN-y: 
interferon-y, Pl: propidium iodide, TGF·P I :  transforming growth factor·P I ,  UVB: ultra violet B. 
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Figure 1 .  






Human lung fibroblasts (MRC-5) at basal conditions (A) and after treatment with 12.5% CSE for 
24 hours (8) were double stained with DiOC6 and Pl followed by flow cytometric analysis. Cells 
were expressed as: 1) apoptotic cells, as defined by the ratio of DiOC6 low and Pl low cells (gate 3) 
divided by all Pl low cells (gate 3 + 4), 2) necrotic cells, defined as the ratio of Pl high cells (gate 1 
+ 2) divided by all cells. CSE: cigarette smoke extract, Pl: propidium iodide. 
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Human lung fibroblasts (MRC-5) were exposed to anti-Fas (A, DJ, UV8 (8, E) and CSE (C, F) and 
evaluated for the percentage apoptotic cells (ratio of Di0C6 low and Pl low cells divided by all Pl low 
cells, D, E, F) and percentage necrotic cells (ratio of Pl high cells divided by all cells, A, 8, CJ. Values 
are presented as medians with ranges. *: p � 0.050 compared to control values. CSE: cigarette 
smoke extract, Pl: propidium iodide. 
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Human lung fibroblasts (MRC-5) were incubated with TGF-� 1 or IFN-y prior to exposure to anti­
Fas (8, F), UV8 (C, G) and CSE (D, H) and evaluated for the percentage apoptotic cells (ratio of 
DiOC6 low and Pl low cells divided by all Pl low cells, E, F, G, H) and percentage necrotic cells 
(ratio of Pl high cells divided by all cells, A, 8, C, D). Values are presented as medians with 
ranges. •: p :5 0.050 compared to values without cytokine preincubation. CSE: cigarette smoke 
extract, IFN-y: interferon-y, Pl: propidium iodide, TGF-� 1: transfonning growth factor-� 1. 
'Transfonn1 113 3rowrhfactor-fll mcreases n3arette smoke mduced cell death 






















MacNee W. Oxidants/antioxidants and COPD. 
Chest 2000;//7:303S 3/7S. 
Barnes PJ, Shapiro SD, Pauwe/s RA. Chronic obstructive pulmonary disease: molecular and cellular 
mechanisms. Eur Respir J 2003;22:672 688. 
Rennard SJ. Inflammation and repair processes in chronic obstructive pulmonary disease. 
Am] Respir Crit Care Med /999;/60:512 S/6. 
Timens W, Coers W, van Straaten ]FM, Postma DS. Extracellular matrix and inflammation: a role for 
fibroblast mediated defective tissue repair in the pathogenesis of emphysema? 
eur respir rev /997;7:119-123. 
Noordhoek]A, Postma DS, Chong LL, Vos]T, Kauffman HF, Timens W, van Straaten]F. 
Different proliferative capacity of lung fibroblasts obtained from control subjects and patients with 
emphysema. Exp lung Res 2003;29:291 302. 
Carneva/i S, Petruzzelli S, Langoni B, Vanacore R, Barale R, Cipollini M, Scatena F, Paggiaro P, 
Celi A, Giuntini C. Cigarette smoke extract induces oxidative stress and apoptosis in human lung 
fibroblasts. Am J Physiol lung Cell Mo! Physiol 2003;284:l955-l963. 
Nakamura Y, Romberger DJ, Tate L, Ertl RF, Kawamoto M, Adachi Y, Mio T, Sisson]H, Spurzem JR, 
Rennard SJ. Cigarette smoke inhibits lung fibroblast proliferation and chemotaxis. 
Am] Respir Crit Care Med /995;151:/497·1503. 
Ishii T, Matsuse T, lgarashi H, Masuda M, Teramoto S, Ouchi Y. Tobacco smoke reduces viability 
in human lung fibroblasts: protective effect ofglutathione S trans/erase Pl. 
Am] Physiol Lung Cell Mo/ Physio/ 2001;280:ll /89 ll 195. 
Holt PG, Keast D. The effect of tobacco smoke on protein synthesis in macrophages. 
Proc Soc Exp Biol Med /973;/42:/243 1247. 
Mitchell RN, and Cotran RS. 2004. Cell Injury, Adaptation and Death. In Contran RS, Kumar V. 
and Collins T. editors Robbins Pathologic Basis of Disease W. B. Saunders Co, Philadelphia. 3 31. 
Kim G, Jun JB, £Ikon KB. Necessary role of phosphatidylinosico/ 3 kinase in transforming growth 
factor beta mediated activation of Akt in normal and rheumatoid arthritis synovtal fibroblasts. 
Arthritis Rheum 2002;46:/504 JS/ I. 
Zhang HY, Phan SH. Inhibition of myofibroblast apoptosis by transforming growth factor beta(//. 
Am] Respir Cell Mo/ Biol /999;21:658 665. 
Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. 
N Engl] Med 1994;331:1286 1292. 
Bonner JC, Badgett A, lindroos PM, Osornio Vargas AR. Transforming growth factor beta I 
downregulaces the platelet derived growth factor alphareceptor subtype on human /ungfibrob/ascs 
in vitro. Am] Respir Cell Mo/ Biol /995;/3:496 505. 
De Boer WI, van Schadewijk A, Sant JK, Sharma HS, Stalk], Hiemstra PS, Van Krieken JH. 
Transforming growth factor beta I and recruitment of macrophages and masc cells in airways in 
chronic obstructive pulmonary disease. Am J Respir Cric Care Med /998; I 58: 195 I 1957. 
Majo J, Ghezzo H, Cosio MG. lymphocyte population and apoptosis in the lungs of smokers and 
their relation to emphysema. Eur Respir J 200/;/7:946 953. 
Finkelstein R, Fraser RS, Ghezzo H, Cosio MG. Alveolar inflammation and its relation co 
emphysema in smokers. Am] Respir Cric Care Med /995;152:/666 1672. 
Wang Z, Zheng T, Zhu Z, Homer R], Riese RJ, Chapman HA, Jr., Shapiro SD, Elias]A. 
Interferon gamma induction of pulmonary emphysema in the adult murine lung. 
J Exp Med 2000;192:/587 1600. 
Chaprcr4 
/9. Jacobs JP, Jones CM, Baille JP. Characteristics of a human diploid cell designated MRC-5. 
Nature /970;227:/68-170. 
20. Griffith RB, Hancock R. Simultaneous mainstream-sides/ream smoke exposure systems I. 
Equipment and procedures. Toxicology /985;34:/23-/38. 
2/. Bel/oc F, Belaud-Rotureau MA, Lavigna/le V, Bascans E, Braz-Pereira E, Durrieu F, Lacombe F. 
Flow cytometry detection of caspase 3 activation in preapoptotic leukemic cells. 
Cytometry 2000;40:/5/-/60. 
22. Vayssier M, Banzet N, Francois D, Bellmann K, Pol/a BS. Tobacco smoke induces both apoptosis and 
necrosis in mammalian cells: differential effects of HSP70. Am] Physiol /998;275:L77/-L779. 
23. Tuder RM, Wood K, Taraseviciene L, Flores SC, Voekel NF. Cigarette smoke extract decreases the 
expression of vascular endothelial growth factor by cultured cells and triggers apoptosis 
of pulmonary endothelial cells. Chest 2000; 117:241 S-242S. 
24. Hoshino Y, Mio T, Nagai S, Miki H, Ito I, Izumi T. Cytotoxic effects of cigarette smoke extract on an 
a/veolar type II cell derived eel/ line. Am] Physiol Lung Cell Mo/ Physiol 200!;28/:L509-L516. 
25. D'Agostini F, Balansky RM, lzzotti A, Lube/ RA, KelloffGJ, De Flora S. Modulation ofapoptosis by 
cigarette smoke and cancer chemopreventive agents in the respiratory tract of rats. 
Carcinogenesis 2001;22:375 380. 
26. Wickenden JA, Clarke MC, Rossi AG, Rahman I, Faux SP, Donaldson K, MacNee W. 
Cigarette smoke prevents apoptosis through inhibition of caspase activation and induces necrosis. 
Am J Respir Cell Mo/ Biol 2003;29:562-570. 
27. Aoshiba K, Yasui S, Nishimura K, Nagai A. Thiol depletion induces apoptosis in cultured lung 
fibroblasts. Am] Respir Cell Mo/ Biol !999;2/:54-64. 
28. Liu R, Liu Y, Forman H, O/man M, Tarpey M. Glutathione regulates transforming growth 
factor-{beta}-stimulated collagen production in.fibroblasts. Am] Physiol Lung Cell Mo/ Physiol 
2004;286:l/2/-l/28. 
29. Elias/A, Jimenez SA, Freundlich B. Recombinant gamma, alpha, and beta interferon regulation of 
human lung.fibroblast proliferation. Am Rev Respir Dis /987;/35:62 65. 
'TransJormin3.9rowthJactor-:f/l 111mases n.9arem smoke 111duced cell death 
in human lun.9.fibroblam 









Hester van der Vaart 
Gerard H .  Kaeter 
Dirkje S .  Postma 
Henk F. Kauffman 
Nick H .T. ten Hacken 
Am J Respir Crit Care Med 2005 ; 1 72(4) :465-8.  
Abstract 
Rationale: Tumor necrosis factor-a is believed to be important in the induction and 
maintenance of airway inflammation in chronic obstructive pulmonary disease. 
Objectives: We aimed to evaluate the effect of the anti-tumor necrosis factor-a drug, 
infliximab, in patients with chronic obstructive pulmonary disease, with percentage of 
sputum neutrophils as the primary endpoint. 
Methods: We performed an exploratory single-center, double-blind, placebo-controlled, 
randomized, phase 2 trial in which 22 current smokers with mild-to-moderate chronic 
obstructive pulmonary disease participated. Fourteen patients received three infusions 
of infliximab (5 mg/kg) at weeks 0, 2 and 6, and 8 patients received placebo infusions. 
Sputum samples, respiratory symptoms, quality of life, exhaled nitric oxide, lung function 
parameters, bronchial hyperresponsiveness, resting energy expenditure, and side effects 
were evaluated. 
Results: This study did not show a positive short-term effect of infliximab on airway 
inflammation, lung function, resting energy expenditure, or quality of life. Exhaled nitric 
oxide increased significantly at day 2, week 6, and week 8 in patients receiving infliximab 
compared with those receiving placebo. Eight patients in the infliximab group (vs. none in 
the placebo group) reported increased coughing, but no serious adverse events or increase 
in respiratory infections were reported during 9 weeks of follow-up. 
Conclusions: In this short-term study, no clinically beneficial effects of infliximab were 
observed, and there were no significant safety issues. Definite conclusions concerning 
the effectiveness of infliximab treatment in chronic obstructive pulmonary disease await 
additional studies including those with a larger number of patients with more advanced 
disease. 
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I ntrod u cti on 
Chronic obstructive pulmonary disease (COPD) is  an inflammatory lung disease resulting 
in progressive lung function loss. It is one of the leading causes of morbidity and mortality 
world-wide and its prevalence is still rising (2). Smoking cessation at an early stage of the 
disease is the most important intervention to slow down lung functional loss, but success 
rates are low (3), and airway inflammation appears to persist (4). Unfortunately, no anti· 
inflammatory agents are currently available that effectively reduce the underlying airway 
inflammation and/or stop this progressive decline in lung function (5). 
Airway inflammation in COPD is characterized by the presence of mononuclear cells, 
neutrophils, and their mediators. The cytokine tumor necrosis factor alpha (TNF-a) 
is believed to play a central role in the pathophysiology of COPD (6). TNF-a enhances 
neutrophil chemotaxis and migration by inducing the expression of chemokine interleukin 
(IL)-8 and upregulating endothelial adhesion molecules (7, 8). In vivo, elevated levels of 
TNF-a have been demonstrated in peripheral blood and sputum of patients with stable 
COPD (9, 10) and a polymorphism of the promoter region of the TNF-a gene has been 
implicated in the occurrence, severity, and mortality risk of COPD (11-13). 
Nutritional depletion is present in 20% of patients with COPD (14) and is associated with an 
increase in daily energy expenditure and in levels of inflammatory mediators (15). TNF-a 
seems to be especially important among these inflammatory mediators because it correlates 
with increased energy expenditure. Furthermore, increased serum TNF-a levels are found 
in a subgroup of patients with nutritional depletion (9, 16, 17). 
Infliximab is a chimeric monoclonal antibody that binds with high affinity and specificity 
to human soluble and membrane-bound TNF-a and neutralizes its biologic activity ( 18, 19). 
Infliximab has been shown to improve clinical and inflammatory parameters in patients 
with Crohn's disease and rheumatoid arthritis (20-23) . We designed a randomized, double­
blind, placebo-controlled, proof-of-principle phase 2 study to evaluate whether short-term 
treatment with infliximab inhibits airway inflammation in patients with stable COPD, with 
percentage sputum neutrophils being the primary endpoint. Secondary objectives of the 
study included evaluation of the effect of infliximab on respiratory symptoms, quality-of-life 
indicators, and lung function parameters. Another secondary objective was the evaluation 
of safety and tolerability of short-term infliximab therapy in COPD. Tertiary objectives 
included evaluation of infliximab treatment's effects on resting energy expenditure (REE) 
levels, and on exhaled nitric oxide (eNO) values. Some of the results of these studies have 
been previously reported in the form of an abstract (!). 
Methods 
Design of the study 
We performed a single-center randomized, double-blind, placebo-controlled pilot study. 
Patients with COPD were randomized to treatment with infliximab (Remicade; Centocor, 
Malvern, PA, US) at 5 mg/kg (14 patients) or with placebo (8 patients), with each treatment 
to be administered by infusion at weeks 0, 2 and 6. A minimization method was used to 
provide groups balanced for age (� 60 or > 60 years), FEV 1 (� 60 or > 60%), and number of 
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exacerbations per year (:=;; 2 or > 2). Sputum samples, spirometry, diffusion capacity, eNO 
and REE were evaluated at day I (baseline), day 2, and at weeks 2, 6, and 8. The clinical 
COPD questionnaire (CCQ) (24) was evaluated at day I, and at weeks 2, 6 and 8. The St. 
George Respiratory Questionnaire (SGRO; assessing quality of life) and the concentration 
of adenosine 5'-monophosphate causing FEY1 to drop 20% (PC20 AMP) were measured at 
baseline and subsequently at weeks 8 and 9, respectively. 
Safety evaluations 
Adverse events were reported at each visit. Patients had to answer the following question: 
'Did you have any complaints (especially fever, or extra or new symptoms) since the last 
visit?'. Physical examinations were also used to elicit information about adverse experiences 
and closely monitor safety. Clinical laboratory tests during the trial were used to detect 
unpredictable and/or subclinical adverse experiences. Particularly, peripheral blood was 
tested on the development of anti-nuclear antibodies (ANA), changes in neutrophils, 
lymphocytes and monocytes. Patients were monitored for 2 hours after the first dose of 
trial drug and I hour after all subsequent doses of infliximab (or placebo) for local and/or 
systemic reactions. 
Subjects 
Twenty-two patients with symptomatic COPD were enrolled, all with a postbronchodilator 
value FEY/FYC ratio below 70% and FEY1 >1.5 L. All patients were current smokers 
[> 5 cigarettes/day, > 10 pack-years). Patients were excluded from participation if they had 
a history of asthma, alpha-I anti-trypsin deficiency or bronchiectasis, or had a history of 
upper respiratory tract infection, use of antibiotics or oral corticosteroids within the prior 
2 months, or a history of serious infections within the last 3 months, evidence of active or 
latent tuberculosis (PPD skin test > 10 mm, or positive chest x-ray), history of opportunistic 
infections within the previous 6 months, current signs or symptoms of severe, progressive or 
uncontrolled disease, concomitant congestive heart failure, and/or malignancy within the 
past 5 years or history of lymphoproliferative disease. The Medical Ethics Committee of our 
institute approved the study. Written informed consent was obtained from all patients. 
Pulmonary function tests, REE and eNO 
FEY1 and FYC were measured according to the guidelines of the European Respiratory 
Society (25). Diffusion capacity for carbon monoxide (expressed by transfer factor for 
carbon monoxide ITLcol and TLco divided by the alveolar volume 1�01) was measured 
using the single breath holding method, according to international guidelines (25). Airway 
hyperresponsiveness to adenosine 5'-monophosphate was determined using standardized 
methods (26). REE was measured by an open-circuit, indirect calorimetry system using a 
ventilated hood system (oxyconbeta; Jaeger, Wurzburg, Germany) as described previously 
(27). ENO levels were determined by a chemiluminescence analyzer (CLO 700 AL, 
Ecophysics, Durnten, Switzerland) using the American Thoracic Society guidelines (28). 
Sputum induction and processing 
Sputum was induced according to a modified standard technique (29) using 4.5% hypertonic 
saline. Sputum was processed within 120 minutes by a modified method of Rutgers et al 
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(29). IL-6 and IL-8 were measured in sputum supernatant by commercial ELISA (Sanquin, 
Amsterdam, the Netherlands). Neutrophil elastase activity was measured by chromogenic 
substrate assay (Nmethoxysuccinyl-ala-ala-pro-val-p-nitroanilide; Sigma, Poole, UK) (30). 
Statistical analyses 
Clinical characteristics are presented as means (± SD) unless stated otherwise. All effect 
parameters are presented as medians with ranges. Differences in changes from baseline 
between the two treatment arms were tested with a Mann-Whitney test. A p value of less 
than 0.05 was considered statistically significant. 
Results 
No significant differences in baseline characteristics were observed between the infliximab 
and placebo treatment groups (Tables 1 and 2). Infliximab treatment was not associated 
with significant changes in the absolute number or percentage of inflammatory cells in 
sputum compared with that in placebo (Table 3) . In particular, infliximab treatment did not 
affect the primary endpoint of the study, the percentage of sputum neutrophils. In addition, 
changes in IL-8 and IL-6 levels did not differ between infliximab and placebo treatment 
groups (Table 3). Neutrophil elastase could not be detected in all sputum samples. 
Changes in FEVP FEV/FVC (data not shown), and �o did not differ between the infliximab 
and placebo treatment groups (Table 2). The median change in exhaled eNO, however, was 
significantly higher at day 2, week 6 and week 8 with infliximab treatment compared with 
placebo. Changes in REE and bronchial hyperresponsiveness to adenosine 5'-monophosphate 
did not differ between the infliximab and placebo treatment groups (Table 2), nor did 
respiratory symptoms and quality-of-life indicators (data not shown). 
No serious adverse events were reported for either treatment group during the 9 week 
follow-up period. All three infusions were generally well tolerated; one subject who received 
infliximab withdrew from the study after the first infusion due to flulike symptoms without 
other evidence of serious disease or any abnormalities shown by physical examination or 
laboratory values. The most frequently reported adverse events are shown in Table 4. 
Eight patients in the infliximab group reported increased cough, an incidence that was 
significantly greater than in the placebo group. Patients did not report more respiratory tract 
infections after infliximab treatment than those who received placebo and no bronchospasm 
occurred. One patient had an asymptomatic increase in antinuclear antibody titer after the 
third infusion of infliximab; otherwise, no significant laboratory changes were observed 
during the study period. 
D iscussion 
The pro-inflammatory cytokine TNF-a is believed to play a central role in the induction and 
maintenance of airway inflammation in COPD. In the present study, however, administration 
of the anti-TNF-a drug infliximab to a group of patients with well-characterized COPD did 
not result in improvement of any of several clinical parameters including FEVP CCO and 
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quality-of-life indices compared with a control group receiving placebo infusions_ Airway 
inflammation, including percentage of sputum neutrophils and level of IL-8 and REE, also 
did not change. 
One explanation for the lack of response may be that the degree of severity of COPD in our 
patients was too low to show a significant response. It has been shown that patients with 
lower FEV 1 values have a greater degree of airway inflammation, as reflected by higher levels 
of sputum neutrophils and IL-8 (IO, 31). Because patients with more severe disease are more 
prone to respiratory tract infections and bronchospasm, we chose to evaluate patients with 
only mild-to-moderate COPD. We had to take into account the safety and tolerability of 
infliximab in patients with COPD, because this was the first study to evaluate infliximab in 
the treatment of this condition. Thus, infliximab could possibly prove effective in patients 
with more severe COPD. Another explanation for the observed lack of clinical response 
may be that TNF-a is not a cytokine that plays a central role in the pathophysiology of 
COPD, and the observed increase of TNF-a is merely an epiphenomenon. There is a wide 
pleiotrophy and functional redundancy among cytokines, with each function potentially 
mediated by more than one cytokine (32). Actions attributable to TNF-a may in fact be 
exerted by other cytokines, such as IL-I�, IL-8 and IL-6. Other conditions, such as sepsis 
and heart failure, which are associated with increases in a variety of proinflammatory 
cytokines, are not mitigated in response to anti-TNF-a therapy as well (33, 34). 
Lack in observed clinical response could also be related to the study design. All of our 
patients were current smokers, and it has been shown previously that, at least in patients 
with Crohn's disease, smoking has a strong adverse ef fect on the rate and duration of 
response to infliximab (35). It might also be that the dose of infliximab used was too low, 
that the duration of our treatment regimen was too short to induce changes in some of our 
parameters, and/or that follow-up may have been too short to measure significant changes. 
The same dose of infliximab, however, has produced anti-inflammatory and clinical effects 
within a few weeks in patients with rheumatoid arthritis and Crohn's disease (20, 23). 
In addition, our study was designed as a pilot study, with a small number of patients and 
low power to detect changes in our parameters. Finally, it is possible that the sputum 
parameters we measured may correlate only moderately with inflammatory parameters in 
lung t issue itself (29). 
ENO levels were unexpectedly higher after infliximab treatment than was observed after 
placebo treatment. Although the change in eNO reached statistical significance, it is of 
questionable clinical importance, because the median change in eNO was only 2 ppb. 
Interestingly, an increase in eNO is also observed after smoking cessation (36), suggesting 
a similar, possibly beneficial mechanism of infliximab treatment in COPD. The significance 
of this finding is only speculative but could merit further investigation. 
Because a higher serum TNF-a has been associated with increased energy expenditure 
in COPD (16), we wanted to see if infliximab would attenuate the REE in our subjects, 
however, no significant effect was demonstrated. This could be explained by the fact that 
the REE values for our patients were generally within the normal range at baseline. 
No serious adverse events were reported within the 9 weeks of follow-up. Patients did not 
report more respiratory tract infections after infliximab treatment than those who received 
placebo, and no bronchospasm occurred in either treatment group. Increased cough was 
reported by eight patients in the infliximab group, but by none of the patients receiving 
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placebo. Coughing is a frequently reported adverse event after infliximab treatment when 
given for other diseases, and might be more pronounced in our patient group (37). However, 
this finding was not supported by the results obtained from the respiratory symptom 
domains in the CCO and SGRO. 
In conclusion, our study did not show a short-term improvement in clinical or inflammatory 
parameters from infliximab treatment in patients with mild-to-moderate COPD, although 
patients so treated did demonstrate an increase in eNO, a finding of uncertain clinical 
relevance. Importantly, no severe adverse events occurred and there was no reported 
increase in the prevalence of respiratory tract infections in 9 weeks of the study. Of patients 
with COPD who received infliximab, 8 of 14 reported increased coughing, yet this was 
not reflected in answers to questions about symptoms in the CCO and SGRO. Definitive 
conclusions as to the effectiveness of anti-TNF·cx treatment in COPD must await additional 
studies involving patients with COPD more severe disease, in larger cohorts and with 
longer follow-up. 
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lnfliximab Placebo 
No. Patients 14  8 
Sex, M/F 1 3/1 5/3 
Age, yr 56.6 ± 6.1 54.8 ± 7.4 
Smoked, pack-yr 60.6 ± 40.3 53.8 ± 35.6 
Smoked, cigarettes/d 23.8 ± 1 5.3 28.8 ± 1 5.9 
BMI, kg/m2 24.0 ± 3.9 26.8 ± 3.0 
FEV,, % pred 80.5 ± 9.2 86.1 ± 1 5.9 
FEV/FVC, % 62.1 ± 4.7 60.8 ± 9.3 
PC20 AMP, mg/ml 1 2.2 (1 .1 - 640) 20.4 (3.7 - 640) 
CCQ, total 1 .2 ± 0.6 1 .7 ± 0.7 
SGRQ, total 34.1 ± 1 2.4 28.0 ± 1 4.5 
Table 1 .  
Patient characteristics. 
Definition of abbreviations: BM/: body mass index; CCO: clinical COPD questionnaire; M/F: male/ 
female; PC20AMP: the concentration of adenosine 5'-monophosphate causing FEV, to drop 20%; 
SGRO: St. George Respiratory Questionnaire. 
Values are presented as means ± SD or as geometric means (ranges). There were no differences 
between the two groups. 
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eNO, ppb 
FEV1 ' % pred 
Kea, %  pred 
REE, % pred 
PC20 AMP, mg/ml • 
eNO, ppb 
FEV1 ' % pred 
Keo• % pred 
REE, % pred 























Lung function parameters. 
Day 2 Week 2 
Placebo 
5.1 6.2 




49.3-1 18.8 54.0-1 15.6 
1 09.4 107.0 









101 .9 1 04.5 
88.6-129.5 95.7-121 .3 
ND ND 
Week 6 Week 8 
4.4 5.9 
2.7-9.1 2.6-1 1 .6 
80.9 79.4 
53.0-99.5 57.0-101 .0 
77.8 80.8 
50.7-1 18.8 45.3-1 14.9 









53.5-107.9 51 .4-1 02.9 
1 03.8 1 03.5 
91 .3-124.0 90.4-136.6 
1 1 .4 
ND 0.9-640 :t: 
Definition of abbreviations: eNO: exhaled nitric oxide; ND: not done; REE: Resting Energy 
Expenditure; PC20 AMP: the concentration of adenosine 5'-monophosphate causing FEV, to drop 
20%; Keo: diffusion capacity for carbon monoxide corrected for the alveolar volume. 
Values are presented as medians or geometric means with ranges (*). t: The change from 
baseline is significantly different with infliximab compared with placebo, p<0.05. :t :PC20 AMP is 
measured at week 9. 
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Baseline Day 2 Week 2 Week 6 Week 8 
Placebo 
Sputum weight, g 7.7 5.8 8.0 7.1 7.1 
1 .6-13.5 2.1-14.5 1 .2-12.1 2.8-12.7 1 .0-10.4 
Total cells, 1 06/ml 2.2 2.5 4.3 3.8 1 .9 
1 .1 -14.8 0.6-1 2.5 1 .9-5.7 0.6-5.3 0.6-12.0 
Macrophages, % 26.7 35.7 27.0 26.8 37.8 
21 .0-41 . 2  19.0-62.2 13.3-35.2 9.8-45.5 13.5-47.3 
Neutrophils, % 68.3 61.4 66.7 68.7 57.3 
56.8-77.3 36.5-74.3 49.0-73.8 50.5-84.2 49.7-82.0 
Eosinophils, % 0.7 0.8 1 .0 1 .2 1 .0 
0.3-1 .8 0.0-1.7 0.5-1 .8  0.3-2.5 0.5-2.0 
Lymphocytes , % 0.3 0.7 0.7 0.7 0.5 
0.2-2.0 0.0-0.8 0.0-5.2 0.0-1 .5 0.0-1 .8 
IL-8, ng/ml 2470 2317  2071 1756 1811 
1117-20749 1485-14286 1 224-28409 697-29015 932-27737 
IL-6, ng/ml 146 106 103 87.4 80.4 
16.3-200 12.4-260 20.1-584 1 0.7-428 9.6-596 
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Baseline Day 2 Week 2 Week 6 Week 8 
lnfliximab treatment 
Sputum weight, g 6.0 7.5 6.2 7.7 8.0 
1 .3-17.0 1 .9-16.3 3.7-14.0 2.3-12.6 1 .6-14.8 
Total cells, 106/ml 3.8 3.5 4.6 5.2 5.2 
0.2-24.5 0.4-1 1 .5 0.5-23.2 0.7-29.2 1 .1 -48.9 
Macrophages, % 26.3 36.0 26.8 27.1 27.0 
1 6.3-48.7 1 0.5-56.5 6.5-55.5 10 .2-42.2 4.8-52.3 
Neutrophils, % 66.5 49.7 62.9 62.0 65.7 
48.7-80.2 31 .3-81 .3 24.3-90.3 47.5-85.0 18.3-92.0 
Eosinophils, % 1 .3 1 .5 1 .8 1 .4 1 .5 
0.3-16.0 0.3-1 8.5 0.2-23.7 0.0-18.7 0.0-18.7 
Lymphocytes, % 0.5 0.5 0.5 0.7 0.8 
0.2-4.8 0.0-1 .3 0.0-2.3 0.0-4.5 0.3-3.0 
IL-8, ng/ml 7199 41 02 5334 4613 3624 
954-16526 1 197-13430 1040-20490 439-32280 1264-32412 
IL-6, ng/ml 223 130 179 1 64 1 23 
18.2-1 181 1 2.5-369 3.8-1595 7.7-1926 9.8-1 181  
Table 3. 
Sputum inflammatory parameters. 
Definition of abbreviation: IL: interleukin. 
Values are presented as medians with ranges. 
There were no significant differences between the two groups. 





































At each visit, the following question was asked to evaluate adverse events: 'Did you have any 
complaints (especially fever, or extra or new symptoms) since the last visit?'. 
* p <0.05 compared with placebo. 
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Letters-to-the-Editor 
Study of infliximab treatment in smokers with COPD: what next? 
We read with great interest the recent Phase II trial of the chimeric mouse/human monoclonal 
anti-TNF-a. antibody infliximab in patients with mild-to-moderate COPD by van der Vaart H 
et al ( 1) .  This study failed to reach any definite conclusions about the efficacy of infliximab 
in COPD. Given the broad effect of TNF-a. on the induction and maintenance of airway 
inflammation in COPD (2) and the recent encouraging findings with anti-TNF-a. drugs in 
chronic asthma (31, the lack of efficacy of infliximab on COPD patients in the present study 
is rather disappointing. 
These authors ascribed the observed lack in clinical response to a number of problems with 
the study design: I .  all participants were current smokers and cigarette smoking appears to 
impair rate and duration of response to infliximab; 2. the degree of disease severity was not 
adequate to show a significant response; 3. it is possible that the dose was too low and the 
duration too short to measure significant changes; 4. duration of follow-up was too short to 
detect significant changes; 5. the small sample size did not have enough power to detect 
changes. Perhaps there are some additional considerations that may explain the negative 
findings of this study. 
Firstly, the occurrence of neutralising antibodies is a common event with infliximab and this 
is likely to compromise drug efficacy (4) ; future studies with infliximab will require careful 
evaluation of neutralising antibodies. 
Secondly, given that TNF-a. antagonists with lower immunogenicity, such as the soluble 
fusion protein etanercept, have proven to be remarkably effective in chronic severe asthma 
in two separate studies (5,6) ,  it would be very important to test etanercept in COPD patients 
before reaching any definite conclusions about the value of TNF-a. inhibition in COPD. 
Finally, the inability of infliximab to modify clinical and inflammatory parameters in smokers 
with COPD is not surprising. It is well known that each and every one of the drugs used for 
treating COPD (bronchodilators, inhaled corticosteroids, and combinations of inhaled steroids 
and long-acting beta2 agonists) have limited effects . Although this disappointing trend may 
reflect the natural history of the disease, it is also likely to result from the deleterious effects of 
active smoking on the clinical and inflammatory parameters under scrutiny. Tobacco smoke 
contains a high concentration of oxidants, and oxidative stress is a significant contributor 
to the pathogenesis of COPD. The consequences of increased oxidative stress in the lung 
include increased transcription of inflammatory genes, protease activity, and mucus secretion. 
Therefore, ongoing oxidative stress is likely to contribute to inability of drugs to modify clinical 
and inflammatory parameters in patients with COPD who smoke, as was the case for those 
participating in the study of van der Vaart H et al. ( I ) .  This interaction has been recently 
reported in asthma, where it has been shown that cigarette smoking markedly reduces the 
efficacy of inhaled corticosteroids (7). In future clinical trials, drugs for COPD should be 
tested only in patients who commit themselves to smoking cessation programs. 
Dr. Cristina Russo, Dr. Francesca D'Angelo, Prof. Riccardo Polosa 
University of Catania, Dipartimento di Medicina Interna e Specialistica 
95125 Catania - ITALY 
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Study of infliximab treatment in smokers with COPD: no definite answers yet 
We appreciate the comments by Russo and colleagues regarding our recent article in the 
American Journal of Respiratory and Critical Care Medicine (I). Our trial was designed as 
a pilot and safety study of infliximab in COPD, which explains the inclusion of rather mild 
COPD patients, moderate dosing of infliximab, short duration of study, and small sample size. 
Russo and colleagues suggested some additional explanations for the negative findings. 
First, they suggest that neutralizing antibodies (human anti-chimeric antibodies: HACA's) may 
affect the efficacy of infliximab. Although we agree, it is clear that infliximab has impressive 
clinical efficacy in Crohn's disease and rheumatoid arthritis (RA). The true incidence of HACA 
formation in adult patients receiving infliximab is unknown. The large ACCENT ! trial in 
Crohn's disease and the ATTRACT trial in RA reported an overall incidence in 8-14% of 
patients during I year treatment. In contrast, Baert et al (2) reported HACA formation in 
68% of Crohn patients who received infliximab 'on-demand', i.e. 3.9 infusions (range 1-17) 
per patient administered over IO months on average. We do not know if the prevalence 
of HACA formation is similar in COPD. Furthermore, we used a short induction scheme 
including 3 infusions within 6 weeks, which is not comparable with aforementioned 
examples. Second, etanercept might be more effective than infliximab. Indeed, etanercept 
has lower immunogenicity and has suggested to be effective in chronic asthma (3). Because 
chronic asthma and COPD are different diseases (specific Th2 mediated eosinophilic response 
to allergens versus nonspecific neutrophilic response to smoke), we are not convinced that 
etanercept's efficacy in asthma will predict efficacy in COPD. Nevertheless, it is of interest 
to test etanercept in COPD before reaching any definite conclusions about the clinical 
value of TNF-a inhibition. The main reason for testing etanercept in our opinion is not 
its lower immunogenicity or efficacy in asthma, but its difference in pharmacokinetic and 
pharmacodynamic profile as compared with infliximab (4). Third, current smoking might 
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have negatively affected the clinical and anti-inflammatory efficacy of infliximab. Reports on 
smoking in relation to response rates in Crohn's disease vary from adverse effects to no effect. 
In our study we intentionally included current smokers instead of ex-smokers for several 
reasons. 
• Most COPD patients smoke and are unable to quit. 
• Smoking COPD patients have more respiratory symptoms than non-smoking 
patients, worse bronchial hyperresponsiveness, and faster lung function decline. The 
need for effective treatment is higher in smokers. 
• We wished to ensure increased TNF-a levels (as far as possible}. Indeed cigarette 
smoke exposure has been shown to increase TNF-a production in animal models 
(5). 
• We reasoned that inclusion of current smokers would provide a more homogeneous 
group of patients, thereby enhancing the putative effects of TNF-a blockade. COPD 
patients who quit smoking show an increase one year later in some aspects of 
inflammation ( 6}, which may fade away within a few years. Little is known about the 
time course and inter-individual differences of this response. COPD patients should 
always try to quit smoking. However, we also feel it is not ethical to exclude smoking 
COPD patients from effective treatments, nor to exclude them from explorative 
research trials. 
Dr. Nick ten Hacken, Dr. Hester van der Vaart, Dr. Gerard Koeter, Dr. Henk Kauffman, 
Dr. Dirkje Postma, Pulmonary Department of the University Medical Centre Groningen, 
University of Groningen, The Netherlands. 
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Abstract 
Rationale: Sputum induction is a tool to monitor airway inflammation, yet it may induce by 
itself a neutrophilic response when repeated within 24 to 48 hours. This limits its repeated 
use in clinical trials. 
Objectives: We aimed to investigate the induction and resolution of inflammation generated 
by repeated sputum inductions. 
Methods: Sixteen healthy intermittent smokers participated in a study on acute effects 
of smoking. The non-smoking arm consisted of seven successive sputum inductions with 
increasing time intervals: 3, 6, 12, 24, 48 and 96 hours. Inflammatory cellular characteristics 
and different soluble mediators were investigated. 
Results: The median (range) percentage of sputum neutrophils increased significantly from 
baseline to 6 hours: 58. 9% ( 3 1.8-94.2) to 83.2% (26. 7-98.3 ). Surprisingly, also the percentage 
of eosinophils increased significantly from baseline to 6, 12, 24 and 48 hours: 0.3% (0.0-1.2) 
to 1.7% (0.0-15.5), 2.2% (0.5- 12.5), 1.2% (0.0-4.8) and 0.8% (0.0-2.8), respectively. IL-8 
increased significantly from baseline to 24 hours: 1553 pg/ml (462-8 192) to 2178 pg/ml 
(666-128544). 
Conclusion: We conclude that repeated sputum inductions induce a short-lived neutrophilic 
and a prolonged eosinophilic inflammatory response in healthy subjects. This is possibly caused 
by local changes in osmolarity and subsequent epithelial cell and/or mast cell activation. 
134 Chapter6  
I ntroduction 
Sputum induction is a safe, non-invasive, and validated technique to assess airway inflammation 
in asthma, COPD and healthy subjects ( 1-3). It is frequently used to monitor inflammation in 
clinical trials. A possible drawback for this application is that a neutrophilic response might 
occur when sputum inductions are being repeated within 8 or 24 hours (4, 5). This 'carry 
over' effect thus limits the iterative use of sputum inductions. The minimum time interval 
between sputum inductions in order to obtain reproducible cellular counts, was variable in 
different reports, i.e. 24 and 48 hours (6-8). Even less is known on the cumulative effect of 
more than two sputum inductions. Based on a review of the literature, the working group 
on sputum induction of the ERS (9) stated recently that sputum inductions should not be 
repeated within 48 hours to avoid 'carry over' effects. In line with this, we used a crossover 
design (including no smoking) in a study on the (sub)acute effects of smoking to correct for 
this 'carry over' effect. Given the possible consequences of the repeated sputum inductions 
for its applicability in research, we have, as a separate study, used the control arm of the above 
study to investigate both induction and resolution of the inflammatory response generated by 
repeated sputum inductions. To this aim we analysed the effects of seven repeated sputum 
inductions performed at increasing time intervals in 16 healthy volunteers. 
Methods 
Study design 
In a study on (sub)acute effects of smoking on inflammation ( I 0) we designed a non-smoking 
arm that consisted of seven sputum inductions separated by increasing time intervals from 
baseline (t=0 hrs): 3, 6, 12, 24, 48, and 96 hours. Healthy subjects refrained from smoking 
during nine days before and during the study period, verified by exhaled carbon monoxide 
(CO < 6 ppm) and urinary cotinine (< 25 ng/ml). 
Subjects 
The 16 participants were older than 40 years and had normal lung function: prebronchodilator 
Forced Expiratory Volume in I second (FEV i JIInspiratory Vital Capacity (NC) > 89% of 
predicted for women and > 88% of predicted for men ( 11 ). All subjects smoked more than 
one cigarette a month, but not daily, during the last 6 months. Excluded were subjects 
with: I )  a history of asthma, allergic rhinitis, or allergic eczema; 2) atopy, confirmed by a 
positive skin prick test; 3) any current respiratory disease, symptoms of cough or sputum 
production; 4) respiratory tract infection within the preceding 8 weeks or a nasal infection 
within the preceding 4 weeks; 5) use of aspirin, NSA!Ds, paracetamol or antihistamines 
within the preceding 4 weeks. The study was approved by the medical ethics committee of 
the University Medical Centre Groningen, the Netherlands. Written informed consent was 
obtained from all subjects. 
Pulmonary function and exhaled carbon monoxide 
FEV 1 and NC were measured according to the guidelines of the European Respiratory 
Society ( 11) using a pneumotachograph (Jaeger, Wurzberg, Germany). Exhaled CO levels 
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were measured, using an infrared CO analyser (UNOR 6N, Maihak AG, Hamburg, Germany) 
( 1 2). 
Sputum induction 
Sputum was induced according to the method of Rutgers et al ( 1 3) with some modifications. 
Hypertonic sodium chloride aerosols (4.5 w/v %) were generated at room temperature by a 
De Vilbiss Ultraneb 2000 ultrasonic nebulizer with a calibrated particle size (MMAD 4.5 µm) 
at maximum output (2.5 ml/min). Aerosols were administered through a I 00-cm long tube 
with an internal diameter of 22 mm and a two-way valve and inhaled via the mouth. Nose 
clips were used. Prior to sputum induction 400 µg salbutamol was administered for safety 
reasons and FEV1 was measured. Hypertonic saline was nebulised during three periods of 5 
minutes. After each inhalation period, or as soon as the subjects experienced cough, they 
were asked to blow their nose, rinse their throat with water and to cough their sputum into a 
plastic container. FEV1 was measured whenever a patient felt discomfort and after completion 
of each inhalation period. Salbutamol 200 µg was administered if FEV1 dropped more than 
20% from the post·salbutamol baseline value. 
Sputum processing 
Whole sputum was processed within 120 minutes according to the modified method of 
Rutgers et al ( 1 3) .  In short, first the weight of the sputum samples was determined. An equal 
volume of 0.1  % sputolysin (dithiotreitol, OTT, Calbiochem, USA) was added and thereafter 
the sample was placed in a shaking water bath (37°C, 1 5  min). The homogenised sputum 
was filtered through a nylon gauze (pore-size approximately 48 µm, Thompson, Ontario) to 
remove clumps, followed by centrifugation (450 x g, 1 0  min, 20°C). Differential cell counts 
of eosinophils, neutrophils, lymphocytes, macrophages, epithelial and squamous cells were 
performed on May Grunwald Giemsa stained cytospins by a cytotechnician in a blinded fashion. 
For each sample, differential cell counts were performed on two cytospins (counting 2 x 300 
non-squamous cells) by the same observer. The mean data were used for statistical analysis. 
Differential leukocyte and cylindric epithelial cell counts were expressed as a percentage of 
600 nucleated cells excluding squamous cells. A sputum sample was considered adequate 
when the percentage squamous cells was < 80%. Absolute numbers of inflammatory cells per 
ml were calculated by multiplying the total number of sputum cells per ml by the differential 
count [it was assumed that 1 mg sputum equals I ml sputum). 
lmmunocytology was performed to quantify the percentage of inducible nitric oxide synthase 
(iNOS) positive macrophages. Cytospins were double stained with a monoclonal antibody 
against CD68 (IgG1 isotype, Dako, Glostrup, Danmark, as a marker for macrophages) and 
rabbit polyclonal antiserum against iNOS (Transduction Laboratories, Lexington, KY, USA). 
The following soluble mediators were measured in sputum supernatant. NO2 /NO3 was 
measured using the Griess reaction, eosinophilic cationic protein (ECP) using the fluorenzyme 
immunoassay Uni CAP ECP (Pharmacia, Uppsala, Sweden). Interleukin (IL)-8 and leukotriene 
B4 (LTB4) were measured by a commercial ELISA (IL-8: Sanquin, Amsterdam, the Netherlands, 
LTB4: Amersham Biosciences, UK). Matrix metalloproteinase (MMP)-9 was measured by 
gelatine zymography, and tissue inhibitor of metalloproteinase (TIMP)-1 by ELISA (R&D, 
Abingdon, UK). Neutrophil elastase (NE) activity was measured by chromogenic substrate 
assay (N-methoxysuccinyl·ala-ala-pro-val-p-nitoanilide, Sigma, UK) ( 1 4) .  
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Statistical analyses 
Clinical, cell and mediator characteristics are presented as medians with ranges (tables 1 -3 , 
or as medians with interquartile ranges (figures 1 -3) . Outliers are presented between 1 .5 and 
3 times the interquartile range (figures 1 -3) . Differences between the subsequent sputum 
inductions and baseline (t=0) were tested with a Wilcoxon Signed Rank test. A p value of < 
0.05 was considered statistically significant. 
Results 
Subjects 
Clinical characteristics of the subjects are listed in table I . All subjects successfully refrained 
from smoking for 9 days before and during the study period. All subjects tolerated the sputum 
induction procedure well and no adverse events were reported during the study period .  
Sputum quality 
The quality characteristics of the sputum samples are shown in table 2. Thirty-four of the 
1 1 2 (30%) sputum samples could not be evaluated for total and differential cell counts, due 
to a too high percentage of squamous cells and/or low cell viability. Apart from a lower total 
number of sputum cells at 6 hours and a trend towards a lower viability at 3 hours compared 
to baseline (t=0, p=0.07), no differences were found in total cell count, viability, sputum 
weight or squamous cell contamination at the different time points. 
Sputum cells 
The percentage and number of sputum cells are shown in figure I and 2, respectively. The 
percentage of neutrophils was significantly higher at 6 hours than at baseline: 83.2% (26.7-
98.3) and 58.9% (31 .8-94.2). The number of neutrophils tended to be lower at 6 hours than 
at baseline: 375 I 03/ml ( 1 2 1 -857) and 557 I 03/ml ( 1 38-1 757) (p=0.05 1 ). Both percentage 
and number of macrophages were significantly lower at 3 and 6 hours than at baseline: 
20.8% (4.5-71 .2), 1 0.3% ( 1 .7-67.8) and 38.5% (4.2-64.0), and 1 1 9 1 03/ml ( 1 9.6-335) ,  42.2 
1 03/ml ( 1 0.3-629) and 287 1 03/ml (24.4-22 1 7) ,  respectively. The percentage of eosinophils 
was significantly higher at 6, 1 2, 24 and 48 hours than at baseline: I .  7% (0.0- I 5.5) , 2.2% 
(0.5- 12.5), 1 .2% (0.0-4.8), 0.8% (0.0-2.8) and 0.3% (0.0- 1 .2), respectively. In addition, the 
number of eosinophils was significantly higher at 12  hours than at baseline: 25.0 1 03/ml 
(2.2-1 15 )  and 1 .9 I 03/ml (0.0- 1 8.8), respectively. Sputum induction had no significant effect 
on the percentage of lymphocytes, but the number of lymphocytes was significantly lower at 
3 and 6 hours than at baseline: 2.0 1 03/ml (0.0-1 6.5), 0.7 1 03/ml (0.0- 1 7.9) and 7.3 1 03/ml 
(0.0-38.8), respectively_ The percentage of iNOS positive macrophages was significantly lower 
at 24 hours than at baseline: 54.2% (20.0-8 1 .7) and 67.3% (33.3-90.2), respectively. 
Inflammatory mediators in sputum 
Sputum ECP and IL-8 are shown in figure 3. ECP tended to be lower at 12 hours than at 
baseline: 73.4 ng/ml (8.0-804) and 75. 1  ng/ml ( 1 2. 1 -346) (p=0.06). IL-8 was significantly 
higher at 24 hours than at baseline: 2 1 78 pg/ml (666-1 28544) and 1 553 pg/ml (462-8 1 92) 
and tended to be lower at 6 hours than at baseline: 1 384 pg/ml (379- 1 2966) and 1 553 pg/ 
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ml (462-8192) (p=0.06 ). Other sputum mediators are shown in table 3. Nitrite/nitrate was 
significantly higher and TIMP-1 was significantly lower at 6 hours than at baseline. Sputum 
induction(s) had no effect on MMP-9 and LTB4 levels at any time point. NE could be detected 
only in three sputum samples; therefore, no statistical analyses could be performed. 
Discussion 
Sputum induction i s  a tool to  monitor airway inflammation, yet some reports have shown a 
neutrophilic response when it is repeated within 8 to 24 hours. This may limit its repeated use 
in clinical trials. We aimed to investigate both the induction and resolution of inflammation 
generated by repeated sputum inductions. The main result of our study is that repeated 
sputum inductions in healthy subjects generate a prolonged increase in sputum eosinophils. 
This is not accompanied by increased sputum ECP. In addition, repeated sputum inductions 
induce a short-lived increase in the percentage sputum neutrophils and IL-8 levels and a short­
lived decrease in the percentage and number of sputum macrophages. Altogether, the results 
of our study show that repeated sputum inductions should be avoided preferably, unless 
separated by at least 48 hours in time. 
To our knowledge it is a new finding that repeated sputum inductions induce an eosinophilic 
response in healthy subjects. In previous studies in asthmatics eosinophils did increase after 
sputum inductions, but were not reported to be significantly higher (3, 4, 15). This may be 
due to higher baseline levels of sputum eosinophils in asthmatics, and thus small changes in 
eosinophils are not significantly different. Another reason may be that our study especially 
focussed on the effects of repeated sputum inductions at relatively short time intervals. 
Interestingly, the sputum eosinophils remained elevated for a longer period of time (48 
hours) than the sputum neutrophils in our study. We can only speculate on this differential 
effect. Apparently, the recruitment and activation of eosinophils and neutrophils by sputum 
inductions differ. In this context eosinophils can be directly activated by hyperosmolar stimuli 
( 16), while they also show increased sensitivity for mast cell mediators ( 17). Regarding to 
ECP levels, Holz et al (4) have shown that sputum ECP levels were increased in healthy as 
well as in asthmatic subjects 24 hours after the first sputum induction. In contrast, in our 
study sputum ECP tended to decrease, the reason for this discrepancy being unclear. 
Repeated sputum inductions increased the percentage of neutrophils at 6 hours in healthy 
subjects in our study. This is in line with two other studies showing increased percentage 
and numbers of sputum neutrophils in healthy subjects at 8 and 24 hours (4, 5). Several 
mechanisms have been proposed to explain the increase in neutrophils. First, hypertonic saline 
may induce local changes in osmolarity (18), which may subsequently result in the release 
of pro-inflammatory mediators from mast cells or epithelial cells ( 19-22). Second, frequent 
coughing during the sputum induction may irritate the mucosa and result in a neutrophilic 
influx into the airway lumen. Increased neutrophils in our sputum due to LPS contamination 
of the hypertonic saline (23) is not very likely, since no LPS could be demonstrated in our 
inhalation fluid. 
In contrast to the increase in percentage of neutrophils, we observed a decrease in neutrophil 
numbers, which may be due to the significant lower total sputum cell count at that time. 
Similarly, we observed a lower number and percentage of macrophages at 3 and 6 hours, 
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which seems to represent a real decrease, as this is more than is to be expected based on 
reduced total cell count. An explanation for this decrease may be that macrophage kinetics 
are rather slow. After a washout of macrophages by a sputum induction, it may take more 
than 6 (up to at least 24) hours before a local homeostasis is reached that again reflects the 
non-affected inflammatory status. Furthermore, the percentage of iNOS positive macrophages 
decreased as well after 24 hours. It has been shown previously that exhaled nitric oxide 
decreases after a single sputum induction (24), which might be explained by the decrease in 
iNOS observed in our study. 
With respect to mediators in sputum we have found that repeated sputum inductions 
increased IL-8 at 24 hours in sputum supernatant. No increase in neutrophils was seen at 
that time point, which makes this cell as a source for IL-8 less likely. Hashimoto et al showed 
increased IL-8 expression when epithelial cells were exposed to a hyperosmolar challenge in 
vitro (20). Furthermore, IL-8 expression in bronchial epithelium increased after lavage with 
isotonic saline challenge in asthmatics (25) .  We therefore assume that the epithelial cell is the 
main source for IL-8 in our study. 
No significant differences were observed for any marker between the sputum inductions at 
48 and 96 hours (time interval 48 hours) .  Therefore we confirm and extend the conclusion 
of the ERS working group (9), showing that 48 hours is needed to avoid a 'carry over' effect 
even if several repeated sputum inductions have been performed. 
Our sputa had a relatively high percentage of squamous cells (60.5% (3.8-94.7)) compared 
to other studies {means and medians varying between 1 .2-53%) ( 1 ,  3, 5, 26). This might be 
due to differences in methods used for induction and processing of the sputum or due to our 
specific study group of healthy intermittent smokers. Many studies used selected sputum 
plugs for cytospin preparation, which are known to contain less squamous cells (27). In 
addition, our repeated sputa had relatively low viability {6 1 .4% (9.2-88.6)) compared with 
other studies {medians and means varying between: 70-88%) (4, 6, 28). In our study, the 
viability and the total cell count decreased at respectively 3 and 6 hours compared to baseline 
which may be due to the short time interval between the sputum inductions as has been 
shown by Richter et al (29). The low total cell count in our study may explain the decreased 
numbers of macrophages, neutrophils and lymphocytes, but strengthens the observed influx 
of eosinophils. 
Our time dependent variations in sputum cells cannot easily be explained by a circadian 
variation. Blood leukocytes have a circadian rhythm with peak levels between 22.30 and 
2.30 hours (30). Only one study has been published investigating circadian variation of 
inflammatory cells in sputum, showing higher eosinophils at 7.00 hours compared to 1 6.00 
hours in asthmatic patients (3 1 ), which is not in line with our data. We therefore assume that 
a circadian rhythm does not explain our results. 
Summarising, our results show that repeated sputum inductions generate inflammatory 
changes. An interesting new observation is that repeated sputum inductions generate a 
prolonged eosinophilic inflammatory response. We can only speculate as to the mechanisms 
underlying this prolonged activation, but a role for mast cells seems attractive. Consistent with 
the literature, sputum inductions induce a short-lived neutrophilic inflammatory response, 
possibly caused by local changes in osmolarity and subsequent epithelial cell and/or mast cell 
activation. Further, at the same early time point macrophages seem to have delayed kinetics, 
resulting in slow restoration of normal numbers after sputum induction. Altogether, it can be 
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concluded that repeated sputum inductions should be avoided preferably, unless separated by 
at least 48 hours in time. 
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49 (39-71)  
4 (0-40) 
1 19  (68-144) 
77.6 (68.1 -87.0) 
Values expressed as medians (ranges). These subjects are the same as in the article on 
(sub)acute effects of smoking on inflammation (10) which is mentioned in the method section. 
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o hours 3 hours 6 hours 12 hours 
Weight, gram 5.3 5.0 4.7 5.2 
(0.3-16.1 ) (1 .4-8.9) (0.9-10.0) (1.0-9.2) 
Total cells, 106/ml** 3.1 2.0 2.1· 2.1 
(0.1-20.4) (0.7-7.9) (0.4-6.2) (0.6-9.5) 
Viability, % 59.4 47.8 ,i 63.1 64.6 
(5.4-80.0) (6.6-80.9) (3.2-91.7) (8.9-93.6) 
Squamous cells, % 63.5 65.0 69.0 66.0 
(1.5-96.5) (6.5-90.5) (4.0-98.5) (2.0-94.5) 
Evaluable sputum, 12 (75) 10 (62.5) 11 (68.8) 10 (62.5) 
number (%) 
Table 2. 
Sputum quality characteristics. 
Values are expressed as medians (ranges). •: p <0.05 compared to baseline values (0 hours), 
1/: p=0.07 compared to baseline values. -rota/ cell counts have also been used in an article on 
(sub)acute effects of smoking on inflammation (10) which is mentioned in the method section. 
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24 hours 48 hours 96 hours 
4.8 4.6 5.0 
(1 .1-10.6) (0.9-1 0.5) (0.8-9.7) 
2.9 4.6 2.8 
(1 .1 -13.0) (0.4-14.0) (0.8-23.8) 
63.2 67.4 71 .2 
(7.6-89.2) (1 0.0-89.6) (14.9-87.7) 
64.5 37.3 42.3 
(0.0-93.5) (0.5-97.0) (3.5-95.0) 
12 (75) 1 1  (68.8) 12 (75) 
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o hours 3 hours 6 hours 12 hours 
LTB4, nM 3.6 2.6 3.2 3.4 
(1.0-14.4) (0.6-10.3) (0.7-13.4) (0.7-15.3) 
MMP-9, nM 2.7 1 .6 2.1 1 .2 
(0.1 -75.1 ) (0.0-30.6) (0.0-69.1) (0.1 -75.5) 
TIMP-1. nM 5.5 4.7 4.6 4.2 
(2.1 -16.0) (2.2-14.3) (1 .3-12.0)* (0.8-14.4) 
Nitrite/nitrate. pM 149 169 254* 1 50 
(66.4-403) (76.0-1323) (65.0-1279) (78.0-618) 
Table 3. 
Sputum inflammatory mediators at different time points. 
Values are expressed as medians (ranges). *: p <0.05 compared to baseline values (0 hours). 
All data from this table has also been used in an article on (sub)acute effects of smoking on 
inflammation (10), which is mentioned in the method section. LTB4: leukotriene 84, MMP-9: matrix 
metalloproteinase-9, nMP-1: tissue inhibitor metalloproteinase-1. 
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24 hours 48 hours 96 hours 
3.1 2.9 4.1 
(1.3-33.6) (1 .5-18.0) (1 .1 -17.7) 
3.8 2.6 3.3 
(0.0-64.0) (0.0-64.0) (0.5-59.3) 
4.4 6.0 5.9 
(1 .1 -1 1 .3) (1 .7-1 3.3) (0.6-10.8) 
140 145 150 
(33.0-601 ) (44.0-555) (54.0-451 ) 
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Figure 1 .  
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Effect of repeated sputum inductions on the percentage of sputum cells. 
In each box plot, the bottom and the top of the box denote the 25th and 75th percentiles, 
respectively, the solid line the median, and the brackets are outliers between 1.5 and 3 times the 
interquartile range. *: p <0.05 compared to baseline, t: p =0.06 compared to baseline. All data 
from this table has also been used in a table in an article on (sub)acute effects of smoking on 
inflammation (10), which is mentioned in the method section. 
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Effect of repeated sputum inductions on the number of sputum cells. 
* 
12 2-4 48 96 
In each box plot, the bottom and the top of the box denote the 25th and 75th percentiles, 
respectively, the solid line the median, and the brackets are outliers between 1.5 and 3 times the 
interquartile range. *: p <0.05 compared to baseline. 



















Effect of repeated sputum inductions on sputum IL-8 and ECP. 
In each box plot, the bottom and the top of the box denote the 25th and 75th percentiles, 
respectively, the solid line the median, and the brackets are outliers between 1.5 and 3 times the 
interquartile range. *: p <0.05 compared to baseline, t: P= 0.06 compared to baseline. All data 
from this table has also been used in a table in an article on (sub)acute effects of smoking on 
inflammation (10), which is mentioned in the method section. 
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Summary and main conclusions of this thesis 
In contrast to the extensive knowledge on the effects of chronic smoke exposure on lung 
function and airway inflammation, there is a paucity of data on the acute effects of smoking 
in this respect. It seems important to know these effects since repetitive acute smoke effects 
may constitute the underlying causal chain leading to the ultimate chronic effects. In chapter 2 
we have reviewed the literature investigating the acute effects of cigarette smoking (within 
24 hours) on inflammation and oxidative stress in human, animal and in vitro models. 
We show that (figure 1 ) : 
• An acute smoking model is a relatively 'straightforward' and sensitive method to 
investigate specific effects of cigarette smoke on oxidative stress and inflammation. 
• Acute cigarette smoking attracts neutrophils and macrophages to the lung tissue 
and activates these cells. 
• An intriguing finding is the suppressive effect of acute cigarette smoking on the 
number of eosinophils and several inflammatory cytokines, possibly explained by 
the anti-inflammatory effect of carbon monoxide in (CO) cigarette smoke or a local 
shift in the Th l -Th2 type cytokine balance. 
• Acute cigarette smoking increases products of lipid peroxidation and degradation 
products of extra cellular matrix proteins, suggesting it results in tissue damage. 
• In low concentrations acute cigarette smoking induces apoptosis of inflammatory 
and mesenchymal cells and in high concentrations it induces necrosis. 
• Acute cigarette smoking can inhibit the function of human lung fibroblasts, which 
may result in diminished tissue repair. 
• The main findings summarised in this review support the hypothesis that an 
imbalance between oxidants and anti-oxidants and between proteases and anti 
proteases may be important to become a 'susceptible' or 'non-susceptible smoker', 
whereas it has also become clear that disturbances in effective tissue repair deserve 
attention. 
It is difficult to draw firm conclusions on the available literature due to the generally small 
sample sizes under study, essential differences between human, animal and in  vitro models and 
other methodological divergences. We conclude that an acute smoking model is supplementary 
to other ways of studying the effects of smoking and an as yet underinvestigated method for 
intervention studies in smoking related diseases, like COPD. 
In the prior paragraph we already explained why we were interested in the acute effects of 
smoking. In chapter 3 we have investigated the acute effects of smoking two cigarettes on 
both induction and resolution of the inflammatory response in blood and sputum in healthy 
intermittent smokers. 
This study has the following results: 
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• Smoking of two cigarettes acutely suppresses blood eosinophils. This decrease in 
eosinophils may be due to a direct (apoptotic) effect by toxic substances in cigarette 
smoke ( I ) , or to anti-inflammatory substances in cigarette smoke, like CO (2, 3). The 
Chaprcr7 
reason why we did not see changes in eosinophils in sputum is probably a lack of 
study power, due to the lower number of successful measurements in sputum than 
in blood, or due to the low baseline levels of sputum eosinophils in our healthy non­
atopic subjects. 
• Smoking two cigarettes induces a biphasic response in sputum lymphocytes, after 
an initial smoke-related suppression, the cells increase more with smoking than 
without smoke exposure. The initial decrease might result from increased adherence 
of lymphocytes in lung tissue due to the fast upregulation of adhesion molecules 
after smoking (4) or may also be caused by the suppressive effect of CO in cigarette 
smoke as described in the prior paragraph [2). The subsequent increase in sputum 
lymphocytes may reflect the washout of lymphocytes from lung tissue into the 
sputum, which may be regarded as the 'waste bin' of lung inflammatory cells. 
• Smoking two cigarettes increases sputum neutrophils and the release of interleukin 
(IL)-8 from whole blood cells. The fast increase in neutrophils in sputum might result 
from detachment of neutrophils from the pulmonary vascular endothelium (the 
so-called marginated pool) (5) or from recruitment from the bone marrow (6, 7). 
Furthermore, the release of IL-8 by lipopolysaccharide stimulated blood cells after 
smoking may have contributed to increased neutrophil chemotaxis as well. 
• 24 hours after smoking two cigarettes no significant changes were observed, 
suggesting resolution of the cigarette smoke induced inflammation. 
We conclude that besides an increase in inflammation, as known from chronic smoking, there 
is also a short-lasting suppressive effect of smoking of two cigarettes on particular inflammatory 
parameters. Although this might seem beneficial at first face value, it may disturb physiologic 
responses, like repair processes in lung tissue, in which inflammatory cells play a role. 
Fibroblasts are the most important cells in tissue repair in the lung. Fibroblast cell death by 
cigarette smoke may contribute to insufficient tissue repair in emphysema. In chapter 4 we 
investigated the effect of cigarette smoke extract on the induction of cell death of human 
lung fibroblasts. Furthermore, we were interested if transforming growth factor [TGF)·P I and 
interferon [IFN)-y, cytokines that are increased in the lungs of emphysema patients and are 
thought to play a role in emphysema, could modulate cigarette smoke extract induced cell 
death. We compared the cigarette smoke extract induced cell death with generally accepted 
stimuli of cell death: ultraviolet B and anti-Fas exposure. 
This study shows that: 
• High concentrations of cigarette smoke extract induce apoptosis, but predominantly 
cause necrosis of human lung fibroblasts. Cigarette smoke induced necrosis of 
fibroblasts in vivo may enhance local inflammation by recruitment of macrophages 
and other inflammatory cells and in this way contribute to the ongoing destruction of 
the alveolar walls. 
• Preincubation with TGF-P I increases the percentage of necrotic cells after cigarette 
smoke extract exposure. This might be explained by the fact that proliferating 
fibroblasts (e.g. by TGF-P I )  are more vulnerable for the induction of cell death by 
oxidants (8, 9). TGF-P I may also augment the vulnerability of fibroblasts in vivo 
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resulting in death, when exposed to cigarette smoke. 
• Preincubation with IFN-y decreases the percentage of necrotic fibroblasts after 
cigarette smoke extract exposure, opposed to the effect of TGF-!3 l . Since IFN-y 
predominantly inhibits, and TGF-131 enhances fibroblast proliferation ( 10, 11 ), this 
might explain their opposite effects on necrosis induction. 
We conclude that cigarette smoke extract exposure mainly induces necrosis of human 
lung fibroblasts, which may in vivo contribute to decreased tissue repair and enhance local 
inflammation. Furthermore, necrosis of fibroblasts is enhanced by TGF-131, therefore increased 
TGF-131 in the lungs of emphysema patients may augment the vulnerability of fibroblasts to 
die when exposed to cigarette smoke. 
The pro-inflammatory cytokine tumor necrosis factor (TNF)-a is thought to play a central role 
in the induction and maintenance of airway inflammation in COPD. So far, anti-inflammatory 
agents are not effective in reducing airway inflammation in COPD. In chapter 5 we 
investigated the anti-inflammatory effects, safety and tolerability of the anti-TNF-a drug 
infliximab in patients with mild-to-moderate COPD. 
The main results of this study are: 
• Infliximab has no effect on the clinical parameters Forced Expiratory Volume in 
I second (FEV 1 ) ,  Forced Vital Capacity, diffusion capacity, PC20 adenosine 
5'-monophosphate, the clinical COPD questionnaire (CCQ), and the St. George 
Respiratory Questionnaire (SGRO; assessing quality of life). 
• Infliximab has no effect on airway inflammation in sputum, including sputum 
neutrophils and IL-8. 
• Infliximab has no effect on resting energy expenditure. 
• No serious adverse events occured in this study and no increased prevalence of 
respiratory tract infections are reported after infliximab compared to placebo. 
• Eight out of fourteen COPD patients reported increased coughing after infliximab 
treatment, yet this was not reflected by questions on symptoms in the CCQ and 
SGRO. Coughing is a frequently reported adverse event after infliximab treatment 
with other diseases and might be more pronounced in our patient group ( 1 2). 
One of the explanations for the lack of response may be that our COPD patients had too 
mild disease. Maybe infliximab is effective in more severe COPD patients, as it has been 
shown that patients with lower FEV 1 values have a higher load of airway inflammation, as 
reflected by sputum neutrophils and IL-8 ( 13, 14). Another explanation may be that the 
observed increase in TNF-a in COPD is an epiphenomenon, instead of a cytokine that plays 
a central role in the pathophysiology of COPD. Besides factors associated with the disease 
itself, the reason for the lack in clinical response may also be related to the design of the 
study (dose of infliximab, short follow-up, study power). Polosa et al suggested in a letter 
to the editor that the formation of neutralizing antibodies [human anti-chimesic antibodies: 
HACA's) might have affected the efficacy of infliximab in our study. However, we do not know 
if the prevalence of HACA formation in Crohn's disease and rheumatoid arthritis is similar in 
COPD. They also suggested that etanercept (a human TNFR p75:Fc lgG 1 fusion protein, that 
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specifically binds TNF-a) might be more effective than infliximab, as it has been shown to be 
effective in chronic asthma. Investigating etanercept in COPD is interesting mainly because 
of its difference in pharmacokinetic and pharmacodynamic properties and because it can be 
given subcutaneously instead of intravenously. Before definite conclusions can be drawn as to 
the effectiveness of anti-TNF-a treatment in COPD, additional studies are needed in COPD 
patients, with more severe disease, with larger groups and with longer follow-up. 
Sputum induction is a tool to monitor airway inflammation, yet some reports have shown a 
neutrophilic response when repeated within 8 to 24 hours. This may limit its repeated use 
in clinical trials. In chapter 6 we investigated the induction and resolution of inflammation 
generated by seven sputum inductions performed at increasing time intervals in 16 healthy 
volunteers. 
The main results of this study are: 
• Consistent with the literature, repeated sputum inductions result in a short-lived 
(3 hours) neutrophilic inflammatory response, possibly caused by local changes in 
osmolarity and subsequent epithelial cell and/or mast cell activation. 
• Repeated sputum inductions also increase sputum eosinophils, which remain 
elevated for a longer period of time (48 hours) than sputum neutrophils. An explanation 
for this difference may be that eosinophils can be directly activated by hyperosmolar 
stimuli ( 15), while they also show increased sensitivity for the concomitant release of 
mast cell mediators ( 16 ). 
• Repeated sputum inductions decrease the number and percentage of macrophages, 
which remain decreased after normalisation of sputum neutrophils. An explanation 
for this longer decrease may be that macrophage kinetics may be rather slow after 
washout of macrophages by sputum inductions. 
• Repeated sputum inductions should be avoided, unless separated by at least 48 
hours in time. 
We conclude that sputum inductions are a useful tool to measure and monitor inflammation 
in clinical trials, provided that a sufficiently large time interval (e.g. at least 48 hours) is 
present when sputum inductions are performed repeatedly. 
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Main conclusions of the studies in this thesis 
1. An acute smoking model is a complementary and understudied method to 
investigate cigarette smoke induced oxidative stress and inflammation. 
2. Smoking of two cigarettes induces both pro-inflammatory and anti-inflammatory 
effects in healthy intermittent smokers. 
3. Smoking of two cigarettes reduces the number of eosinophils in blood in healthy 
intermittent smokers. 
4. Cigarette smoke extract induces low level of apoptosis and predominantly 
necrosis of human lung fibroblasts, of which the latter is enhanced by TGF-� I in 
vitro. 
5. Our study did not show beneficial effects of the anti-TNF·a drug infliximab on 
clinical and inflammatory parameters in patients with mild-to-moderate COPD 
within 9 weeks of treatment. 
6. Repeated sputum inductions result in a short-lived (3 hours) neutrophilic 
response, and a prolonged (48 hours) eosinophilic inflammatory response 
in sputum in healthy non-atopic subjects. 
7. Repeated sputum inductions should be avoided to monitor airway inflammation, 
unless separated by at least 48 hours in time. 
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Discussion of this thesis 
Anti-inflammatory aspects of smoking and its role in COPD 
In chapters 2 and 3 of this thesis we report on our investigations with regard to the acute 
effects of smoking on inflammation and oxidative stress in order to gain more insight in the 
pathogenetic mechanisms of smoking induced COPD. These studies generated new interesting 
findings in that acute cigarette smoke exposure induces an increase in inflammation on one 
hand, just as is the case with chronic smoking, yet, decreases certain aspects of inflammation 
on the other hand. The latter was shown for reduction of eosinophil numbers in human blood 
and in animal lung tissue and for reduced release of various inflammatory cytokines in vitro. 
These effects of cigarette smoke are so far fairly unknown and unexpected, and it is therefore 
challenging to speculate about potential mechanisms and the implication of these effects. A 
number of potential underlying mechanisms for these suppressive effects can be considered. 
First of all, smoke contains numerous toxic compounds and in addition some substances 
with anti-inflammatory features, one of them being CO. At first sight this is surprising since 
CO is predominantly known as a toxic substance. However, in low concentration it has been 
shown to have anti-inflammatory effects as well, both in vitro and in animal models (3, 1 7). 
CO inhalation decreases eosinophil numbers in broncho-alveolar lavage fluid from allergic 
mice ( 3) and CO suppresses the release of cytokines, as TNF-a and IL- I p  from macrophages 
in vitro (2). On the other hand, CO can be generated in the lung itself in reaction to oxidants 
from cigarette smoke. The anti-oxidant enzyme haem oxygenase- 1 (HO- I )  catalyses the 
conversion of haem in biliverdin in the lung and ferrous iron and CO are also released during 
this reaction ( 1 7). HO- I can be induced by various stimuli associated with oxidative stress, 
like cigarette smoke and several cytokines, and it is expressed in different cell types. Thus, it 
is possible that cigarette smoke suppresses inflammation both directly and indirectly via the 
anti-inflammatory gas CO. 
Another substance of cigarette smoke with immunosuppressive features is nicotine. 
Nicotine can modulate both the innate and adaptive immune responses ( 1 8) .  For example, 
in vitro studies have shown that alveolar macrophages have decreased phagocytic capacity 
to pathogenic bacteria after exposure to nicotine and animals treated with nicotine have 
significant loss of antibody response and T-cell proliferation ( 1 9). In addition, it has been 
shown that nicotine treatment prevents disease relapse in patients with ulcerative colitis ( 1 9). 
Until now effects of nicotine on eosinophils have not been reported in the literature. Also 
other substances from cigarette smoke, like hydroquinone and catechol fractions have been 
shown to induce strong inhibitory effects on cytokine production (20). 
A third possible mechanism for the suppressive effect of cigarette smoke may be an increase 
in apoptosis (i.e. natural cell death) of inflammatory cells in the lung. This has been shown for 
macrophages after exposure to cigarette smoke in vitro ( I ) . Furthermore, nitric oxide (NO), 
a major substance in cigarette smoke increases apoptosis of activated eosinophils in vitro 
(2 1 ). Since both studies showed cell apoptosis to occur only 24 hours after cigarette smoke 
exposure, this mechanism may not account for the effect that we have observed in blood 
eosinophils, i.e. a decrease at 3 hours after cigarette smoke exposure. 
A fourth potential mechanism, which is likely to be more important in long-term smoking, 
is a shift in the Th 1 -Th2 cytokine balance in favour of the Th I cells. Imbalance in favour of 
Th2 cytokines is thought to favour the expression of allergy and asthma, characterised by 
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eosinophilic inflammation. Imbalance in favour of Th I cytokines results in less eosinophilic 
inflammation. It has been recently shown that short-term cigarette smoke exposure 
attenuates eosinophilic airway inflammation in allergic mice (22], suggesting a shift in 
Th l -Th2 cytokines. Unfortunately, this could not be confirmed by differences in Th I and 
Th2 cytokines in the lavage fluid of these mice, because of too low concentrations. This 
suppressive effect on eosinophils was not shown by another study by Joos et al (23), which 
may be explained by differences in study design and HbCO levels. Another example of a 
possible Th l -Th2 cytokine shift induced by cigarette smoke is that smoking asthmatics have 
decreased eosinophil numbers in sputum en blood compared to non-smoking asthmatics (24· 
26] . The Th l -Th2 cytokine shift as an explanation of the anti-inflammatory effects of cigarette 
smoke seems less likely in our acute smoking studies, since changes in this cytokine balance 
can not be expected at these early time points. 
Finally, as was shown in the review (chapter 2], in vitro cigarette smoke exposure inhibits 
release of certain cytokines. For example, IL- ! �  together with soluble intercellular adhesion 
molecule release by epithelial cells and TNF·a. release by alveolar macrophages decreased 
after short-term smoke exposure. (27, 28). This might contribute to the anti-inflammatory 
effects as was observed in our acute smoking study (chapter 3]. 
Another important question raised by our studies is the relevance of this (acute) suppressive 
effect in COPD. The most interesting hypothesis is the potential immunosuppressive role for 
CO and the CO generating enzyme HO· 1 .  The relevance of CO/HO- 1 in COPD is twofold. 
Firstly, an individual heterogeneity in susceptibility to upregulate the expression of HO-1 may 
play a role in the pathogenesis of COPD. It has been shown that the expression of HO- ! is 
decreased in alveolar macrophages from patients with COPD compared to those from healthy 
smokers (29, 30). Furthermore, a polymorphism in the promoter region of HO-! has been 
found in patients with COPD, which is associated with decreased inducibility of HO-1 by 
reactive oxygen species (31  ]. This suggests that insufficient upregulation of HO· I after smoke 
exposure might play a role in the development of COPD. 
Secondly, the anti-inflammatory features of CO may be used as a therapeutic tool in patients 
with COPD. It has been extensively shown that CO has anti-inflammatory features in vitro 
and in animal studies (3, 1 7). However, this has not been demonstrated in humans yet. It 
would be of clinical importance to evaluate the effect of inhaled CO, CO-releasing molecules 
(32) or local induction of HO-! ( 33) as a potential anti-inflammatory therapy in patients with 
COPD. Bathoorn and colleagues from Groningen currently study the effect of CO inhalation 
in ex-smoking patients with stable COPD. Novel anti-inflammatory therapies, like the 
mentioned CO inhalation, are urgently needed, since effective anti-inflammatory therapy that 
reduce the underlying airway inflammation and/or stop the excess decline of lung function is 
unavailable in patients with COPD. 
Acute smoke studies, improvement of the study design 
In chapter 3 we described our study on acute inflammatory effects of smoking of two cigarettes 
in healthy intermittent smokers. The design of the study was an open randomised, two-period 
crossover study. Sputum was induced at 3, 6, 1 2, 24, 48, 96, 1 92 hours after smoking and 
no smoking. We had expected to observe a general pro-inflammatory response with regard to 
neutrophils and macrophages and their related cytokines like IL-8 and TNF-a. and to obtain 
information on their kinetics in time. As we described in the discussion of chapter 3 we 
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observed an anti-inflammatory effect after smoking of two cigarettes, next to a short lived pro­
inflammatory response. In addition, cigarette smoking did not affect all inflammatory markers 
as we had expected. For instance, no effect was observed with respect to blood neutrophils 
and monocytes, and TNF-a release from blood cells, or sputum cytokines like IL-8. A few 
factors may be responsible for this lack of response. 
Firstly, the number of subjects included and the number of cigarettes (n=2) smoked , might 
have been too low. With regard to the number of subjects, it was not possible to make 
a correct power calculation in advance, because no earlier studies had been performed 
with respect to acute effects of smoking on sputum. There was also no literature available 
concerning the number of cigarettes to be smoked and possible dose-response effects. Indirect 
information can be obtained from chapter 2, in which we summarise the literature on acute 
effects of smoking. We retrieved 1 5  studies in humans from the literature, investigating the 
effect of smoking, ranging from I to 24 cigarettes. Regarding a pro-inflammatory effect on 
blood cells, especially neutrophils, it seems that inhalation of minimally four cigarettes results 
in an inflammatory response. Since we are the first to investigate the acute effects of smoking 
in sputum, we had no information on the minimally effective dose of cigarettes with this 
method. One study investigating the response to cigarette smoke in broncho-alveolar lavage 
fluid, also showed that inhalation of two cigarettes is not sufficiently effective (34). Therefore, 
a study on the effects of increasing numbers of cigarettes is advisable before starting follow-up 
studies, but is also time consuming. 
Secondly, we may have included a heterogeneous group of subjects regarding their response 
to cigarette smoke. When analysing the individual response curves, a wide variety in response 
to two cigarettes was observed for almost all parameters. The variability in response may 
be caused by differences in smoking history, which varied from O to 40 pack-years and/or 
by differences in current smoking ranging from 1 to 60 cigarettes a month and/or genetic 
heterogeneity in cigarette responsiveness. With regard to the variety in smoking history, the 
airways from subjects with a higher number of pack-years will probably show signs of airway 
remodelling and subsequently respond differently to smoke exposure. With regard to the 
differences in current smoking, it might be that the time the subjects refrained from smoking 
(i.e. 9 days) was not enough to normalise the airway inflammation due to prior smoking, 
especially for the 'heavy' smokers. In a future study it would be reasonable to include a 
more homogeneous study population to avoid these confounding factors. Furthermore, an 
important question in a future study is how to discern the susceptible smoker. As is known 
from the literature, 20% of the heavy smokers develop COPD. An approach to further clarify 
why only 20% of smokers develop COPD is to investigate the acute smoke response in a 
large group of smokers with a low number of pack years starting at relatively young age and 
to evaluate the response to acute cigarette smoking in time with intervals of several years. 
In this way it might be possible to separate the susceptible from the non-susceptible smokers 
at an early stage of the disease. To increase the chances of finding a subgroup of susceptible 
smokers, subjects could be randomised based on a strongly positive family history of COPD, 
on polymorphisms in genes known to be associated with COPD, on early emphysematous 
changes on high resolution computed tomography (CT) (35) or on differences in the single­
breath nitrogen tests (36), which may help identify early airflow limitation in small airways of 
smokers. Another approach would be to investigate differences in the acute smoke response 
in asymptomatic smokers and smokers with COPD. Smokers with COPD by definition 
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respond differently i.e. more extensively on chronic smoke exposure than healthy smokers, 
since they have developed COPD. Therefore differences in the acute smoke response might 
occur as well. 
Thirdly, sputum may reflect only a part of the acute inflammatory changes of the airways. 
Rutgers et al (37) have already shown that inflammatory cell counts in sputum, bronchial 
biopsies, bronchial wash and lavage fluid poorly correlate in healthy subjects and patients 
with COPD. This suggests that the different materials obtained from the lungs reflect 
different aspects of airway inflammation and/or other compartments of the lung. It would be 
important to investigate effects of acute smoking on airway inflammation both in sputum and 
in bronchial biopsies, since biopsies are still thought to be the golden standard to investigate 
airway inflammation. Furthermore, it is unfortunate that it is still not possible to investigate 
certain inflammatory mediators in sputum. Proteases in sputum and the added dithiotreitol, 
which is needed to homogenise sputum, break down disulfide bonds and subsequently 
affect cytokine enzyme linked immunosorbent assay (ELISA) measurements (38, 39) . Other 
techniques have to be developed to homogenise sputum in order to avoid these problems 
(40). Another possibility is to evaluate inflammatory markers in for example exhaled breath 
condensate, which is a novel and promising non-invasive research tool to investigate airway 
inflammation (41 ) .  
Fourthly, we possibly did not investigate the correct effect parameters after acute smoke 
inhalation. A number of interesting effect parameters may be added in a fmure study. In 
chapter 2 we reviewed the literature on acute effects of smoking in human, animals and 
in vitro studies. This review demonstrated that acute smoke exposure resulted in increased 
desmosin and hydroxyproline concentrations in broncho-alveolar lavage fluid from mice (42-
45). These are degradation products of elastin and collagen, which suggests breakdown of 
the extracellular matrix of the lung after acute smoke exposure. These proteins have not 
been investigated in humans after acute smoke exposure. Besides studying the inflammatory 
response to smoke, it seems important to investigate these measurements, since this might 
be the start of lung tissue breakdown as seen in patients with COPD. Another fascinating 
parameter, as discussed in the prior paragraph is the anti-oxidant HO· 1 ,  since insufficient 
up-regulation of HO- I after smoke exposure may play a role in the development of COPD. 
A next step would be to investigate if acute cigarette smoking results in differences in HO-I 
expression in sputum and lung macrophages, but also in constitutional cells (e.g. epithelial 
cells) in the lung, since this may contribute to the individual susceptibility to smoke. 
Furthermore, by using new techniques, like proteomics, novel proteins can be discovered in 
for example sputum, urine, breath condensate and serum that may give new insight in the 
pathogenesis of smoking induced inflammation and tissue damage (46) .  
Finally, our study design with repeated sputum inductions may have blurred the response to 
cigarette smoke. In chapter 6 we described the pro-inflammatory effects of repeated sputum 
inductions on neutrophils and eosinophils within 48 hours. Although we used a control arm 
without smoking and therefore were able to correct for this pro-inflammatory effect, this 
disturbing factor should be avoided in a future study design. This can be done by using 
parallel study arms, performing sputum inductions at selected time points (for example 3, 
12 and 24 hours) after separate sessions of cigarette smoking. Alternatively, other techniques 
can be used to investigate airway inflammation, like exhaled breath condensate. With this 
knowledge, the following recommendations in the study design investigating acute effects of 
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smoking can be put forward: 
• Increase the number of cigarettes smoked to at least 4 cigarettes. 
• Include younger people with a low number of pack-years and evaluate the acute 
smoke response in time . 
• Select high and low susceptible smokers on basis of for example a strongly positive 
family history of COPD and/or early emphysematous changes on CT. 
• Include, besides intermittent smokers, also smokers with and without COPD to 
compare the acute effects between the groups. 
• Select a more homogeneous group of subjects regarding smoking history and 
current smoking. 
• Do not repeat sputum inductions within 48 hours. 
• Use exhaled breath condensate in addition to sputum induction to increase the 
possibility to measure certain inflammatory markers. 
• Collect information from bronchial biopsies and compare it with sputum to 
investigate differences in compartments and aspects of airway inflammation. 
• Investigate markers of tissue damage (e.g. desmosin, hydroxyproline and decorin 
breakdown products) and oxidative stress (HO- 1 ). 
• Use proteomics to discover novel markers in sputum, blood, breath condensate and 
urine. 
The role of anti-TNF-a treatment in COPD 
In chapter 5 we described the first study evaluating the effect of the anti-TNF-a drug infliximab 
in patients with mild-to-moderate COPD. We showed that infliximab had no significant effect 
on clinical and inflammatory parameters in these patients. We have offered several explanations 
for this lack of response. One important explanation is that we selected a relatively mild 
patient group. We choose to investigate this stage of disease, for good reasons, since our study 
was the first and thus was also used as a safety and tolerability study. However, to investigate 
anti-inflammatory and clinical effects of infliximab these patients may not have been ideal. 
First of all, the inflammatory burden in these patients might have been too low to show 
significant anti-inflammatory effects. It has been shown that patients with lower FEV 1 values 
have a higher load of airway inflammation, as reflected by sputum neutrophils and IL-8 ( 13, 
14, 47). Therefore, it would be sensible to evaluate more severe patients. Furthermore, TNF­
a has been shown to be important in emphysema patients suffering from malnourishment 
and muscle wasting (48-50). This is shown by the fact that TNF-a is increased systemically in 
a subgroup of COPD patients with malnourishment and is associated with increased energy 
expenditure. In addition, TNF-a induces apoptosis of myocytes (51, 52) and may increase 
apoptosis of muscle cells from patients with severe emphysema (53). Rennard et al (54) 
recently showed that the 6-minute walking distance did not improve after infliximab therapy 
in patients with COPD. However, in a subgroup analysis patients with cachexia did improve 
their walking distance. Given these data, infliximab may be useful in patients with more severe 
COPD expressing characteristics of systemic disease, for example patients with increased 
serum TNF-a levels, increased energy expenditure and low lean body mass. In addition, the 
clinical relevance of infliximab therapy, i.e. effects on quality of life and mortality, may be 
much larger in this subgroup of severe emphysema patients. Since quality of life and exercise 
performance are decreased by skeletal muscle disease in COPD patients, antagonising the 
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increased TNF-a induced apoptosis by infliximab may improve skeletal muscle function and 
subsequently also quality of life and exercise performance (55, 56). Furthermore, low body 
weight and fat-free-body mass are independent risk factors for mortality in COPD (57, 58). If 
anti-TNF-a reduces TNF-a levels and thereby improves body weight, it might conceptually 
even indirectly ameliorate mortality rate in severe COPD patients. 
A potential drawback of treating more severe COPD patients with anti-TNF-a is that these 
patients have more frequently respiratory tract infections ( 59), which may be further enhanced 
by treatment with infliximab. TNF-a is a pro-inflammatory cytokine that has a pathologic role 
in some diseases but is also involved in a wide range of important physiologic processes, like 
the defense against intracellular infections. The use of infliximab and other TNF-a inhibitors 
has been associated with increased rate of tuberculosis, mycosis, and intracellular bacterial 
infections (59). In addition, many patients with COPD in European countries born before 
1945 are infected with M. tuberculosis during the Second World War. Since treatment with 
infliximab increases the risk of reactivation of latent tuberculosis, this might limit the extensive 
use of this drug in older patients (60). In addition, long-term use of infliximab in COPD may 
be limited by the formation of neutralizing antibodies (HACA's), as is shown for Crohn's 
disease and rheumatoid arthritis (61, 62). However, we do not know if the prevalence of 
HACA formation is similar in COPD. 
Another factor to explain the lack of the anti-inflammatory effect of infliximab in our COPD 
patients is that (airway) inflammation in COPD is mediated by a broad range of cytokines 
and chemokines. These mediators have many overlapping functions, with each function 
potentially mediated by more than one cytokine (63). Thus, it is of further importance to 
investigate the effect of broad-spectrum cytokine antagonists or combinations of different 
single-cytokine antagonists on inflammation in COPD. To reach the best effect it seems most 
rational to focus on combinations of inhibitors of pro-inflammatory mediators, so as to block at 
the beginning of the inflammatory cascade, for example anti-lL-8 and anti-TNF-a. It has been 
shown that the monoclonal antibody against IL-8 decreases dyspnea in patients with COPD, 
but no significant differences were observed in lung function, health status, and 6-min walking 
distance (64). Combining these two antibodies may have a synergistic anti-inflammatory 
effect on neutrophilic inflammation, since TNF-a is responsible for recruitment of neutrophils 
to the lung by upregulating intercellular adhesion molecule on endothelial cells and IL-8 is 
chemotactic for neutrophils in lung tissue. Another option may be drugs that interfere with 
gene transcription or intracellular signal transduction, which simultaneously can block the 
transcription of several pro-inflammatory cytokines and chemokines (65). However, inhibition 
by all of the above-described drugs of these molecules may impair defence mechanisms as 
well and increases the risk of (potential lethal) infections. 
The role of disturbed tissue repair in emphysema 
In chapter 4 we showed that high concentrations of CSE predominantly caused necrosis of 
human lung fibroblasts, whereas a less pronounced effect was seen with respect to induction 
of apoptosis. Rather unexpectedly, TGF-Pl increased and IFN-y diminished the percentage 
of necrotic cells after CSE exposure. When this is also the case in vivo, this suggests that 
TGF-P l , which is increased in the lungs of emphysema patients (66), might increase the 
vulnerability of fibroblasts with subsequent death upon exposure to cigarette smoke. Recently, 
Noordhoek et al (67) have shown that TGF-P 1 caused more profound reductions in decorin 
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production in fibroblasts from severe emphysema patients compared to mild emphysema 
patients, which suggests an intrinsic dysfunction of fibroblasts with respect to tissue repair 
in severe emphysema patients. It is conceivable that fibroblasts from mild and severe 
emphysema patients also react differently to TGF-PI when combined with CSE, with respect 
to the induction of cell death. To evaluate this, differences in response to CSE and TGF-P I 
in primary lung fibroblasts from emphysema patients in different Chronic Obstructive Lung 
Disease (GOLD} stages of the disease and also from healthy smokers must be investigated. 
This study may give information on the susceptibility to CSE induced cell death between those 
groups and may therefore give more insight in the pathogenesis of COPD. A next step would 
be to perform immunohistochemical stainings of markers of necrosis and apoptosis on lung 
tissue to investigate cell death of fibroblasts from emphysema patients in vivo. However, this 
may be difficult since fibroblasts are difficult to identify as an individual part of the connective 
tissue in the lung. Such studies have yet been performed on apoptosis and necrosis from 
epithelial and endothelial cells in patients with COPD, showing increased apoptosis (68-70). 
In our study, CSE predominantly induced necrosis, whereas a less pronounced effect is seen with 
respect to induction of apoptosis. Contradictory results have been published on this subject. 
We have offered several explanations for these differences in response. Firstly, as was shown 
by Ishii et al (71 } lower concentrations of CSE induce apoptosis and higher concentrations 
induce necrosis. Compared to other studies, we used relatively high concentrations of CSE. 
Theoretically, the degree of cigarette smoke concentration locally in the lung, might also be 
responsible for the type of cell death ( apoptosis or necrosis}. The difference in type of cell 
death is important, i.e necrosis of fibroblasts may result in considerable additional local tissue 
damage, because the release of intracellular content in necrosis in general will induce ongoing 
inflammation in contrast to the situation with apoptosis. Secondly, the method of fibroblasts 
culture, which might have rendered the cells more vulnerable to the toxic smoke extract and 
the method of analyses of cell death may have been responsible for these inconsistent results 
as well. A last remark should be made about most models using cigarette smoke extract, as 
cigarette smoke in vivo is administered in 'gas' form, which may have quite different effects. 
The composition of cigarette smoke extract and cigarette smoke can differ considerably 
especially regarding the water insoluble substances and free radicals, which is currently under 
study by Slebos and colleagues from Groningen (72-74). Further studies will have to confirm 
whether cigarette smoke itself has the same effect as cigarette smoke extract on the balance 
between apoptosis and necrosis. 
Our study showed that CSE predominantly induced necrosis of human lung fibroblasts. As 
we already described in the prior two paragraphs, the drawback of necrosis compared to 
apoptosis is the induction of local inflammation by the release of intracellular content and 
in this way necrosis contributes to the ongoing inflammation and destruction of the alveolar 
walls. Therefore it would be challenging to influence the route of cell death, and to try to 
turn necrosis into apoptosis to reduce local tissue damage. One of the requirements for a cell 
to go into apoptosis is to have enough intracellular adenosine triphosphate (ATP}, the energy 
storage of the cell. When enough ATP could be preserved, a cell prefers to go into apoptosis. 
Recently, van der Toorn et al (75) from Groningen demonstrated that CSE caused a dose­
dependent decrease in ATP formation in airway epithelial cells, by direct blockage of the 
mitochondrial complex I and II. Furthermore, it has been shown by Scarabelli et al (76) that 
preincubation with urocortin increased ATP in myocardial cells after induction of ischemia in 
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a rat model. Recovered ATP stores might allow damaged myocytes that would otherwise die 
by necrosis to die by the alternative apoptotic pathway. The paradoxical increase in apoptosis 
can be accepted when it results in a decrease of necrosis. Prevention of oxidative stress 
induced apoptosis can be achieved by anti-oxidants like HO- I .  Even CO, a gas released by the 
conversion of haem into biliverdin by HO- I ( 17), has anti-apoptotic features in TNF-a induced 
apoptosis. As mentioned in the first part of the discussion, it would be interesting to evaluate 
the effect of inhaled CO, or the local induction of HO-I as a potential anti-inflammatory as 
well as an anti-apoptotic therapy in patients with COPD. 
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COPD , van af de eerste sigaret tot aan 
behandel ing 
Wat is  COPD? 
Dit proefschrift gaat over de effecten van roken, het ontstaan van de ziekte COPD en over een 
nieuwe behandeling voor patienten met COPD. De afkorting COPD komt uit het Engels en 
staat voor 'chronic obstructive pulmonary disease', letterlijk vertaald chronische obstructieve 
longziekte. Chronisch obstructieve longziekte is een verzamelnaam van chronische bronchitis 
en longemfyseem, ook we! 'rek uit de long' genoemd. COPD wordt gekenmerkt door een 
chronische ontsteking van de luchtwegen en de longen en door een verminderde longfunctie. 
Patienten met COPD hebben klachten van bijvoorbeeld hoesten, slijm opgeven, een piepende 
ademhaling en/of kortademigheid in rust of bij inspanning. Tevens hebben veel patienten 
met COPD vaker en !anger last van luchtweginfecties. 
In het jaar 2000 telde Nederland ruim 300.000 patienten met de ziekte COPD. Wereldwijd 
zijn dit zelfs ongeveer 600 miljoen patienten en dit aantal neemt jaarlijks toe. De wereld 
gezondheidsorganisatie (WHO) beschouwt COPD als de vijfde meest dodelijke aandoening, 
na hartinfarcten, beroertes, luchtweginfecties en aids. In Nederland is COPD doodsoorzaak 
nummer 3. 
Oorzaak van COPD 
De achteruitgang van de longfunctie bij patienten met COPD ontstaat door een abnormale 
ontstekingsreactie van de luchtwegen en het longweefsel na langdurige blootstelling aan 
tabaksrook of andere prikkelende stoffen in de lucht, zoals bijvoorbeeld uitlaatgassen en 
fabrieksuitstoot. In de loop van de jaren raken de luchtwegen en het longweefsel steeds 
meer beschadigd en neemt de longfunctie onherstelbaar af. Tabaksrook is de belangrijkste 
oorzaak voor het krijgen van COPD, echter niet alle rokers ontwikkelen COPD. Ongeveer 
15 tot 20% van de forse rokers die meer dan 10 jaar gerookt heeft, krijgt uiteindelijk COPD. 
Het is nog onduidelijk waarom niet iedere roker COPD ontwikkelt. Bij het ontstaan van 
COPD spelen dan ook vrijwel zeker naast het roken genetische factoren een rol, echter het 
is nog niet duidelijk welke genen dat zijn. Een van de belangrijkste onderzoeksvragen met 
betrekking tot het ontstaan van COPD is dus waarom slechts 15-20% van de rokers COPD 
krijgt. Daarbij is men op zoek naar de rokers die gevoelig zijn om COPD te ontwikkelen en 
om deze rokers in een vroeg stadium van de ziekte te herkennen, wij noemen deze groep 'de 
gevoelige rokers'. Dit is een van de vragen waar de onderzoekers in dit proefschrift zich mee 
bezig hebben gehouden. 
Sigarettenrook 
Sigarettenrook is een complex mengsel van meer dan 5.000 chemische stoffen. Het bestaat 
uit een mengsel van gassen, waterdamp en minuscule deeltjes. Het gasgedeelte bevat onder 
andere koolzuurgas (CO2) en koolmonoxide (CO). De vaste deeltjes, ook we! 'teer' genoemd, 
bestaan uit verschillende kankerverwekkende stoffen, prikkelende stoffen, metalen, radicalen 
en nicotine [figuur I ). 
Rokers inhaleren niet alle rook die tijdens het roken vrijkomt. Het grootste dee! ervan komt 
tussen elke trek in de lucht terecht via het brandende uiteinde van de sigaret. Daarnaast 
blaast de roker ook altijd een dee! van de ingeademde rook uit. Passief roken is het inademen 
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van tabaksrook uit de omgevingslucht, ook we! 'meeroken' genoemd. Het is aangetoond dat 
ook meeroken een verhoogde kans op het ontwikkelen van COPD geeft. 
Theorieen over bet ontstaan van COPD 
Er is maar weinig bekend over welke deeltjes in rook nu precies COPD veroorzaken. Wei is 
bekend dat sigarettenrook het slijmvlies, dat de luchtwegen bedekt, irriteert en de slijmklieren 
van de luchtwegen stimuleert tot extra slijmproductie. Dit kan lijden tot chronische 
bronchitis. 
Bij rokers die geen COPD hebben, worden door het inademen van sigarettenrook 
ontstekingscellen naar de luchtwegen aangetrokken en geactiveerd om de schadelijke 
rookdeeltjes op te ruimen. Daarentegen wordt bij patienten met COPD een overdreven 
ontstekingsreactie gezien na blootstelling aan tabaksrook. Hierbij komen heel veel 
ontstekingscellen naar de longen, die daar langdurig aanwezig blijven. Het gevolg hiervan is 
dat deze ontstekingscellen zelf de luchtwegen en het longweefsel kunnen beschadigen in plaats 
van de schade door het roken te voorkomen. Naast deze overdreven ontstekingsreactie zijn er 
nog 3 theorieen die het ontstaan van COPD bij gevoelige rokers proberen te verklaren: 
• De eerste theorie is dat gevoelige rokers onvoldoende in staat zijn om radicalen 
(schadelijke deeltjes) uit rook weg te vangen, waardoor de luchtwegen beschadigd 
raken. Om radicalen weg te kunnen vangen heb je anti-oxidanten nodig, die 
gemaakt worden door cellen in de long in reactie op blootstelling aan radicalen in 
sigarettenrook. Wanneer er onvoldoende anti-oxidanten worden gemaakt, kunnen 
radicalen het longweefsel blijvend beschadigen. 
• De tweede theorie is dat bij gevoelige rokers de ontstekingscellen, die aangetrokken 
en geactiveerd warden om rookdeeltjes op te ruimen, te veel schadelijke stoffen 
vrijlaten. Deze schadelijke stoffen, proteasen genoemd, kunnen dan schade aanrichten 
in het omliggende longweefsel en zo bijdragen aan het ontstaan van COPD. 
• De derde theorie is dat bij gevoelige rokers het lichaam onvoldoende in staat is om 
de schade die de_ �igarettenrook en de proteasen hebben aangericht te herstellen. Met 
andere woorden het reparatiemechanisme werkt onvoldoende. 
Behandeling van COPD 
Stoppen met roken is de belangrijkste stap om de snelheid waarmee de longfunctie bij 
patienten met COPD achteruit gaat te verminderen en dus om het verergeren van de ziekte 
te vertragen. Het is nooit te laat om te stoppen met roken. Het succespercentage van stoppen 
met roken na 12 maanden varieert afhankelijk van de stopmethode (bijvoorbeeld stoppen 
met of zonder het gebruik van nicotinevervangende medicijnen of stoppen met of zonder 
begeleiding). De getallen van het succespercentage van stoppen met roken varieren tussen 
de 7 en 24%. Tot nu toe zijn er geen medicijnen die de ontsteking van de luchtwegen 
kunnen stoppen of verminderen. Daarom wordt veel onderzoek gedaan naar nieuwe 
ontstekingsremmende medicijnen, met de hoop om in de toekomst de ontsteking van de 
luchtwegen we! te kunnen beYnvloeden en zo de achteruitgang van de ziekte te kunnen 
stoppen. Vee! COPD patienten gebruiken luchtwegverwijdende medicijnen, deze kunnen 
verlichting geven van kortademigheidsklachten en daardoor de kwaliteit van !even vergroten. 
Daarnaast kunnen patienten met COPD, die vaak last hebben van acute verslechteringen van 
hun klachten, baat hebben bij het dagelijks gebruik van inhalatiesteroYden. Helaas hebben 
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deze inhalatiesteroiden voor zover wij weten geen lange termijn effect op de ontsteking 
van de luchtwegen en/of de achteruitgang van de longfunctie. Dus onderzoek naar nieuwe 
ontstekingsremmende medicijnen blijft nodig. 
Samenvatting van de onderzoeken 
in dit proefschrift 
Hoofdstuk 2 en 3: acute versus chronische effecten van roken 
Er is tot nu toe veel onderzoek gedaan naar de effecten van langdurig roken op de ontsteking 
van de luchtwegen in het kader van het ontstaan van COPD. Er is echter veel minder vaak 
onderzoek gedaan naar de acute, of we! korte termijn effecten van roken. De onderzoekers 
die mee hebben gewerkt aan de onderzoeken in <lit proefschrift zijn van mening dat dit echter 
wel heel belangrijk is omdat de acute effecten van roken de basis zijn van de lange termijn 
effecten van langdurig roken. Onze gedachte is dat wanneer je de acute effecten van roken 
goed begrijpt, je mogelijk ook beter de lange termijn effecten kunt begrijpen. 
In hoofdstuk 2 van dit proefschrift wordt daarom een overzicht gegeven van alle gepubliceerde 
onderzoeken tot en met het jaar 2003 over de acute effecten van roken. Acute effecten 
van roken hebben wij omschreven als de effecten binnen 24 uur. Omdat er maar 1 5  acute 
rookstudies bij mensen zijn gedaan, hebben we in dit overzichtsartikel ook alle rookstudies 
bij dieren en op cellen samengevat. 
De belangrijkste conclusies van dit overzichtsartikel zijn: 
• Sigarettenrook trekt ontstekingscellen naar de longen aan en activeert deze 
cellen. 
• Blootstelling aan sigarettenrook leidt binnen 24 uur al tot schade aan cellen in de 
long en kan zelfs leiden tot celdood. 
• Blootstelling aan sigarettenrook had op sommige ontste�gscellen en mediatoren 
( 'boodschappers' tussen de verschillende cellen} een remmend effect. Het is bekend 
van eerder onderzoek dat een aantal van de 5.000 bestanddelen in rook een 
ontstekingsremmend effect kan hebben, een van deze stoffen is koolmonoxide. 
• Blootstelling aan rook vermindert de functie van fibroblasten, de reparatiecellen 
van de long. 
Samenvattend, het bestuderen van de acute effecten van roken naast de chronische effecten 
van roken levert extra informatie op over de schadelijke effecten van roken. Daarnaast is het 
belangrijk te onderkennen dat het vergelijken van onderzoeken van mensen, dieren en cellen 
niet altijd goed mogelijk is. 
Hoofdstuk 3 van <lit proefschrift gaat over een onderzoek naar de acute effecten van roken 
bij gezonde gelegenheidsrokers. Gelegenheidsrokers zijn rokers die niet dagelijks roken, 
maar af en toe, ook we! 'partyrokers' genoemd. Aan hen werd gevraagd om vanaf 9 dagen 
voor het onderzoek niet meer te roken en in het ziekenhuis 2 sigaretten achter elkaar te 
roken. Vervolgens hebben wij de ontstekingsreactie die optreedt na het roken onderzocht in 
de luchtwegen, bloed, urine en uitademingslucht. Voor het onderzoek van de luchtwegen 
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hebben wij opgehoest slijm uit de luchtwegen, ook we! sputum genoemd, bestudeerd. Om 
dat sputum te verkrijgen werd een sputuminductie verricht. Hierbij ademden de deelnemers 
gedurende 1 5  minuten zoute mist in, waardoor sputum in de luchtwegen gevormd werd en 
ze dit gemakkelijker konden ophoesten. 
De belangrijkste resultaten van dit onderzoek zijn: 
• Het roken van 2 sigaretten veroorzaakt een kortdurende stijging van 
ontstekingscellen (neutrofielen en lymfocyten) in het sputum. Deze ontstekingscellen 
warden aangetrokken naar de luchtwegen om rookdeeltjes op te ruimen. 
• Het roken van 2 sigaretten veroorzaakt een kortdurende dating van het aantal 
eosinofiele ontstekingscellen in het bloed. Dit resultaat komt overeen met de 
onderzoeken, die in hoofdstuk 2 zijn samengevat. 
• 24 uur na het roken waren er geen effecten meer waar te nemen. 
De meest opvallende bevinding van dit onderzoek is dat rook een remmend effect heeft 
op de aanwezigheid van eosinofiele cellen in bloed. De vraag is hoe dit komt en wat dit 
betekent. Zoals eerder genoemd is het bekend dat koolmonoxide, een van de bestanddelen 
in sigarettenrook, een ontstekingsremmend effect kan hebben. Het ontstekingsremmend 
effect van koolmonoxide is tot nu toe alleen onderzocht op cellen in het laboratorium en 
bij dierexperimenteel onderzoek. Om te onderzoeken of koolmonoxide ook bij mensen een 
ontstekingsremmend effect heeft, zou je het aantal eosinofiele cellen kunnen bestuderen 
bij patienten met een ontsteking van de luchtwegen, bijvoorbeeld patienten met COPD, na 
blootstelling aan pure koolmonoxide, dus zonder rook. 
Hoofdstuk 4: gestoorde reparatie van de long 
In hoofdstuk 4 is een onderzoek beschreven waarin we in het laboratorium het effect van 
sigarettenrook op fibroblasten hebben onderzocht. Fibroblasten zijn belangrijk voor het 
herstellen van schade aan het longweefsel, doordat zij allerlei bouwstenen en groeifactoren 
(stofjes die een eel kunnen activeren) kunnen maken. Dit is van belang wanneer het 
longweefsel beschadigd raakt door bijvoorbeeld langdurige blootsteling aan sigarettenrook. 
Een probleem ontstaat wanneer deze fibroblasten zelf beschadigd raken door sigarettenrook 
en niet meer goed kunnen functioneren. Wij hebben daarom onderzocht of sigarettenrook 
deze fibroblasten kan beschadigen en we hebben hierbij met name gekeken of deze cellen 
ook 'dood gaan' na blootstelling aan sigarettenrook. Bij ons experiment hebben we gebruik 
gemaakt van een sigarettenrookoplossing, die gemaakt wordt door sigarettenrook door een 
vloeistof te bubbelen, zodat de rook erin opgelost wordt. De fibroblasten warden vervolgens 
aan deze oplossing toegevoegd. 
De belangrijkste resultaten van dit onderzoek zijn: 
• Blootsteling aan een hoge dosis sigarettenrookoplossing leidt tot celdood van 
fibroblasten in het laboratorium. Wat betekent dit voor de mens? Wanneer dit in 
het menselijk lichaam ook gebeurt, kan dit leiden tot een afname van het aantal 
fibroblasten in de long. Omdat fibroblasten belangrijk zijn voor het herstellen van 
schade aan het longweefsel, zou dit kunnen leiden tot minder goed herstel van 
beschadigd longweefsel na blootstelling aan rook. 
• Fibroblasten gaan sneller dood wanneer er naast de sigarettenrookoplossing ook 
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een groeifactor van de fibroblast TGF·� 1 wordt toegevoegd. Blijkbaar zijn fibroblasten 
dan gevoeliger voor sigarettenrook. Wat betekent dit voor de mens? Het is bekend 
dat in de longen van patienten met COPD veel meer van deze groeifactor aanwezig is 
dan in de longen van 'normale' rokers. Het kan dus zijn dat deze groeifactor bijdraagt 
aan het eerder dood gaan van de fibroblasten in de longen van COPD patienten, 
waardoor het beschadigde longweefsel minder goed gerepareerd kan worden. 
Hoofdstuk 5: een nieuwe behandeling van COPD? 
Zoals al eerder besproken, zijn er tot nu toe nog geen medicijnen beschikbaar die de ontsteking 
van de luchtwegen bij patienten met COPD kunnen stoppen of verminderen. Daarom wordt 
er nog steeds veel onderzoek gedaan naar nieuwe ontstekingsremmende medicijnen, met de 
hoop dat we in de toekomst de ontsteking van de luchtwegen en waarschijnlijk daarmee de 
achteruitgang van de longfunctie we! kunnen beYnvloeden. 
In hoofdstuk 5 beschrijven we een onderzoek naar de effecten van een nieuwe 
ontstekingsremmer, infliximab, bij patienten met COPD. Infliximab remt het stofje TNF·a, 
waarvan wordt gedacht dat het een beiangrijke rol speelt in de ontsleking van de luchtwegen 
bij patienten met COPD. Het medicijn infliximab werkt heel goed bij patienten met reuma 
en de ziekte van Crohn, een chronische darmontsteking. De ontsteking van de luchtwegen 
bij patienten met COPD lijkt veel op de ontsteking bij patienten met reuma en de ziekte 
van Crohn. Omdat infliximab bij de behandeling van deze ziekten heel goed werkt, hebben 
we onderzocht of infliximab ook verbetering geeft van de ontsteking in de luchtwegen bij 
patienten met COPD. In dit onderzoek hebben we 22 patienten met een milde vorm van 
COPD onderzocht, waarvan er 14 zijn behandeld met infliximab en 8 met een placebo (nep) 
medicijn. Het onderzoek heeft echter geen positief effect van infliximab op de ontsteking van 
de luchtwegen laten zien. Ook verbeterden de klachten van de luchtwegen en de longfunctie 
van de behandelde patienten niet. Wij hebben daar een aantaI mogelijke verklaringen voor. Ten 
eerste kan het zijn dat het stofje TNF·a toch niet zo'n belangrijke rol speelt bij de ontsteking 
van de luchtwegen bij patienten met COPD als we dachten. Ten tweede kan het zijn dat we 
patienten met een te milde vorm van COPD hebben onderzocht. Omdat het de eerste keer 
was dat dit medicijn werd onderzocht bij patienten met COPD en er dus niets bekend was 
over mogelijke bijwerkingen bij deze patienten groep, hebben we ervoor gekozen om alleen 
naar patienten met een milde vorm van COPD te kijken. In dit onderzoek hebben we geen 
ernstige bijwerkingen gezien van infliximab bij onze patienten. In een vervolgonderzoek zou 
het interessant zijn om te kijken of infliximab we! een ontstekingsremmend effect laat zien bij 
patienten met een ernstigere vorm van COPD. 
Hoofdstuk 6: effect van meerdere sputuminducties 
Zoals al eerder genoemd is sputuminductie een methode om slijm te verkrijgen uit de 
luchtwegen. Het is een methode die veel wordt gebruikt bij wetenschappelijk onderzoek en 
relatief weinig belastend is voor de patient. Bij een sputuminductie adem je gedurende 15 
minuten zoute mist in, waardoor sputum dat in de luchtwegen gevormd is makkelijker kan 
worden opgehoest. Daarna wordt het sputum in het laboratorium volgens een aantal stappen 
behandeld en kan er bepaald worden hoeveel en welke ontstekingscellen en mediatoren er 
in het sputum aanwezig zijn. Dit geeft informatie over de mate van ontsteking en het soort 
ontsteking van de luchtwegen. Echter, het inademen van de zoute mist op zich geeft ook al 
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een soort van tijdelijke 'ontsteking', die het onderzoek ongewenst kan beYnvloeden. 
In hoofdstuk 6 van dit proefschrift wordt het effect beschreven van 7 sputuminducties achter 
elkaar, met verschillende tussenpozen bij gezonde vrijwilligers. 
De belangrijkste resultaten van dit onderzoek zijn: 
• Herhaalde sputuminducties geven een kortdurende (3 uur} stijging van het aantal 
neutrofiele cellen (bepaalde type ontstekingscellen} in het sputum. 
• Herhaalde sputuminducties geven een langdurige (48 uur) stijging van het aantal 
eosinofiele ontstekingscellen. Blijkbaar is de eosinofiel gevoeliger voor de zoute 
mist prikkel of voor stoffen die door het inademen van zoute mist in de luchtwegen 
vrijkomen. 
Samenvattend, sputuminducties moeten niet binnen 48 uur herhaald warden omdat ze zelf 
een soort 'ontstekingsreactie' kunnen geven. 
Conclusies 
De onderzoeken in dit proefschrift hebben nieuwe inzichten gegeven in acute effecten van 
roken op ontstekingsreacties in de luchtwegen en in cellen die belangrijk zijn voor het herstel 
van longschade. Daarnaast is een nieuw ontstekingsremmend medicijn, infliximab, niet 
effectief gebleken bij patienten met een milde vorm van COPD. Tenslotte blijken herhaalde 
sputuminducties met tussenpozen korter dan 48 uur niet toepasbaar voor onderzoek naar de 
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